

Carolyn Crandall

Disclosure Annual Governance Disclosure 2024-25 (Expiration Date: 03/29/2025), Forums (Expiration Date: 03/29/2025), Internal Medicine Meeting 2024 faculty (Expiration Date: 03/29/2025)

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American Cancer Society	Grant / Contract	Spouse/Partner	\$1200000.00
<p>Recipient Name: Harley Kornblum Grant / Contract Description: regarding glioma stem cells Contract Start Date: 07/21/2023 Grant / Contract Amount:\$1,200,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 06/30/2028</p>			
American Society for Bone and Mineral Research	Other	Self	-
<p>Category: Other End Date: 09/30/2023 Compensation Type: Unpaid Compensation: No Additional Information: Member of the Council</p> <p>Start Date: 01/01/2017</p>			
California Institute for Regenerative Medicine	Grant / Contract	Spouse/Partner	\$1404001.00
<p>Recipient Name: Frank Pajonk Grant / Contract Description: to develop novel multi-kinase inhibitors against glioblastoma Contract Start Date: 05/01/2023 Grant / Contract Amount:\$1,404,001.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 03/29/2024 Contract End Date: 10/31/2025</p>			
David Geffen School of Medicine, University of California, Los Angeles	Employment Current Employment	Self	-
<p>Title: Professor of Medicine Start Date: 07/01/2017 Additional Information:</p> <p>Position Description: Professor in the Dept. Of Internal Medicine End Date:</p>			
David Geffen School of Medicine, University of California, Los Angeles	Employment	Spouse/Partner	-
<p>Title: Professor Start Date: 01/01/2017 Additional Information:</p> <p>Position Description: Professor on Faculty End Date:</p>			
Dr. Miriam and Sheldon G. Adelson Medical Research Foundation	Grant / Contract	Spouse/Partner	\$1111812.00
<p>Recipient Name: Harley Kornblum Grant / Contract Description: Neural repair and brain cancer Contract Start Date: 01/01/2017 Grant / Contract Amount:\$1,111,812.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 09/09/2025</p>			
Eunice Kennedy Shriver National Institute of Child Health and Human Development	Grant / Contract	Spouse/Partner	\$6207759.00

Entity	Type	Interest Held By	Value
Recipient Name: Harley Kornblum Grant / Contract Description: research into the causes, mechanisms, and treatments of intellectual and developmental disorders. Contract Start Date: 08/01/2020 Grant / Contract Amount: \$6,207,759.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 07/28/2022 Contract End Date: 05/31/2025			
National Cancer Institute	Grant / Contract	Spouse/Partner	\$2313255.00
Recipient Name: Harley Kornblum Grant / Contract Description: This project will study novel combination therapies against glioblastoma Contract Start Date: 01/01/2022 Grant / Contract Amount: \$2,313,255.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 12/30/2026			
National Institutes of Health	Grant / Contract	Self	\$309862.00
Recipient Name: Carolyn Crandall Grant / Contract Description: R21 grant R21AR078905 regarding osteoporosis risk prediction Contract Start Date: 09/21/2022 Grant / Contract Amount: \$309,862.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 08/31/2024			
National Institutes of Health	Grant / Contract	Self	\$2711621.00
Recipient Name: Carolyn Crandall Grant / Contract Description: R01 Grant PI R01AG071611 The COcoa SSupplement and Multivitamins Outcomes Study (COSMOS)..... Contract Start Date: 05/05/2021 Grant / Contract Amount: \$2,711,621.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/18/2021 Contract End Date: 02/28/2025			
National Institutes of Health	Grant / Contract	Self	\$2527938.00
Recipient Name: Carolyn Crandall Grant / Contract Description: NIH R01 grant AG071592-01 Sleep, Falls and Fractures in men and women: Role of Nocturnal Hypoxia Contract Start Date: 09/15/2021 Grant / Contract Amount: \$2,527,938.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 05/31/2026			
National Institutes of Health	Grant / Contract	Spouse/Partner	\$1660734.00
Recipient Name: Harley Kornblum Grant / Contract Description: Texas University-NIH-NCI research on glioblastoma invasion Contract Start Date: 02/01/2022 Grant / Contract Amount: \$1,660,734.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 01/31/2025			
National Institutes of Health	Grant / Contract	Self	\$25000.00
Recipient Name: Carolyn J. Crandall Grant / Contract Description: Contract from Western Regional Center for NHLBI-funded Women's Health Initiative Study Contract Start Date: 01/01/2019 Grant / Contract Amount: \$25,000.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 12/23/2019 Contract End Date: 10/15/2023			
National Institutes of Health	Grant / Contract	Spouse/Partner	\$2348720.00

Entity	Type	Interest Held By	Value
Recipient Name: Harley Kornblum Grant / Contract Description: NIH-NINDS grant for research on glioblastoma Contract Start Date: 12/15/2021 Grant / Contract Amount: \$2,348,720.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 11/30/2026			
National Institutes of Health	Grant / Contract	Spouse/Partner	\$11018165.00
Recipient Name: Linda Liau Grant / Contract Description: NIH-NCI UCLA SPORE in brain cancer Contract Start Date: 08/01/2022 Grant / Contract Amount: \$11,018,165.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/16/2023 Contract End Date: 07/31/2027			
National Institutes of Health	Grant / Contract	Spouse/Partner	\$3128076.00
Recipient Name: Frank Pajonk Grant / Contract Description: prevention of glioblastoma tumor recurrence Contract Start Date: 07/01/2023 Grant / Contract Amount: \$3,128,076.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 03/29/2024 Contract End Date: 06/30/2028			
U.S. Department of Defense	Grant / Contract	Spouse/Partner	\$665075.00
Recipient Name: Harley Kornblum Grant / Contract Description: brain tumor research Contract Start Date: 09/01/2021 Grant / Contract Amount: \$665,075.00 Additional Information:			
Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 07/28/2022 Contract End Date: 08/31/2023			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Carolyn J. Crandall

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	none
Hypertension	None
Menopausal Therapy	See link to pubmed bibliography http://www.ncbi.nlm.nih.gov/sites/myncbi/carolyn.crandall.1/bibliography/40835218/public/?sort=date&direction=descending
Migraine	None
Obesity	None
Osteoporosis	See link to pubmed bibliography

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Carolyn J. Crandall

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Carolyn J. Crandall

Carol Crandall 4/9/2024

Signature

Date

Lauri Hicks

Discloser Identifier: 01189285

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Centers for Disease Control and Prevention	Employment Current Employment	Self	-
Title: Branch Chief, Medical Product Safety, Director, Office of Antibiotic Stewardship Start Date: 07/15/2007 Additional Information:		Position Description: I lead CDC's public health efforts related to medical product safety, including improving antibiotic use, medication safety and blood, organ, and tissue safety. I am also leading efforts related to the COVID-19 pandemic response. End Date: Ongoing / No Known End Date	
GI Specialists of Georgia	Employment	Spouse/Partner	-
Title: Physician Start Date: 09/01/2010 Additional Information:		Position Description: Patient care End Date:	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	none
Hypertension	none
Menopausal Therapy	none
Migraine	none
Obesity	none
Osteoporosis	none

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Lauri Hicks

Name

Lauri Hicks

4/11/24

Signature

Date

Disclosure Purpose: Annual Governance Disclosure 2024-25, Contractor/Guest Annual Disclosure 2023 - 24

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value								
Agency for Healthcare Research and Quality	Grant / Contract	Self	\$2000000.00								
<p>Recipient Name: Brown University Grant / Contract Description: Multi year contract providing opportunity to apply for project contracts Contract Start Date: 03/29/2019 Grant / Contract Amount:\$2,000,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 12/01/2023 Contract End Date: 12/22/2025</p>											
American association gynecologic laparoscopists	Consultant	Self	-								
<p>Category: Consultant End Date: 06/30/2023 Compensation Type: Cash Compensation: Yes Additional Information: Methodologic consultant for society's guideline development group (ended)</p> <p>Start Date: 04/01/2021</p>											
American Society of Hematology	Grant / Contract	Self	\$450000.00								
<p>Recipient Name: Brown University Grant / Contract Description: Systematic review on acute lymphocytic leukemia Contract Start Date: 06/01/2022 Grant / Contract Amount:\$450,000.00 Additional Information: Lead</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 12/15/2023 Contract End Date: 11/30/2023</p>											
Brown University	Employment Current Employment	Self	-								
<p>Title: Professor Start Date: 07/01/2014 Additional Information:</p> <p>Position Description: Center Co-Director End Date:</p>											
Centers for Disease Control and Prevention	Consultant	Self	\$6000.00								
<p>Category: Consultant End Date: 06/30/2024 Compensation Type: Cash Compensation: Yes</p> <p>Start Date: 11/15/2023</p> <table border="1"> <thead> <tr> <th>Year</th> <th>Amount</th> <th>Amount Type</th> <th>Compensation Type</th> </tr> </thead> <tbody> <tr> <td>2024</td> <td>\$6,000.00</td> <td>Estimated</td> <td></td> </tr> </tbody> </table> <p>Additional Information: Training workshop for CDC staff</p>				Year	Amount	Amount Type	Compensation Type	2024	\$6,000.00	Estimated	
Year	Amount	Amount Type	Compensation Type								
2024	\$6,000.00	Estimated									
Kidney disease improving clinical outcomes	Grant / Contract	Self	\$450000.00								

Entity	Type	Interest Held By	Value
Recipient Name: Brown University Grant / Contract Description: Systematic review and guideline development (ADPKD) Contract Start Date: 09/01/2021 Grant / Contract Amount: \$450,000.00 Additional Information: Lead Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 12/15/2023 Contract End Date: 06/30/2024			
Kidney disease improving clinical outcomes	Consultant	Self	\$15000.00
Category: Consultant End Date: 06/30/2024 Compensation Type: Cash Compensation: Yes Start Date: 11/01/2020			
Year	Amount	Amount Type	Compensation Type
2023	\$15,000.00	Actual	
Additional Information: Conduct systematic reviews for guideline update			
National Academies of Sciences, Engineering, and Medicine	Consultant	Self	-
Category: Consultant End Date: 01/15/2023 Compensation Type: Unpaid Compensation: No Additional Information: Workgroup panel member for daily recommended intake review (ended) Start Date: 11/30/2021			
Society of gynecologic surgeons	Consultant	Self	\$18000.00
Category: Consultant End Date: Ongoing / No Known End Date Compensation Type: Cash Compensation: Yes Start Date: 01/01/2007			
Year	Amount	Amount Type	Compensation Type
2023	\$18,000.00	Actual	
Additional Information: Methodological consultation to the society's systematic review group			
Wolters Kluwer Health, Inc.	Other	Self	\$1200.00
Category: Other End Date: Ongoing / No Known End Date Compensation Type: Cash Compensation: Yes Start Date: 06/01/2016			
Year	Amount	Amount Type	Compensation Type
2023	\$1,200.00	Estimated	
Additional Information: Chapter author			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Ethan Balk

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	Treatment of postpartum mental health conditions, ongoing (AHRQ EPC)
Hypertension	None
Menopausal Therapy	None
Migraine	Treatment of perinatal migraine, 2021 (AHRQ EPC)
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Ethan Balk

4/10/2024



Signature

Date

Thomas Cooney

Disclosure Purpose: Annual Governance Disclosure 2024-25, CME Conference, Adam Rodman's podcast, AMA Delegation

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
U.S. Department of Veterans Affairs	Employment Current Employment	Self	-

Title: Staff Physician
Start Date: 08/08/1979
Additional Information:

Position Description: Attending physician, supervising residents and medical students
End Date: Ongoing / No Known End Date

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Thomas G Cooney

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Thomas G Cooney



04/09/2024

Signature

Date

Jacob Cross

Discloser Identifier: 00084806

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Jacob Cross	Employment Current Employment	Self	-
Title: President Start Date: 01/01/2012 Additional Information:			
Position Description: President and CEO End Date: Ongoing / No Known End Date			
Ochsner Health System	Consultant Current Employment	Self	-
Category: Consultant End Date: Compensation Type: Cash Compensation: Additional Information:			
Start Date: 04/01/2020			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

J. Thomas Cross, MD

Name



Signature

4/9/2024

Date

Nick Fitterman

Disclosure Purpose: Annual Governance Disclosure 2024-25, CME Contributor

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
nick fitterman	Employment Current Employment	Self	-

Title: executive director Huntington Hospital
Start Date: 10/03/2018
Additional Information:

Position Description: executive director
End Date: Ongoing / No Known End Date

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Nick fitterman

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).


Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	none
Hypertension	none
Menopausal Therapy	none
Migraine	none
Obesity	none
Osteoporosis	none
Diabetes	none
Cardiovascular Disease	none

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Nick fitterman



Disclosure Purpose: Contractor/Guest Annual Disclosure 2022 - 23, Contractor/Guest Annual Disclosure 2024 - 25, Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
University of Arkansas at Little Rock	Employment Current Employment	Self	-
Title: Associate Dean/Professor of History Start Date: 08/15/1991 Additional Information:		Position Description: Responsible for curriculum and student success in the College of Humanities, Arts, Social Sciences and Education End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Print Name

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years If none, write "None"
Depression	none
Hypertension	none
Menopausal Therapy	none
Migraine	none
Obesity	none
Osteoporosis	none

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Print Name Johanna Miller Lewis


Signature

4/9/2024
Date

Amy Linsky

Discloser Identifier: 03620908

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
US Department of Veterans Affairs	Employment Current Employment	Self	-

Title: Physician
Start Date: 07/01/2010
Additional Information:

Position Description: Clinician-investigator
End Date: Ongoing / No Known End Date

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	none
Hypertension	none
Menopausal Therapy	none
Migraine	none
Obesity	none
Osteoporosis	none

<https://orcid.org/0000-0002-8090-3431>

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Amy Linsky

Name

Signature

April 9, 2024

Date

Michael Maroto

Discloser Identifier: 03367997

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
The Maroto Law Group, PC	Employment Current Employment	Self	-
Title: Managing Partner Start Date: 12/01/1994 Additional Information:		Position Description: Attorney End Date:	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Michael Maroto

Name

Michael Maroto Digitally signed by Michael Maroto
Date: 2024.04.25 15:59:39 -04'00'

Signature

Date

Matthew Miller

Discloser Identifier: 00020934

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Perelman School of Medicine, University of Pennsylvania	Employment Current Employment	Self	-
Title: Clinical Professor of Medicine Start Date: 07/01/2001 Additional Information:		Position Description: Physician End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	NONE
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Matt Miller MD

Name

Matt Miller MD

Signature

4/13/24

Date

Adam Obley

Disclosure Annual Governance Disclosure 2024-25 (Expiration Date: 04/15/2025), Population Health Committee **Employment** Currently
Purpose: (Expiration Date: 04/15/2025), Internal Medicine Meeting 2024 faculty (Expiration Date: 04/15/2025), ACP/ Annals Forum (Expiration Date: 04/15/2025) **Information:** Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Center for Evidence-based Policy	Employment	Self	-
Title: Clinical Epidemiologist Start Date: 08/01/2014 Additional Information: Position Description: CEbP supported 0.5 FTE until August 2020 CEbP supports 0.05 FTE since August 2020 Non-FTE consultative work since September 2021 End Date: Ongoing / No Known End Date			
Milbank Memorial Fund	Travel	Self	\$10000.00
Location(s): Various meetings and state workshops (as faculty) Travel End Date: 03/31/2022 Valuation Date: 04/14/2022 Additional Information: Travel Start Date: 01/01/2015 Estimated Value: \$10,000.00 Purpose: Faculty for Evidence-informed Health Policy Workshops			
Oregon Medical Association	Fiduciary Officer	Self	-
Official Title: Trustee at-large Compensation Type: Unpaid Start Date: 01/01/2021 Compensation: Additional Information: Position Description: Trustee End Date:			
Portland VA Medical Center	Employment Current Employment	Self	-
Title: Associate Chief of Staff for Community Care and Staff Physician Start Date: 07/01/2013 Additional Information: Position Description: ACOS for Community Care, Chief of Staff Office Staff Physician, Division of General Medicine, Department of Hospital and Specialty Medicine End Date: Ongoing / No Known End Date			
School of Medicine, Oregon Health and Science University	Employment	Self	-
Title: Associate Professor of Medicine Start Date: 07/01/2013 Additional Information: Position Description: Faculty appointment, not compensated End Date: Ongoing / No Known End Date			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Adam Obley

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee and Population Health and Medical Sciences Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Adam Obley

Signature

Date

Discloser Identifier: 00090725

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Agency for Healthcare Research and Quality	Grant / Contract	Other - my employer	\$2000000.00
<p>Recipient Name: Stanford University Grant / Contract Description: Stanford Health Services Research Training Program, training grant for health poliyc Contract Start Date: 07/01/2018 Grant / Contract Amount:\$2,000,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/29/2022 Contract End Date: Ongoing / No Known End Date</p>			
Centers for Disease Control and Prevention	Grant / Contract	Self	\$960000.00
<p>Recipient Name: Stanford University Grant / Contract Description: The goals are to conduct health and economic modeling to inform decision-making on HIV, HCV, STDs Contract Start Date: 09/30/2019 Grant / Contract Amount:\$960,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 04/26/2021 Contract End Date: Ongoing / No Known End Date</p>			
NIH	Grant / Contract	Self	\$424600.00
<p>Recipient Name: Stanford University Grant / Contract Description: Project Number: R21MD019394 Public health surveillance Contract Start Date: 04/01/2024 Grant / Contract Amount:\$424,600.00 Additional Information: Project Number: R21MD019394 Source of Support: NIH Major Goals: The goal of this project is to use RADx-UP COVID-19 data to test the performance of public health resource allocation and infection surveillance tools toward mitigating health disparities during future pandemics. Project/Proposal Start and End Date: (MM/YYYY) (if available): 04/01/2024 – 03/31/2026 Total Award Amount (including Indirect Costs): \$424,600</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 01/18/2024 Contract End Date:</p>			
NIH	Grant / Contract	Self	\$2023500.00
<p>Recipient Name: Stanford University Grant / Contract Description: Sexual harassment training of principal investigators. Goal: To train PIs of T32s. Contract Start Date: 07/01/2022 Grant / Contract Amount:\$2,023,500.00 Additional Information: I am co-investigator on the grant</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 01/18/2024 Contract End Date: 06/01/2027</p>			
NIH	Grant / Contract	Other - my employer	\$2318888.00
<p>Recipient Name: Stanford University Grant / Contract Description: To identify an optimal SAR-COV 2 screening strategy in dialysis facilities Contract Start Date: 01/02/2022 Grant / Contract Amount:\$2,318,888.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/29/2022 Contract End Date: Ongoing / No Known End Date</p>			
NIH	Grant / Contract	Self	\$4000000.00

Entity	Type	Interest Held By	Value
<p>Recipient Name: Stanford University Grant / Contract Description: Grant to study opioid use, HIV, HCV. Contract Start Date: 11/01/2019 Grant / Contract Amount:\$4,000,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 04/26/2021 Contract End Date: Ongoing / No Known End Date</p>			
NIH	Grant / Contract	Self	\$1000000.00
<p>Recipient Name: Stanford University Grant / Contract Description: Grant to study implicit bias in diagnostic decision making Contract Start Date: 01/01/2020 Grant / Contract Amount:\$1,000,000.00 Additional Information: Co-investigator on NIH grant, i don't know full amount, I get salary support</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 04/26/2021 Contract End Date: Ongoing / No Known End Date</p>			
NIH	Grant / Contract	Other - my employer	\$2023500.00
<p>Recipient Name: Stanford University Grant / Contract Description: To train PIs to understand implicit bias and methods for having fair and inclusive research groups. Contract Start Date: 07/01/2022 Grant / Contract Amount:\$2,023,500.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 08/29/2022 Contract End Date: Ongoing / No Known End Date</p>			
School of Medicine, Stanford University	Employment Current Employment	Self	-
<p>Title: Professor Start Date: 07/01/1991 Additional Information:</p> <p>Position Description: Professor End Date: Ongoing / No Known End Date</p>			
Stanford University	Grant / Contract	Self	\$46296.00
<p>Recipient Name: Stanford Grant / Contract Description: Median survival to life expectancy: cancer trial outcomes Contract Start Date: 03/01/2022 Grant / Contract Amount:\$46,296.00 Additional Information: I am co-investigator on this internal Stanford grant to study methods of translating cancer trial outcomes to clinical benefit and population health</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 01/05/2023 Contract End Date:</p>			
U.S. Department of Veterans Affairs	Grant / Contract	Self	\$321000.00
<p>Recipient Name: VA Palo Alto Health Care System Grant / Contract Description: Grant to study the cost effectiveness of treatment for opioid use disorder Contract Start Date: 04/01/2018 Grant / Contract Amount:\$321,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 04/26/2021 Contract End Date: 12/31/2021</p>			

Intellectual Property

Type	Is Licensed	Interest Held By	Value
Other Intellectual Property - USPSTF	-	Self	-
<p>Description: USPSTF Additional Information: Guideline development Income: Additional Information: Guideline development</p> <p>Income Source: NONE</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence



Relevant Publications and Other Intellectual Interests for Ongoing Projects

Print Name Douglas K Owens

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Print Name Douglas K Owens

4-9-24

Douglas K Owens

Signature

Date

CURRICULUM VITAE

Douglas K. Owens, M.D., M.S.

Address:

Department of Health Policy
Center for Health Policy
615 Crothers Way
Stanford, California 94305-6006
Voice: 650 723-0933 Fax: 650 723-1919
Email: owens@stanford.edu

Education:

1978 B.S. Stanford University; Stanford, California
1982 M.D. University of California - San Francisco;
San Francisco, California
1991 M.S. Stanford University; Stanford, California

Postdoctoral Training:

1982 – 1983 Internship, Internal Medicine, Hospital of the University of Pennsylvania;
Philadelphia, Pennsylvania
1983 – 1985 Residency, Internal Medicine, Hospital of the University of Pennsylvania;
Philadelphia, Pennsylvania
1985 – 1986 Post-Doctoral Research, Stanford University; Stanford, California. Research
in Decision Analysis supported by a grant from the National Fund for
Medical Education
1988 – 1991 Fellowship in Health Care Research and Health Policy, Stanford University;
Stanford, California.

Licensure and Certification:

1985 American Board of Internal Medicine
1985 State of California, Board of Registration in Medicine

Hospital Appointments:

1977 – 1980 Research Assistant, Stanford University Medical Center; Stanford, California
(research in neurochemistry)
1984 – 1985 Staff Physician, Emergency Medicine Associates, Hospital of the University
of Pennsylvania Emergency Department; Philadelphia, Pennsylvania (Part-
time position in an adult urgent care clinic).

1985 Staff Physician, Kaiser Permanente Medical Center; Oakland, California
(Part-time position in the Emergency Department)

1985 – present Staff Physician, Ambulatory Care, Department of Veterans Affairs Medical
Center; Palo Alto, California

1986 – 1988 Chief, General Medical Clinic, Ambulatory Care, Department of Veterans
Affairs Medical Center; Palo Alto, California

1987 – 1988 Acting Associate Chief of Staff for Ambulatory Care, Department of
Veterans Affairs Medical Center; Palo Alto, California (Administrative chief
of 27 medical and surgical outpatient clinics)

1991 – 1992 Chief, General Medical Clinic, Ambulatory Care, Department of Veterans
Affairs Medical Center; Palo Alto, California

**Academic
Appointments:**

1985 – 1986 Clinical Instructor in Medicine, Division of General Internal Medicine,
Stanford University School of Medicine; Stanford, California

1987 – 1991 Clinical Assistant Professor of Medicine, Division of General Internal
Medicine, Stanford University School of Medicine; Stanford, California

1991 – 1997 Assistant Professor of Medicine, Division of General Internal Medicine and
Section on Medical Informatics, Department of Medicine, Stanford
University School of Medicine

1991 – 2007 Director, Fellowship in Ambulatory Care Research and Practice, Department
of Veterans Affairs Medical Center; Palo Alto, California

1991 – 1993 Chief, Section of General Internal Medicine, Department of Veterans Affairs
Medical Center; Palo Alto, California

1992 – 1997 Assistant Professor of Health Research and Policy (by courtesy), Department
of Health Research and Policy, Stanford University School of Medicine

1994 – 2011 Associate Director, Fellowship Program in Health Care Research and Health
Policy, Stanford University

1994 – 2021 Director, Postdoctoral Fellowship in Medical Informatics, VA Medical
Center, Palo Alto and Stanford University, Stanford, California.

1997 – 2006 Associate Professor of Medicine, Center for Primary Care and Outcomes
Research, Department of Medicine, Stanford University School of Medicine

1997 – 2006 Associate Professor of Health Research and Policy (by courtesy),
Department of Health Research and Policy, Stanford University School of
Medicine

1997 – 2011 Director, Program on Clinical Decision Making and Guideline Development,
Center for Primary Care and Outcomes Research, Stanford, California.

2002 – 2010	Director, Stanford University-University of California, San Francisco Evidence Based Practice Center, funded by the Agency for Healthcare Research and Quality.
2003 – 2004	Acting Director, Center for Primary Care and Outcomes Research (PCOR), Stanford University School of Medicine, and Center for Health Policy (CHP), Institute for International Studies, Stanford University.
2005 – 2021	Director, Physician Post-Residency Fellowship Program in Health Services Research and Development, Veterans Affairs Palo Alto Health Care System, Palo Alto, California.
2006 – present	Professor of Medicine, Center for Primary Care and Outcomes Research, Department of Medicine, Stanford University School of Medicine
2006 – 2019	Professor of Health Research and Policy (by courtesy), Department of Health Research and Policy, Stanford University School of Medicine
2011 – 2018	Associate Director, Center for Innovation to Implementation, Health Services Research and Development Center of Excellence, VA Palo Alto Health Care System, Palo Alto, California
2011 – present	Director, Center for Health Policy, Freeman Spogli Institute for International Studies, Stanford University
2011 – 2021	Director, Center for Primary Care and Outcomes Research, Stanford University
2011 – 2014	Director, Fellowship Program in Health Care Research and Health Policy, Stanford University
2011 – present	Senior Fellow, Freeman Spogli Institute for International Studies, Stanford University
2012 – present	Professor of Management Science and Engineering (by courtesy), Stanford University
2013 – 2015	Co-Director, Stanford Center for Population Health Sciences, Stanford University
2016 – 2017	Interim Division Chief, Stanford Prevention Research Center (SPRC), Stanford University
2017 – present	Executive Committee, Freeman-Spogli Institute for International Studies
2018 – present	Co-director, Stanford-AHRQ Fellowship in Health Services Research
2021 – present	Chair, Department of Health Policy, School of Medicine, Stanford University.

Honors and Awards:

1978	Graduated with Distinction, Biological Sciences, Stanford University, Stanford California
------	---

- 1978 Phi Beta Kappa Honor Society, Stanford University, Stanford California
- 1982 Gold Headed Cane Honor Society, University of California School of Medicine, San Francisco, California
- 1991 2nd place, Sixth Annual Decision Analysis Special Interest Group National Student Competition, Operations Research Society of America
- 1991 1st Place, Ninth Annual Lee Lusted National Post-doctoral Student Research Competition, Thirteenth Annual Meeting, Society for Medical Decision Making
- 1992 Research Associate Career Development Award, VA Health Services Research and Development Service (1992 to 1995)
- 1995 Senior Research Associate Career Development Award, VA Health Services Research and Development Service (1995 to 1999)
- 1996 Annual Outstanding Paper Award, Society for Computer Simulation International, Simulation in the Medical Sciences Conference, 1996
- 2000 Elected member, The American Society for Clinical Investigation (ASCI)
- 2003 Center for Primary Care and Outcomes Research Division Teaching Award, Stanford University, Stanford, California
- 2007 Under Secretary's Award for Outstanding Achievement in Health Services Research, U.S. Department of Veterans Affairs
- 2008 Elected member, Association of American Physicians (AAP)
- 2009 Elected Fellow, American College of Physicians
- 2010 John Eisenberg Award in Recognition of Exemplary Leadership in the Practical Application of Medical Decision Making Research, Society for Medical Decision Making
- 2010 Center for Primary Care and Outcomes Research Division Teaching Award, Stanford University, Stanford, California
- 2011 Henry J. Kaiser, Jr, Endowed Professorship, Stanford University
- 2014 British Medical Association (BMA) Medical Book Awards, 2014, Highly Commended, section on Health and social care, for Medical Decision Making, 2nd edition.
- 2017 Elected, Alpha Omega Alpha Medical Honor Society
- 2019 MERIT Award, National Institutes on Drug Abuse (NIDA), National Institutes of Health.

Memberships:

Member, American College of Physicians
 Member, Society for Medical Decision Making

Research Interests: Methods for the development of clinical guidelines
 Analytic methods for medical decision making
 Technology assessment
 Quantitative policy analysis: HIV disease, cardiovascular disease

Selected Committees, Boards and Consultantships

1991 – 1992	Nominating Committee, Society for Medical Decision Making, Washington, D.C.
1991 – 1993	Consultant, Agency for Health Care Policy and Research, HIV Guideline Development Panel; Rockville, Maryland
1991 – 1994	VA Western Region Ambulatory Care and Education Program Development and Evaluation Subcommittee Study Section
1991 – 2002	Doctoral Dissertation Qualifying Examination Committee, Medical Information Sciences Program, Stanford University, Stanford, California
1993 – 1994	Review Committee, Ambulatory Care Fellowship Programs, Department of Veterans Affairs Central Office; Washington D.C.
1993 – 2004	Research Review Committee, Center for Health Care Evaluation, VA Health Services Research and Development Field Program; Palo Alto, California
1994	Special Scientific Review Committee, Development of Practice Guidelines, Agency for Health Care Policy and Research; Bethesda, Maryland
1994 – 1995	Chair, Pharmacy and Therapeutics Committee, VA Medical Center, Palo Alto
1994 – present	Admissions Committee, Graduate Program in Health Services Research, Stanford University
1994	Special Scientific Review Committee, Agency for Health Care Policy and Research; Bethesda, Maryland
1994 – 1995	Consultant, National Institute of Child Health and Human Development, National Institutes of Health, Guideline Development Panel, Adolescent HIV; Rockville, Maryland
1995	Chair, Abstract Selection Committee, National Research Service Award (NRSA) Trainee Research Conference; Chicago, Illinois
1996 – 1999	Editorial Board, Medical Decision Making
1995 – 1997	Trustee, Society for Medical Decision Making, Washington, DC.
1996	Scientific Program Co-Chair, Second Annual National Research Service Award (NRSA) Trainee Research Conference, Atlanta, Georgia; June 8, 1996
1997	VA Cooperative Studies Evaluation Committee
1997	VA HSR&D Scientific Review and Evaluation Committee, Washington, D.C.

1997 – 2000	Financial Management Group, Sierra Pacific Veterans Integrated Service Network, VA, San Francisco, California
1997 – 2010	Executive Committee, Evidence-Based Practice Center, Stanford University and University of California San Francisco
1997 – 2010	Governing Committee, Evidence-Based Practice Center, Stanford University and University of California San Francisco
1997 – 2000	Professional Standards Board, VA Palo Alto Health Care System
1997 – 2001	Executive Committee, Section on Medical Informatics, Stanford University
1997 – 1998	President Elect, Society for Medical Decision Making, Washington, D.C.
1998, 2000	Admissions Committee, Medical Information Sciences Training Program, Stanford University
1998 – 2009	VA Quality Enhancement Research Initiative, National Executive Committee, HIV Disease, Washington, D.C.
1998 – 1999	President, Society for Medical Decision Making, Washington, D.C.
1998 – 2003	Advisory Board, Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard University
1999 – 2000	Past President, Society for Medical Decision Making, Washington, D.C.
1999	VA Career Development Program Review Committee, Washington, D.C.
2000	Consultation on Anti-retroviral Therapy for HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, December 4.
2001 – 2010	Clinical Efficacy Assessment Subcommittee, American College of Physicians, Philadelphia, Pennsylvania.
2001 – 2003	Blue Shield of California, Medical Policy Committee on Quality and Technology, San Francisco, California.
2001	Consultation on Prevention Effectiveness at CDC: Development of a Five-Year Plan, Centers for Disease Control and Prevention, Atlanta, Georgia, July 12.
2002	Consultation on Use of Partially Effective HIV Vaccines, Centers for Disease Control and Prevention, Atlanta, Georgia, January 16-17.
2002 – 2004	Chair, 2004 Annual Meeting, Society for Medical Decision Making, Atlanta, Georgia.
2002	Guest Editor, Special Supplement on Clinical Decision Making and Public Health, Medical Decision Making.
2002 – 2004	Steering Committee, VA Health Services Research Enhancement Award Program (REAP): Enhancing VA Health Services Research in Patient-Centered Care.

2002	Consultation on Use of Partially Effective HIV Vaccines. World Health Organization, UNAIDS, and Centers for Disease Control and Prevention, Geneva, Switzerland.
2003 – 2004	Stanford Institute for International Studies, Standing Search Committee and Executive Committee
2004	Co-chair, Scientific Abstract Selection Committee, 27 th Annual Meeting, Society for General Internal Medicine, Chicago, Illinois, May 2004.
2004 – 2010	Admissions Committee, Biomedical Informatics Training Program, Stanford University
2004 – 2012	Research and Development Review Committee, VA Palo Alto Health Care System
2005 – 2009	Chair, Clinical Efficacy Assessment Subcommittee, American College of Physicians, Philadelphia, Pennsylvania.
2005 – 2006	Education Committee, American College of Physicians, Philadelphia, Pennsylvania.
2006 – 2010	Data Safety Monitoring Board, VA Cooperative Study #553, Chemotherapy After Prostatectomy, San Francisco, California
2007 – 2009	Advisory Committee on the Development of Interactive Decision Aids, Agency for Healthcare Research and Quality
2007 – 2009	Advisory Research Committee, Palo Alto Institute for Research and Education (PAIRE), VA Palo Alto Health Care System
2007 – 2012	Expert Advisory Panel for the National Guideline and National Quality Measures Clearing House, Agency for Healthcare Research and Quality
2008	National Institutes of Health, AIDS, Clinical Studies, and Epidemiology (ACE) Study Section
2008 – 2010	Technical Expert Advisory Panel on Clinical Decision Support, Agency for Healthcare Research and Quality
2008 – 2012	Chair, Research and Development Review Committee, VA Palo Alto Health Care System
2008 – 2012	Board of Directors, Palo Alto Institute for Research and Education (PAIRE), VA Palo Alto Health Care System
2008 – 2009	Committee on Effectiveness of National Biosurveillance Systems: BioWatch and the Public Health System, Institute of Medicine and National Research Council, Washington D. C.
2009 – 2010	Immediate Past Chair, Clinical Efficacy Assessment Subcommittee, American College of Physicians, Philadelphia, Pennsylvania.
2010	Technical Expert Panel, systematic review of methods for decision modeling, Agency for Healthcare Research and Quality

2010	Technical Expert Panel, systematic review of diagnosis and management of obstructive sleep apnea, Agency for Healthcare Research and Quality
2010 – 2011	International Society for Pharmacoeconomics and Outcomes Research- Society for Medical Decision Making Task Force on Good Modeling Research Practices
2011 – 2021	Executive Committee, Center for Health Care Evaluation, VA Palo Alto Health Care System, Palo Alto, California
2012 – 2015	United States Preventive Services Task Force, funded by the Agency for Health Care Research and Quality, Rockville, Maryland
2012 – 2016	Second Panel on Cost Effectiveness in Health and Medicine, Washington, D.C.
2012 – 2013	Technical Expert Panel, Guidance on Use of Decision Modeling in Systematic Reviews, Agency for Healthcare Research and Quality, Rockville, Maryland
2013 – present	Stanford Health Policy Forum Advisory Committee
2014	Co-chair, University-wide Provost’s committee to evaluate policy initiatives at Stanford.
2014 – present	Editorial Board, Annals of Internal Medicine
2014 – present	Chair, External Advisory Board, University of California San Francisco Global Health Economics Consortium
2015 – present	Executive Committee, Stanford Doctoral Program in Health Policy
2016 – 2017	Dean’s Committee on Future of Biomedicine at Stanford
2017 – 2019	Vice-Chair, United States Preventive Services Task Force
2018 – 2020	National Academies of Sciences, Engineering and Medicine’s Committee on Evidence-Based Practices for Public Health Emergency Preparedness and Response
2018 – 2019	Stanford President’s Precision and Population Health Design Team, Stanford University.
2019 – 2020	Chair, United States Preventive Services Task Force
2020 – 2021	Past Chair, United States Preventive Services Task Force
2021 – present	Clinical Guideline Committee, American College of Physicians
2021 – present	Executive Committee, Stanford University School of Medicine
2021 – present	Justice, Equity, Diversity and Inclusion Committee, Department of Health Policy

2022 – present	Health Equity Excellence Action Planning Workgroup, School of Medicine, Stanford University
2022 – present	Advisory Board of the Academic Council, Stanford University
2023 – present	Chair, Advisory Board of the Academic Council, Stanford University

Selected Teaching Experience (Stanford University):

1985 – 1992	Lecture series on Outpatient Medicine, two conferences per week on a variety of topics, Ambulatory Care, Department of Veterans Affairs Medical Center; Palo Alto, California
1986 – 1987	"Probability Assessment," Medical Information Sciences 211
1986 – 1992	"Test Performance"; "Bias in Study Design"; "Literature Evaluation"; "Decision Theory"; "Threshold Analysis"; "Preventive Health Screening"; "Assessing Patient Preferences"; "Cost-Effectiveness Analysis"; Stanford Faculty Development Program
1986 – 1992	"Problem List and Differential Diagnosis"; "Clinical Reasoning"; Preparation for Clinical Medicine
1987 – 1988	Co-Director, Clerkship in Ambulatory Care
1988	Course Coordinator, Clinical Reasoning Section in Preparation for Clinical Medicine
1991	"The Interface of Medicine and Economics," Human Values in Medicine
1991	"Principles of Screening: Human immunodeficiency virus infection," Health Research and Policy 200
1991 – 1993	"Decision Theory and Screening for Human Immunodeficiency Virus," Graduate School of Business 243 (Analysis of Costs, Risks and Benefits of Health Care)
1991 – 1993	"Health Policy and Informatics," Medical Information Sciences 210.
1992	"Occupational Risk Assessment in the Medical Environment," Engineering-Economic systems 421.
1992 – 1993	"Ethical Dilemmas and AIDS," Medical Ethics II, Medicine 250B
1993 – 2008	Co-Instructor, Health Research and Policy 283, (Seminar in Research Methods)
1994	"Screening for HIV Disease," Health Research and Policy 202 (Biostatistics and Epidemiology)
1995	"Model Based Analyses of Transmission Risks and screening programs: HIV in the medical workplace," Operations Research
1996	"Introduction to Decision Models", and "Clinical Practice Guidelines", Health Research and Policy 200

1996	"Screening Physicians and Patients for HIV", Human Biology 142 (Impact of AIDS)
1997 – 1998	Co-instructor, Engineering 63, Engineering Applications in Medicine, 3 units, Fall Quarter
1998 – 2010	Co-instructor, Economics 332, Analysis of Costs, Risks, and Benefits in Health Care, Graduate School of Business
2001	"Translating Clinical Trials into Improved Health", Design and Conduct of Clinical Trials, Fall 2001, School of Medicine.
2001 – present	"Screening for HIV Disease", Management Science and Engineering 290
2003 – 2008	"Cost effectiveness of HIV Vaccines", Management Science and Engineering 292
2009 – present	"Cost effectiveness of Screening for HIV", Management Science and Engineering 292
2011 – present	Course Instructor, Health Research and Policy 392, Analysis of Costs, Risks, and Benefits in Health Care, Graduate School of Business, Department of Medicine, Department of Health Policy (depending on year)

Graduate Students/Postdoctoral Fellows Supervised:

Postdoctoral Fellows:

1. Thomas W. McDonald, M.D, VA Ambulatory Care Fellowship, Project: Evaluation of a physician workstation
2. Brian Gage, M.D. (thesis advisor), VA Ambulatory Care Fellowship, Project: Cost-effectiveness of antithrombotic therapy for prevention of strokes in patients with atrial fibrillation
3. David Stern, M.D. VA Ambulatory Care Fellowship, Project: Evaluation of the role of journal clubs in medical education
4. Barry Rotman, M.D., VA Ambulatory Care Fellowship, Project: Impact of a physician workstation on costs of care
5. Ida Sim, M.D., Ph.D. (thesis advisor), VA Ambulatory Care Fellowship, Project: Computer-based publication of clinical trial data; VA Postdoctoral Medical Informatics Fellowship, Project: A computer-based trail bank
6. Cindy Mason, Ph.D., VA Medical Informatics Fellowship, Project: Development of a user interface for research databases
7. Anne Dembitzer, M.D. (thesis advisor), VA Ambulatory Care Fellowship, Project: Cost-effectiveness of mammography
8. Michael Gould, M.D., Fellowship Program in Health Care Research and Health Policy, Project: Staging non-small cell lung cancer
9. Patricia Pepper, M.D. (thesis advisor). VA Ambulatory Care Fellowship, Project: Perioperative complications in Parkinson's patients

10. Ahmed Bayoumi, M.D., VA Ambulatory Care Fellowship, Project: Cost effectiveness analysis of prophylaxis for opportunistic infection in HIV disease
11. Paul Heidenreich, MD, Fellowship Program in Health Care Research and Health Policy, Project: Cost-effectiveness of echocardiography for diagnosis of endocarditis.
12. Eric Bradford, MD, Fellowship Program in Health Care Research and Health Policy.
13. Dena Bravata, MD, VA Ambulatory Care Fellowship, Project: A systematic review of the effect of liver transplantation on quality of life
14. Amber Barnato, MD, Fellowship Program in Health Care Research and Health Policy, Project: Cost effectiveness of potential vaccines for *Coccidioides immitis*
15. Lauren Gerson, MD, Fellowship Program in Health Care Research and Health Policy, Project: Management of anticoagulation in patients undergoing endoscopy
16. Thomas Alloggiamento, MD, VA Ambulatory Care Fellowship, Project: Cost-effectiveness of revascularization of single-vessel coronary artery disease.
17. Herb Szeto, MD, VA Ambulatory Care Fellowship, Project: Cost-effectiveness of strategies to diagnose pulmonary embolism.
18. Mark Schleinitz, MD, VA Ambulatory Care Fellowship, Project: Cost-effectiveness of clopidogrel for prevention of stroke.
19. Melissa Fisher, MD, VA Ambulatory Care Fellowship, Project: Educational curricula development..
20. Otto Lin, MD, Fellowship Program in Health Care Research and Health Policy, Project: Cost effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis secondary to chronic hepatitis C.
21. Bahman Nouri, MD, VA Ambulatory Care Fellowship, Project: Cost effectiveness of vaccination for anthrax.
22. Rohini Vij, MD, Fellowship Program in Health Care Research and Health Policy, Project: Cost effectiveness of photodynamic therapy for high grade dysplasia of the esophagus.
23. Pete Groeneveld MD, Fellowship Program in Health Care Research and Health Policy, Project: Cost effectiveness of training unselected laypersons in cardiopulmonary resuscitation and defibrillation.
24. Corinna Haberland MD, Fellowship Program in Health Care Research and Health Policy, Project: Use of information technologies for biodefense.
25. Ram Duriseti, MD, VA Medical Informatics Fellowship (2002-2004), Project: Inference methods for decision making in the emergency room.
26. Jon-Erik Holty, MD, VA Ambulatory Care Fellowship (2002-2005), Project: Regionalization of bioterrorism response.
27. David Buckeridge, MD, VA Medical Informatics Fellowship (and doctoral thesis defense committee), Doctoral Dissertation, Biomedical Informatics, (2002-2005) Thesis: Evaluation of outbreak detection in public health surveillance systems.
28. Michael Ong, MD, PhD, VA Ambulatory Care Fellowship (2003-2005), Project: Tobacco and health.
29. Roni Zeiger, MD, PhD, VA Postdoctoral Medical Informatics Fellowship (2003-2006).

30. Smita Nayak, MD, VA Ambulatory Care Fellowship (2003-2006), Project: Best Practices for Quality Health Care.
31. Hau Liu MD, Fellowship Program in Health Care Research and Health Policy (2004-2007), Project: Cost effectiveness of treatments for osteoporosis.
32. Nancy Lin, PhD. Fellowship Program in Health Care Research and Health Policy (2005-2007), Project: Closing the quality gap: care coordination.
33. Swati Tole MD, (thesis advisor) Fellowship Program in Health Care Research and Health Policy (2005-2008), Project: Cost effectiveness of screening for HIV in Russia.
34. Kanaka D. Shetty MD, VA Ambulatory Care Fellowship (2005-2008), Project: Quality improvement strategies to prevent nosocomial infections.
35. Katherine Herz, MD, (thesis advisor) Fellowship Program in Health Care Research and Health Policy (2005-2008), Project: Cost effectiveness of alternative therapies for malaria.
36. Amar Desai MD, Fellowship Program in Health Care Research and Health Policy (2006-2007), Project: Cost effectiveness of alternative strategies for hemodialysis.
37. Nayer Khazeni MD, (thesis advisor) Fellowship in Pulmonary and Critical Care (2006-2008), Project: The cost effectiveness of prophylactic vaccination and antiviral strategies in a southeast asian avian influenza pandemic.
38. Eran Bendavid MD, (thesis advisor) Fellowship Program in Health Care Research and Health Policy (2006-2009), Project: Cost effectiveness of alternative strategies to manage HIV disease in developing countries.
39. Daniella Perloth, MD, VA Informatics Fellowship (2007-2009), Project: Cost effectiveness of preparedness for pandemic influenza.
40. Jennifer Schneider, MD, (thesis advisor) VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2007-2010), Project: Cost effectiveness of screening for tuberculosis.
41. Barrett Levesque, MD, Fellowship Program in Health Care Research and Health Policy (2008-2010), Project: Cost effectiveness of alternative diagnostic strategies for Crohn's disease.
42. Keane Lee, MD, Cardiovascular Medicine (2008-2010), Project: Cost effectiveness of screening for c-reactive protein in patients at intermediate risk for cardiovascular disease.
43. Kathleen O'Leary, MD, Fellowship Program in Health Care Research and Health Policy (2008-2011).
44. Crystal Smith-Spangler, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2008-2011), Project: Strategies to reduce cardiovascular disease by reducing salt in processed foods.
45. Vivian Tsai, MD, Fellowship Program in Health Care Research and Health Policy (2009-2011).
46. Kit Delgado, MD, Fellowship Program in Health Care Research and Health Policy (2009-2012).
47. C. Torrey Simons, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2009-2012).
48. Shanthi Kappagoda, MD, Fellowship Program in Health Care Research and Health Policy (2010-2013), Project: preventing mother-to-child transmission of HIV in resource-limited settings.

49. Kevin Ericson, MD, Fellowship Program in Health Care Research and Health Policy (2010-2013), Project: Use of statins in patients with chronic kidney disease.
50. Jonathan Shaw, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2011-2014).
51. Suzann Pershing, MD, Fellowship Program in Health Care Research and Health Policy (2011-2013).
52. Zachary Kastenber, MD, Fellowship Program in Health Care Research and Health Policy (2011-2014).
53. Lauren Aquino Shluzas, PhD, VA Postdoctoral Informatics Fellowship (2011-2013).
54. Kimberly Brayton, MD, Fellowship Program in Health Care Research and Health Policy (2012-2014)
55. Graham Abra, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2012 to 2013)
56. Yan Liu, PhD, VA Postdoctoral Informatics Fellowship (2013 to 2015).
57. Tiffany Leung, MD, VA Postdoctoral Informatics Fellowship (2013 to 2015).
58. Megan Vanneman, PhD, VA Postdoctoral Health Services Research Fellowship (2013 to 2016).
59. Hawre Jalal, PhD, VA Postdoctoral Informatics Fellowship (2013 to 2015).
60. Manali Patel, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2013 to 2015).
61. Alexander Sandhu, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2014 to 2016).
62. Ilana Richman, MD, VA Physician Post-Residency Fellowship Program in Health Services Research and Development (2014 to 2016).
63. Jonathan Chen, MD, PhD, VA Postdoctoral Informatics Fellowship (2014 to 2015).
64. Frances Wu, PhD, VA Postdoctoral Health Services Research and Development Fellowship (2014 to 2016).
65. Geoffrey Tso, MD, VA Postdoctoral Informatics Fellowship (2015 to 2017).
66. James Barnes, MD, VA Postdoctoral Health Services Research and Development Fellowship (2015 to 2018).
67. Lesley Park, PhD, Postdoctoral Research Fellow, Stanford University, 2015-2016.
68. Meena Chelvakumar, MD, VA Postdoctoral Health Services Research and Development Fellowship (2016 to 2018)
69. Jody Lin, MD, KL2 Mentored Career Development Award, Clinical Instructor, Pediatrics (2016 to 2019).
70. John Lin, MD, VA Postdoctoral Health Services Research and Development Fellowship (2017 to 2019).
71. Christian Rose, MD, VA Postdoctoral Informatics Fellowship (2017 to 2019).
72. Omar Usman, MD, VA Postdoctoral Informatics Fellowship (2017 to 2019).
73. Elizabeth George MD, VA Postdoctoral Health Services Research and Development Fellowship (2018 to 2020).

74. Divya Parikh, MD, Stanford-AHRQ Fellowship in Health Service Research (2019 to 2021).
75. Kirbi Yelorda, MD, Stanford-AHRQ Fellowship in Health Service Research (2019 to 2021).
76. Rebecca Tisdale, MD, VA Postdoctoral Health Services Research and Development Fellowship (2020 to 2022)
77. Charlotte Rajasingh, MD, Stanford-AHRQ Fellowship in Health Service Research (2020 to 2022).
78. Neha Shirish Joshi, MD, Stanford Pediatric Hospital Medicine Fellowship, (2020 to 2022).
79. Meghan Halley, PhD, MPH, K-award secondary mentor, (2021-2025).
80. Kaylynn Purdy, MD, Health Policy masters program, (2021-2023).
81. Shernaz Dossabhoy, MD, Stanford-AHRQ Fellowship in Health Service Research 2022-2024
82. James Dickerson, MD, Stanford-AHRQ Fellowship in Health Service Research 2022-2024
83. Christopher Bennett, MD, Stanford KL2 Award mentor, 2022-2024.

Graduate Students:

1. Seema Sonnad (committee), Doctoral Dissertation, Health Economics, University of California, Berkeley
2. Ryan Harris (advisor), Master's thesis, Health Services Research: Screening patients for HIV infection
3. Rebecca Lee (committee), Doctoral Dissertation, Engineering-Economic Systems, Thesis: Therapy for HIV Disease
4. Donna Edwards (committee), Doctoral Dissertation, Engineering-Economic Systems, Thesis: Costs and benefits of vaccination strategies for HIV disease
5. Gillian Sanders (advisor), Doctoral Dissertation, Medical Information Sciences, Thesis: Automated creation of clinical practice guidelines from decision models
6. Anke Richter (committee), Doctoral Dissertation, Engineering-Economic Systems, Thesis: Resource allocation in HIV disease
7. Shyoko Honiden (advisor), Master's thesis, Health Services Research: Quality of life with HIV infection
8. Jill Frederickson (advisor), Master's thesis, Health Services Research: Cost-effectiveness of virtual colonoscopy for colon cancer screening
9. Joe Norman (committee), Doctoral Dissertation, Medical Information Sciences
10. Marcia Tsugawa (committee), Doctoral Dissertation, Engineering Economic Systems and Operations Research, Thesis: Cost effectiveness of vaccine for *Helicobacter pylori*
11. Greg Zaric (committee), Doctoral Dissertation, Industrial Engineering, Thesis: Resource allocation for epidemic control
12. Christina Friedrich (committee), Doctoral Dissertation, Industrial Engineering, Thesis: Optimal investment in HIV prevention programs.

13. Charlotte Haug, MD, PhD. (advisor), Master's thesis, Health Services Research, Cost effectiveness of screening women for chlamydia trachomatis.
14. Vilija (Gulbinas) Joyce (advisor), Master's thesis, Health Services Research: Measurement of quality of life with HIV infection in the era of highly active antiretroviral therapy.
15. Kyeen Mesesan (committee), Doctoral Dissertation, Department of Epidemiology and Public Health, Yale School of Medicine, New Haven, Connecticut, Thesis: Evaluation of Partially Effective HIV Vaccines.
16. Elisa Long (committee), Doctoral Dissertation, Department of Management Science and Engineering, Thesis: Modeling HIV interventions.
17. Piya Sorcar, Doctoral student, School of Education, Project: HIV/AIDS Education.
18. David Hutton (committee), Doctoral Dissertation, Department of Management Science and Engineering, Thesis: Modeling screening and treatment of hepatitis.
19. Sabina Alistar (committee), Doctoral student, Department of Management Science and Engineering.
20. Jessie Juusola (committee), Doctoral student, Department of Management Science and Engineering.
21. Lauren Cipriano (committee), Doctoral student, Department of Management Science and Engineering.
22. Shan Liu (committee), Doctoral student, Department of Management Science and Engineering.
23. Diana Negoescu, Doctoral student, Department of Management Science and Engineering.
24. Stacie Vilendrer, Medical Student, School of Medicine, Medical Scholars Project, Prenatal genetic testing.
25. Allie Leeper, Doctoral student, Department of Management Science and Engineering.
26. Cora Bernard (committee), Doctoral student, Department of Management Science and Engineering, 2013 – 2018.
27. Allison Pitt (committee), Doctoral student, Department of Management Science and Engineering, 2013 – 2018.
28. Erika Strandberg (committee), Doctoral student, Biomedical Informatics, 2015 – 2017.
29. Kyu Lee (committee), Doctoral student, Health Policy, 2015 – 2019.
30. Geoff Barrow, Master's student, Health Service Research, 2016 – 2017.
31. Rui Fu (committee), Doctoral student, Department of Management Science and Engineering, 2015 – 2019.
32. Tess Ryckman (committee), Doctoral student, Health Policy, 2016 –2020.
33. Michael Fairley, Doctoral student, Department of Management Science and Engineering, 2016-2021
34. Jack Ching (advisor, committee), Doctoral student, Health Policy, 2016 – 2021.
35. Matt Kauffman (committee), Doctoral student, Health Policy, 2019 – 2024
36. Grace Guan, Department of Management Science and Engineering, 2020-2024
37. Marika Cusick (advisor, committee), Doctoral student, Health Policy, 2020 – 2025.

38. Melissa Franco (advisor, committee), Doctoral student, Health Policy, 2021 – 2026.
39. Eliza Ennis (advisor), Doctoral student, Health Policy, 2022 – 2027
40. Alyssa Amick (advisor), MD and Doctoral student, Health Policy, 2023-2029.

Lusted Award winners: Brian Gage, Donna Edwards, Ida Sim, Gillian Sanders, Dena Bravata, Kyeen Mesesan, Hau Liu, Elisa Long, Sabina Alistar, Kit Delgado, Cora Bernard, Kyuen Lee, Tess Ryckman.

Undergraduate Advising: Freshman and Sophomore Undergraduate Advisor, Stanford University, Stanford, California, 1991 – 2004.

Invited Lectures and Presentations:

1. "Threshold Analysis Using Diagnostic Tests with Multiple Results," Ninth Annual Meeting, Society for Medical Decision Making; Philadelphia, Pennsylvania; October, 1987.
2. "Measures of Test Performance," Department of Medicine, Wright-Patterson Air Force Base; Dayton, Ohio; February, 1988.
3. "Post-test Probability: Bayes' Theorem," Department of Medicine, Wright-Patterson Air Force Base; Dayton, Ohio; February, 1988.
4. "Probability Assessment: Heuristics and Clinical Prediction Rules," Department of Medicine, Wright-Patterson Air Force Base; Dayton, Ohio; February, 1988.
5. "Decision Analysis," Department of Medicine, Wright-Patterson Air Force Base; Dayton, Ohio; February, 1988.
6. "AIDS: Epidemiologic and Therapeutic Concepts," Peking Union Medical College; Beijing, China; March, 1988.
7. "Lung Cancer Staging," Peking Union Medical College; Beijing, China; March, 1988.
8. "Decision Analytic Approach to Lung Cancer Staging," Annual Meeting, American Thoracic Society; Las Vegas, Nevada; May, 1988.
9. "Cost Accounting in Ambulatory Care," Annual Meeting, Veterans Administration Health Services Research and Development Field Program; San Francisco, California; June, 1988.
10. "Decision Analytic Approach to Staging Non-Small Cell (T1) Lung Cancer," Tenth Annual Meeting, Society for Medical Decision Making; Richmond, Virginia; October, 1988.
11. "Invasive versus Non-Invasive Tests For Staging Non-Small Cell Lung Cancer of Unknown Extent: A Decision Analytic Model," (poster presentation) Twelfth Annual Meeting, Society of General Internal Medicine; Washington, D.C.; 1989.
12. "Application of Influence Diagrams in Medical Decision Making," Eleventh Annual Meeting, Society for Medical Decision Making; Minneapolis, Minnesota, October, 1989.
13. "Occupational Risk from HIV and Hepatitis B," Medical Grand Rounds, Veterans Administration Medical Center; San Francisco, California; January 1990.

14. "Occupational exposure to HIV and hepatitis B virus (HBV): A comparative analysis of risk," (poster presentation), Sixth International Conference on AIDS; San Francisco, California; June 20-24, 1990.
15. "Occupational Infection with the Human Immunodeficiency Virus: A Model-Based Analysis of Risk to Surgeons," Operations Research Society of America/The Institute of Management Science (ORSA/TIMS) Joint National Meeting; Philadelphia, Pennsylvania; October 29-31, 1990.
16. "Morbidity and Mortality in the Analysis of Risk: Effect of Incorporation of Preferences for Diminished Health States," Twelfth Annual Meeting, Society for Medical Decision Making; Boston, Massachusetts; November 11-14, 1990.
17. "Identifying Test Alternatives with Value of Information Calculations: Analysis of the Timing of Thoracotomy after Myocardial Infarction," (poster presentation) Twelfth Annual Meeting, Society for Medical Decision Making; Boston, Massachusetts; November 11-14, 1990.
18. "Analysis of Occupational Risk of HIV and Hepatitis B Infection," Medical Grand Rounds, Monterey Hospital; Monterey, California; November 21, 1990.
19. "Methodologic Approaches to Guideline Formulation," Agency for Health Care Policy and Research; Washington, D. C; April 4, 1991.
20. "Model-based Design of Clinical Guidelines: Approaches for Customizing Guidelines," Institute of Medicine; Washington, D. C; April 5, 1991.
21. "Optimal test strategy for staging peripheral non-small cell lung cancer with potential chest wall invasion," (poster presentation) National Meeting, American Federation for Clinical Research; Seattle, Washington, May 3-6, 1991.
22. "Evaluating the Impact of Variation in Clinical Circumstance on Optimal Guideline Development: The Expected Value of Customization," (poster presentation) Thirteenth Annual Meeting, Society for Medical Decision Making; Rochester, New York, October 20 - 23, 1991.
23. "A Model-based Approach for Prioritizing Information Acquisition During Guideline Development," Thirteenth Annual Meeting, Society for Medical Decision Making; Rochester, New York: October 20 - 23, 1991.
24. "Advanced Topics in Probabilistic Medical Reasoning: Influence Diagrams and Belief Networks," Thirteenth Annual Meeting, Society for Medical Decision Making, Rochester; New York, October 20 - 23: 1991.
25. "Health Risks During the Provider-patient Encounter: Analysis of the Hazard from HIV and Hepatitis B Infection," Thirty-third Joint National Meeting, Operations Research Society of America/The Institute of Management Science (ORSA/TIMS); Anaheim, California; November 3 - 6, 1991.
26. "Guideline Development for HIV Disease: Methodologic Issues," Conference on HIV-AIDS Health Services Research and Delivery, Agency for Health Care Policy and Research; Miami, Florida; December 4 - 6, 1991.
27. "HIV Screening for the Public Good," Sixth Annual Stanford Health Policy Forum, Stanford Medical School; Stanford, California; January 25, 1992.
28. "Use of the polymerase chain reaction for the diagnosis of HIV infection in adults: A meta-analytic evaluation of test performance," (poster presentation) Fifteenth Annual Meeting, Society of General Internal Medicine; Washington, D.C.; April 29 - May 1, 1992.
29. "The polymerase chain reaction for the diagnosis of adult HIV infection: Contributions of technical aspects and study population to performance," Dartmouth Summer Institute on Technology Assessment, Dartmouth Medical School; Hanover New Hampshire; July 23 - 24, 1992.

30. "Advanced Topics in Probabilistic Medical Reasoning: Influence Diagrams and Belief Networks," Fourteenth Annual Meeting, Society for Medical Decision Making; Portland, Oregon; October 17 - 20: 1992.
31. "Diagnosis of Pediatric HIV Infection with the Polymerase Chain Reaction: A meta-Analytic Evaluation of Test Performance," Fourteenth Annual Meeting, Society for Medical Decision Making; Portland, Oregon; October 17 - 20: 1992.
32. "HIV Transmission Between Physicians and Patients: Estimating the Risk," Thirty-fourth Joint National Meeting, Operations Research Society of America/The Institute of Management Science (ORSA/TIMS); San Francisco, California; November 1-4, 1992.
33. "Decision Analysis and HIV-Related Health Policy," Thirty-fourth Joint National Meeting, Operations Research Society of America/The Institute of Management Science (ORSA/TIMS); San Francisco, California; November 1 - 4, 1992.
34. "Risk of Hepatitis B Transmission from Athletic Injuries," Sports Medicine Program Grand Rounds; Stanford University, Stanford, California; January 21, 1993.
35. "Technology Assessment: A Case Study and Proposal for Sponsorship of Evaluative Research," Health Services Research Seminar, Stanford University; Stanford, California; February 8, 1993.
36. "Developing a Method for Customizing Screening Guidelines," VA Health Services Research and Development Service Research Career Development Award Conference; Washington, D.C., April 21 - 22, 1993.
37. "Standards and Guidelines for HIV Care," Learning to Choose HIV Therapies, sponsored by the Food and Drug Administration and the Illinois Department of Public Health; Chicago, Illinois; September 8, 1993.
38. "Screening for HIV infection in acute-care settings: Determinants of cost-effectiveness," . Fifteenth Annual Meeting, Society for Medical Decision Making; Research Triangle, North Carolina; October 24 - 27, 1993.
39. "Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings," Fifteenth Annual Meeting, Society for Medical Decision Making; Research Triangle, North Carolina; October 24 - 27, 1993.
40. "An Evaluation of the Cost-effectiveness of Screening Physicians for HIV Infection to Prevent Transmission to Patients," Fifteenth Annual Meeting, Society for Medical Decision Making; Research Triangle, North Carolina; October 24 - 27, 1993.
41. "Practice Guidelines: Past Problems and Future Promises," Visiting Professorship, Medical Grand Rounds, University of Hawaii at Manoa, Honolulu, Hawaii; July 19, 1994.
42. "Tailoring Clinical Practice Guidelines for a Specific Practice Setting," Visiting Professorship, University of Hawaii at Manoa, Honolulu, Hawaii; July 20, 1994.
43. "A Practical Guide to Practice Guidelines," Fourteenth Annual Update and Review of Internal Medicine, sponsored by the American College of Physicians and the University of Hawaii at Manoa, Kapalua Maui, Hawaii; July 22 - 26, 1994.
44. "Preventive Medicine: Principles of Screening and Cost-Effectiveness," Fourteenth Annual Update and Review of Internal Medicine, sponsored by the American College of Physicians and the University of Hawaii at Manoa, Kapalua Maui, Hawaii; July 22 - 26, 1994.
45. "Controversies in Screening," Fourteenth Annual Update and Review of Internal Medicine, sponsored by the American College of Physicians and the University of Hawaii at Manoa, Kapalua Maui, Hawaii; July 22 - 26, 1994.

46. "An Overview of Practice Guideline Development," Center for the Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, New Hampshire; October 20, 1994.
47. "Who Should be Screened for HIV: Physicians, Patients, Both, Neither?," Medical Grand Rounds, Stanford University School of Medicine, Stanford, California; November 3, 1994.
48. "Considerations in Adopting Practice Guidelines: Management of HIV in Adolescent Patients," Adolescent Medicine HIV/AIDS Research Network, sponsored by the National Institute for Child Health and Human Development, Bethesda, Maryland; December 8, 1994.
49. "Should Physicians and Patients be Screened for HIV?," Medical Grand Rounds, Marin General Hospital, Greenbrae, California; January 31, 1995.
50. "An Overview of Practice Guidelines: Science and Clinical Wisdom or Witches Brew?" Health Services Research Seminar, Center for Health Care Evaluation, HSR&D Field Program, VA Medical Center, Menlo Park, California; February 3, 1995.
51. "Physicians and Patients: Who Should be Screened for HIV?," Annual Meeting, Institute for Operations Research and the Management Sciences, Los Angeles, California; April 23 - 26, 1995.
52. "Health Care Policy: Past, Present, and Future," Third Annual Clinical Exercise Physiology and Cardiac Rehabilitation Conference, Palo Alto, California; August 11, 1995.
53. "A Model-Based Analysis of the Costs and Benefits of Screening Physicians for HIV," Scientific Decision Making in Health Care, Palo Alto, California; September 22, 1995.
54. "Individualizing Medical Care to Accommodate Diverse Patient Preferences: New Approaches to Preference Assessment and Guideline Development.," Medical Grand Rounds, Stanford University School of Medicine, Stanford, California; October 5, 1995.
55. "Cost-Effectiveness of Third-Generation Implantable Cardioverter-Defibrillators for Prevention of Sudden Cardiac Death," Seventeenth Annual Meeting, Society for Medical Decision Making; Tempe, Arizona; October 14 - 17, 1995.
56. "Health Policy and Managed Care: Implications for the VA," VA Palo Alto Health Care System Management Retreat, Menlo Park, California; December 1, 1995.
57. "How to Order Diagnostic Tests Based on the Evidence," Fourth Annual James Kung Primary Care Conference, Stanford University; Stanford, California; May 18, 1996.
58. "Identification of Patients at High Risk for Sudden Cardiac Death," Eighteenth Annual Meeting, Society for Medical Decision Making, Toronto, Canada; October 13 - 16, 1996.
59. "Sudden Cardiac Death: Evaluation of the Costs and Benefits of the Implantable Cardioverter Defibrillator," Section on Medical Informatics Symposium, Stanford University; Stanford, California; May 6-7, 1997.
60. "Assessment of the Cost Effectiveness of the Implantable Cardioverter Defibrillator: Technology at a Turning Point?," Department of Veterans Affairs Medical Center, West Roxbury, Massachusetts; May 13, 1997.
61. "Preparing to Implement Practice Guidelines," Sierra Pacific Veterans Integrated Service Network, Guideline Implementation Planning Conference, Concord, California; July 16, 1997.
62. "An Analytic Framework for Development of Site-Specific HIV Screening Guidelines," Third Plenary Meeting, European Union Concerted Action on Multinational Scenario Analysis Concerning Epidemiological Social and Economic Impacts of HIV/AIDS on Society, Bilthoven, The Netherlands; October 1-3, 1997.

63. "The Cost Effectiveness of Potential HIV Vaccines," Third Plenary Meeting, European Union Concerted Action on Multinational Scenario Analysis Concerning Epidemiological Social and Economic Impacts of HIV/AIDS on Society, Bilthoven, The Netherlands; October 1-3, 1997.
64. "Sudden Death and the Implantable Defibrillator: Technology at a Turning Point?," Harvard Center for Risk Analysis, Harvard, Massachusetts; May 1, 1998.
65. "Preventing Sudden Cardiac Death with the Implantable Cardioverter Defibrillator: Can We Afford It?," Research Institute, Palo Alto Medical Foundation, May 12, 1998.
66. "Cost-Effectiveness Analysis of HIV Vaccines," Conference on Quantitative Evaluation of HIV Vaccine Programs, Divonne-les-Bains, France, Sponsored by the Societal Institute of the Mathematical Sciences, New Canaan, Connecticut; July 6-8, 1998.
67. "Development and Dissemination of Clinical Policies: Decision Models and Cost-Effectiveness Analysis", Keynote Address, Conference on Methodological Issues in Pharmacoeconomics and Outcomes Research, Roche Global Pharmaceconomics, Palo Alto, California; November 3- 5, 1998.
68. "Development and Dissemination of Clinical Policies: Clinical Trials, Decision Models, and Cost-Effectiveness Analysis", Hematology Division Seminar, Stanford University School of Medicine, Stanford, California; December 2, 1998.
69. "Clinical Guidelines and Decision Support", Workshop on Career Paths in General Internal Medicine Informatics, Twenty-second Annual Meeting, Society for General Internal Medicine, San Francisco, California, April 29 - May 1, 1999.
70. "The Society for Medical Decision Making at the Millennium", Presidential Keynote Address, Twenty-first Annual Meeting of the Society for Medical Decision Making, Reno, Nevada, October 3-6, 1999.
71. "Costs and Benefits of Potential HIV Vaccines", Conference on Policy Modeling For Better Decisions: The Public Health Impact and Cost Effectiveness of HIV Intervention Programs, Sponsored by the Societal Institute of the Mathematical Sciences, and the National Institute of Drug Abuse, The Cosmos Club, Washington D. C., January 14, 2000.
72. "Cost effectiveness of the implantable defibrillator in patients who have had myocardial infarction", American Society for Clinical Investigation and Association of American Physicians Joint Meeting, Baltimore, Maryland, May 5-7, 2000.
73. "Cost effectiveness of positron emission scanning in the evaluation of metastatic colon cancer", Guy's Hospital, King's College, London, England August 4, 2000
74. "Economic Analysis and Public-Health Interventions", Epidemic Intelligence Service Prevention Effectiveness Course, Centers for Disease Control and Prevention, Atlanta, Georgia, November 8, 2000.
75. "Evaluation of Decision Support Systems for Response to a Bioterrorist Event", Bioterrorism Contractors' Meeting, Agency for Healthcare Research and Quality, Washington D.C., November 27, 2000.
76. "Estimating the Cost Effectiveness of Antiretroviral Therapy for Prevention of HIV Transmission", Centers for Disease Control and Prevention and National Institutes of Health Office of AIDS Research, Consultation on Antiretroviral Therapy for HIV Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, December 4, 2000.
76. "Cost effectiveness of Potential HIV Vaccines in High-Risk Populations", National Institute of Drug Abuse Community Epidemiology Working Group Conference, San Francisco, California, December 13, 2000.

77. "Using Cost-Effectiveness Analysis to Develop Practice Guidelines for Specific Clinical Populations", Lille University Hospital, Lille, France, April 20, 2001.
78. "Screening for Helicobacter Pylori to Prevent Gastric Cancer", Lille University Hospital, Lille, France, April 20, 2001.
79. "Population Health Benefits and Costs of Potential Preventive and Therapeutic HIV Vaccines", 9th International Conference on AIDS, Cancer and Related Problems, St. Petersburg, Russia, May 27-June 1, 2001.
80. "Evaluating the Cost and Benefits of Potential Preventive and Therapeutic HIV Vaccines", Department of Medicine Research Conference, Stanford University, Stanford, California, November 5, 2001.
81. "Health Care System Preparedness for Bioterrorism", California Biodefense Forum, Berkeley, California, November 10, 2001.
82. "Bioterrorism: Are We Prepared?", World Affairs Council of Northern California, San Francisco, California, November 15, 2001.
83. "Technology Assessment and Clinical Decision Making", Center for Health Care Evaluation Research Conference, VA Health Care System, Palo Alto, November 27, 2001.
84. "Cost Effectiveness of HIV Screening in the VA", Department of Veterans Affairs National HIV Quality Enhancement Research Initiative Executive Committee Meeting, Orlando, Florida, December 12-13, 2001.
85. "Costs and Benefits of Potential HIV Vaccines", HIV Vaccine Consultation, Centers for Disease Control and Prevention, Atlanta, Georgia, January 16-17, 2002.
86. "Comprehensive Systematic Reviews: Methods of Stanford-UCSF Evidence-Based Practice Center," Center for Information Technology Leadership, Partners Healthcare System, Boston, Massachusetts, July 23, 2002.
87. "Costs and Benefits of Partially Effective HIV Vaccines", HIV Vaccine Consultation, World Health Organization, Geneva, Switzerland, November 20-21, 2002.
89. "Affordable Benefits Package for Universal Health Care", Integrated Healthcare Association, Oakland California, January 29, 2003.
90. "Seroprevalence of HIV Infection at VA Health Care Systems", Twenty-fifth Annual Meeting, Society for Medical Decision Making, Chicago, Illinois, October 19-22, 2003.
91. "An Overview of Evidence-Based Practice Centers", VA National Quality Enhancement Research Initiative (QUERI) Meeting, Washington D.C., December 17-19, 2003.
92. "Cost Effectiveness of Screening for HIV in Acute Care Settings", VA National Quality Enhancement Research Initiative (QUERI) Meeting, Washington D.C., December 17-19, 2003
93. "HIV Testing and Counseling in the VA: Implications for Screening Guidelines", Veterans Health Administration Public Health Strategic Health Care Group Retreat, Washington D.C., December 17, 2003.
94. "Changing Clinical and Health Policy with Modeling," 12th International Conference on AIDS, Cancer, and Related Problems, St. Petersburg Russia, May 24-31, 2004.
95. "Cost Effectiveness of Partially Effective HIV Vaccines in the Era of Highly Active Antiretroviral Therapy" 12th International Conference on AIDS, Cancer, and Related Problems, St. Petersburg Russia, May 24-31, 2004.
96. "Bioterrorism Preparedness and Response," Young President's Organization, Menlo Park, California, January 12, 2005.

97. "Cost Effectiveness of the Implantable Cardioverter Defibrillators (ICD) for Secondary Prevention of Sudden Cardiac Death," ICD Cost Effectiveness Think Tank, Sponsored by Duke University, Washington, D.C., March 21-22, 2005.
98. "The Threat from Bioterrorism," Stanford Institute for International Studies, International Day, Stanford University, May 6, 2005.
99. "Cost effectiveness of screening for HIV in the era of highly active antiretroviral therapy in the United States," 14th International Conference on AIDS, Cancer, and Related Problems, St. Petersburg Russia, May 23-27, 2005.
100. "Future directions for screening policy for HIV", 2005 National HIV Prevention Conference, June 12-15, Atlanta, Georgia.
101. "Evaluating the Benefits and Costs of HIV Screening: Why Voluntary HIV Screening Should be Routinely Offered in Health Care Settings", University of California San Francisco, Department of Medicine Grand Rounds, September 8, 2005.
102. "Rating the Strength of a Body of Evidence", Evidence-Based Practice Centers Director's Meeting, Agency for Healthcare Research and Quality, Gaithersburg, Maryland, March 23, 2006.
103. "Is Screening for HIV Worth the Costs? Lessons from the United States," Freeman Spogli Institute for International Studies, Stanford University, April 20, 2006.
104. "Economic analysis and cost effectiveness of HIV screening," 2006 National Sexually Transmitted Disease Prevention Conference, May 10, 2006, Jacksonville, Florida.
105. "Preparing for bioterrorism: Does syndromic surveillance work?," A World At Risk, Second Annual International Conference, Freeman Spogli Institute for International Studies, November 16, 2006, Stanford University, Stanford, California.
106. "Translating Evidence into Policy and Practice," Judging the Evidence: Standards for Determining Clinical Effectiveness, A Workshop of the Institute of Medicine Roundtable on Evidence-Based Medicine, Institute of Medicine, February 5, 2007, Washington D.C.
107. "Evaluating the benefits and costs of HIV Screening: Why voluntary HIV screening should be routinely offered in health care settings," Infectious Disease Seminar, VA San Francisco Health Care System, San Francisco, California, February 7, 2007.
108. "Research in HSR&D," VA Health Services Research and Development National Meeting 2007, Arlington, Virginia, February 22, 2007.
109. "Biodefense", Annual Continuing Medical Education Symposium, Stanford University Medical Center Alumni Association, Stanford University, May 5, 2007.
110. "Grading Strength of Evidence for a Body of Literature," Evidence-Based Practice Centers Methods Meeting, Agency for Healthcare Research and Quality, Gaithersburg, Maryland, June 15, 2007.
111. "Screening Mammography in Women 40 to 49: Development of a Guideline from the American College of Physicians", Breast Cancer Grand Rounds, Stanford University, Stanford, California, August 10, 2007.
112. "Evidence-Based Comparative Effectiveness in the United States – Where Is It Going and What Role Should the Society for Medical Decision Making Play?," 29th Annual Meeting of the Society for Medical Decision Making, Pittsburgh, Pennsylvania, October 20, 2007.

113. "HIV in Russia: Drugs, Sex, and Democracy," Freeman Spogli Institute for International Studies, Stanford University, Stanford, California, November 15, 2007.
114. "The end of risk-based screening for HIV? Evaluating the costs and benefits of routine HIV screening in health care settings," Medicine Grand Rounds, VA Greater Los Angeles Healthcare System, Los Angeles, California, December 5, 2007.
115. "Do the benefits of screening mammography outweigh the harms in women 40 to 49 years of age? New recommendations from the American College of Physicians", Women's Health Medical Forum, Stanford University, Stanford, California, January 9, 2008.
115. "Anatomy of a guideline: The making (and remaking) of the new American College of Physicians' guideline on screening mammography in 40 to 49 year-old women. Research-in-Progress Seminar, Center for Primary Care and Outcomes Research, Stanford University, Stanford, California, January 16, 2007.
116. "Failing in many ways? Detection and response for anthrax bioterrorism," Center for International Security and Cooperation, Freeman Spogli Institute for International Studies, Stanford University, Stanford, California, January 22, 2008.
117. "The end of risk-based screening for HIV? The evidence for routine opt-out screening for HIV in health-care settings," Department of Medicine Grand Rounds, Stanford University, Stanford, California, January 23, 2008.
118. "Translation of research into practice: Cost effectiveness and infectious diseases," American College of Physicians Annual Meeting 2008, Washington D.C., May 15, 2008.
119. "Anatomy of a guideline: Systematic reviews and rating the quality of evidence and strength of recommendations," Agency for Healthcare Research and Quality, Washington D. C., September 8, 2008.
120. "Cost effectiveness and infectious disease: Is there a case for routine HIV screening?" Infectious Disease Citywide Conference, Ochsner Health System, New Orleans, Louisiana, February 20, 2009.
121. "The end of risk-based screening for HIV? The evidence for routine opt-out screening for HIV in health-care settings," Department of Medicine Grand Rounds, Louisiana State University, New Orleans, Louisiana, February 20, 2009.
122. "Guideline Update: Screening mammography in women 40 to 49 years of age" Internal Medicine 2009, American College of Physicians, Philadelphia, Pennsylvania, April 23, 2009.
123. "Screening mammography in women 40 to 49 years of age" Medical Grand Rounds, Department of Veterans Affairs Greater Los Angeles Healthcare System, VA West Los Angeles Healthcare Center, March 10, 2010.
124. "Health care reform and comparative effectiveness research" Joint symposium sponsored by the Institute of Medicine, the McKinsey & Company, and Stanford Health Policy, San Francisco, California, March 24, 2010.
126. "Clinical practice guidelines and a systematic review data repository", Tufts New England Medical Center Evidenced-based Practice Center, and Agency for Healthcare Research and Quality, Boston, Massachusetts, June 3, 2010.
127. "Model-based analyses of HIV vaccines with efficacy similar to RV144" AIDS Vaccine 2010, Satellite Symposium, Centers of Disease Control and Prevention and UNAIDS, Atlanta, Georgia, September 28, 2010.
128. "Eisenberg award lecture: successes and opportunities in decision modeling", 32nd Annual Meeting of the Society for Medical Decision Making, Toronto, Canada, October 26, 2010.
129. "Comparative effectiveness of therapies for stable ischemic heart disease", Comparative Effectiveness Working Group Meeting, Agency for Health Care Research and Quality, Washington, D.C., December 8-9, 2010.

130. "Decision Modeling and comparative effectiveness", Robert Wood Johnson Faculty Scholars Program Conference, February 23, 2011, Palo Alto, California.
131. "Initial steps in the systematic review process", Institute of Medicine Workshop on Systematic Reviews, Washington D.C., May 10-11, 2011.
132. "Technology assessment: An overview", China Senior Health Care Executive Education Program, Stanford University, Stanford, California, May 24, 2011.
133. "A technology assessment case study: Evaluating the cost effectiveness of the implantable cardioverter defibrillator", China Senior Health Care Executive Education Program, Stanford University, Stanford, California, May 14, 2011.
134. "The end of mammography? Guidelines for screening for breast cancer in 40 to 49 year-old women", Medicine Grand Rounds, Stanford University, Stanford, California, May 29, 2013.
135. "The end of mammography? Guidelines for screening for breast cancer in 40 to 49 year old women", Medicine Grand Rounds, Cleveland Clinic, Cleveland, Ohio, August 22, 2013.
136. "High-value cost conscious care: Evaluating the benefits, harms, and costs of medical interventions", Cleveland Clinic, Cleveland, Ohio, August 22, 2013.
137. "Technology assessment, decision theory, and cost effectiveness of the implantable cardioverter defibrillator", Dublin, Ireland, January 16, 2014.
138. "Ebola: Health, Governance, Security, and Ethical Dimensions", Freeman Spogli Institute for International Studies, Stanford University, Stanford, California, September 23, 2014.
139. "Lung cancer screening: a debate of science, ethics, and policy", 36th Annual Meeting of the Society for Medical Decision Making, October 18, 2014.
140. "Can we put a price on good health? Controlling the cost of health care", Stanford Medicine Health Policy Forum, Stanford University, Stanford, California, October 28, 2014.
141. "Population Health Science and Big Data", Big Data in Biomedicine Conference, Stanford University, Stanford, California, May 20, 2015.
142. "Decision Modeling and Overdiagnosis: Experience of the U.S. Preventive Services Task Force", Preventing Overdiagnosis Conference, National Institutes of Health, Bethesda, Maryland, September 3, 2015.
143. "Cost effectiveness of HIV pre-exposure prophylaxis for injection drug users in the United States", Society for Medical Decision Making Asia-Pacific Meeting, Hong Kong, January 8, 2016.
144. "Health technology assessment: evidence synthesis", Society for Medical Decision Making Asia-Pacific Meeting, Hong Kong, January 8, 2016.
145. "Screening for breast cancer: new guidelines, old controversies", Medical Grand Rounds, Department of Medicine, University of Wisconsin, Madison, Wisconsin, April 22, 2016.
146. "Comparative effectiveness and the development of clinical guidelines", Association of Health Care Journalists Fellowship Program, Washington D.C., September 13, 2016.
147. "Individualizing Guidelines in an era of personalized medicine," Opening Plenary Presentation, Guidelines International Conference, Philadelphia, Pennsylvania, September 28, 2016.

148. "High Value Care", Health Policy through 2020: The ACA, Payment Reform and Global Challenges, sponsored by Stanford Health Policy, October 14th, 2016.
149. "Updates from the US Preventive Services Task Force", Society for General Internal Medicine, Washington D.C, April 21, 2017.
150. "Updates from the US Preventive Services Task Force", Society for General Internal Medicine, Denver, Colorado, April 12, 2018.
151. "When does prevention work? Approach of the U.S. Preventive Services Task Force for assessing the benefits and harms of preventive services", Department of Population Health Sciences, Duke University Medical Center, May 21, 2018.
152. "Should we incorporate costs into clinical guidelines?". G-I-N Conference 2018, Guidelines International Network, Plenary Session, Manchester, England, September 12, 2018.
153. "Beyond the Guidelines: Screening for Prostate Cancer", Medicine Grand Rounds, Beth Israel Deaconess Hospital, January 24, 2019.
154. "Prevention that works: Screening for colorectal, lung, and breast cancer.", Primary Care Grand Rounds, Beth Israel Deaconess Hospital, January 25, 2019.
155. "Screening for cancer: recommendations of the US Preventive Services Task Force.", University of California, San Francisco, September 13, 2019.
156. "How the US Preventive Services Task Force determines whether to recommend preventive services.", Early Detection of Cancer Conference, Stanford University, Stanford, California, September 26, 2019.
157. "Recommendations on the conduct of cost-effectiveness analysis from the Second Panel on Cost-Effectiveness in Health and Medicine," VA Health Economics Resource Center Cyberseminar, January 21, 2020.
158. "SARS-Cov-2, COVID-19, and Health Policy", Freeman-Spogli Institute for International Studies Town Hall, April 3, 2020, Stanford University, Stanford, California.
159. "COVID-19 Policy Research at FSI", Freeman-Spogli Institute for International Studies Advisory Council Meeting, April 24, 2020, Stanford University, Stanford, California.
160. "Reopening the economy in during the COVID-19 Pandemic", Medicine Grand Rounds, Department of Medicine, April 29, 2020, Stanford University, Stanford, California.
161. "Stanford Medicine COVID-19 briefing", Stanford Medicine Corporate Council, May 7, 2020, School of Medicine, Stanford University, Stanford, California.
162. "SARS-Cov-2 epidemiology and transmission", Workshop for the Provost and Executive Council, June 5, 2020, Stanford University, Stanford, California.
163. "Approach and rationale for the use of different types of evidence", Evidence-based practice for public health emergency preparedness and response, Virtual Stakeholder meeting on an evidence review and evaluation methodology for public health emergency preparedness and response. National Academies of Science, Engineering and Medicine, November 16, 2020.
164. "Approaches for further testing and refining the Public Health Emergency Preparedness and Response evidence review methodology", Evidence-based practice for public health emergency preparedness and response, Virtual Stakeholder meeting on an evidence review and evaluation methodology for public health emergency preparedness and response. National Academies of Science, Engineering and Medicine, November 16, 2020.

165. “Health Policy at Stanford”, School of Medicine Board of Fellows Advisory Council Meeting, January 14, 2021, Stanford University, Stanford, California.
166. “Under construction: draft guidelines from the U.S. Preventive Services Task Force on colorectal and lung cancer screening”, Research-in-Progress Seminar, Stanford Health Policy, January 22, 2021, Stanford University, Stanford, California.
167. “Modeling in the development of national prevention policy: US Preventive Services Task Force Guidelines on screening for lung and colorectal cancer”, Public Health Modeling Unit, School of Public Health, Yale University, January 24, 2022.
168. “Guidelines for the conduct of cost-effectiveness analysis: recommendations from the second Panel on Cost Effectiveness in Health and Medicine”, VA Health Economics Resource Center Cyberseminar, January 26, 2022.
169. “The public health problem”, Pandemic Puzzle Series, October 28, 2021, Stanford University, Stanford California.
170. “Evidence synthesis in practice and policy”, Evidence-Based Practice Center Grand Rounds, Agency for Healthcare Research and Quality, Washington D.C., June 9, 2022.
171. “Developing national prevention guidelines”, Stanford Center for Longevity, September 13, 2022, Stanford University, Stanford, California.
172. “Covid – What’s next?”, Stanford Center for Longevity, September 23, 2022, Stanford University, Stanford, California.
173. “News you can use: Current Clinical Guidelines for treatment of depression and COVID-19”, American College of Physicians Annual Meeting, April 27, 2023, San Diego, California.

Grants and Awards

1. Grant Title: Policy Analysis of HIV Screening and Intervention
Principal Investigator: Margaret Brandeau
Project Management: Margaret Brandeau
Agency: University of California, Universitywide Task Force on AIDS
ID Number: AIDS R90ST020
Term: July 1990 to July 1992
Position: Co-investigator

2. Grant Title: Analysis of the performance of the polymerase chain reaction as a screening/ diagnostic test for human immunodeficiency virus infection
Principal Investigator: Douglas K. Owens
Project Management: Douglas K. Owens
Agency: VA Center for Health Care Evaluation: HSR&D Field Program, Palo Alto
ID Number: OWE0001
Term: March 1991 to September 1991

3. Grant Title: Screening for Human Immunodeficiency Virus
Principal Investigator: Douglas K. Owens
Project Management: Douglas K. Owens
Agency: Health Services Research and Development Service, Department of Veterans Affairs
ID Number: IIR #91-044
Term: July 1991 to October 1992

4. Grant Title: A Dissemination Model for Faculty Development to improve Ambulatory Care Education at Western Region VAMCs.

Principal Investigator: Douglas K. Owens, M.D.

Project Management: Georgette Stratos, Ph.D.

Agency: Department of Veterans Affairs

ID Number: ACE proposal 91-03

Term: January 1992 to December 1993

5. Grant Title: Cost-Effectiveness of HIV Screening

Principal Investigator: Douglas K. Owens

Project Management: Douglas K. Owens

Agency: VA Center for Health Care Evaluation: HSR&D Field Program, Palo Alto

ID Number: OWE0001

Term: March 1992 to September 1992

6. Grant Title: Evaluation of Diagnostic Tests for HIV Infection

Principal Investigator: Douglas K. Owens

Project Management: Douglas K. Owens

Agency: NIH

ID Number: 5P30 AI 27762-04

Term: August 1992 to August 1993

7. Grant Title: Guidelines for HIV Screening

Principal Investigator: Douglas K. Owens

Project Management: Douglas K. Owens

Agency: Agency for Health Care Policy and Research

ID Number: 1 R03 HS07232-01

Term: September 1992 to February 1994

8. Grant Title: Costs and Benefits of Screening for HIV Infection (Career Development Award)

Principal Investigator: Douglas K. Owens

Agency: VA Health Services Research and Development Service

ID Number: 92-308A

Term: October 1992 to September 1995

9. Grant Title: VA Ambulatory Care Fellowship Program

Program Director: Douglas K. Owens

Agency: VA Office of Academic Development

Term: July 1993 to June 2007

10. Grant Title: Women, Adolescents and HIV Infection: Cost/Benefit Analysis

Principal Investigator: Douglas K. Owens

Agency: Universitywide AIDS Research Project, University of California

Term: January 1993 to June 1994

11. Grant Title: Development and evaluation of a physician's computer workstation for use in the General Medical Clinic at the VA Medical Center, Palo Alto

Principal Investigator: Douglas K. Owens

Agency: Department of Veterans Affairs

Term: October 1993 to September 1995

12. Grant Title: Cost-Effectiveness Analysis of Warfarin and Aspirin in Elderly Patients with Nonvalvular Atrial Fibrillation

Principal Investigator: Douglas K. Owens

Agency: Palo Alto Institute for Research and Education

Term: October 1993 to September 1994

13. Grant Title: An Evaluation of the Costs and Benefits of Screening Inpatients for HIV Infection

Principal Investigator: Douglas K. Owens

Agency: Palo Alto Institute for Research and Education

Term: May 1994 to April 1995

14. Grant Title: Cardiac Arrhythmia PORT

Principal Investigator: Mark A. Hlatky

Agency: Agency for Health Care Policy and Research

ID Number: 1 R01 HS08362-01

Term: 8/01/94 - 7/31/00

Position: Co-investigator

15. Grant Title: VA Medical Informatics Postdoctoral Fellowship Program

Program Director: Douglas K. Owens

Agency: VA Office of Academic Development

Term: July 1995 to June 2007

16. Grant Title: Prevention of Sudden Cardiac Death

Principal Investigator: Douglas K. Owens

Agency: VA Health Services Research and Development

ID Number:

Term: 10/1/95 to 9/30/99

17. Grant Title: Public Health Impact and Cost-Effectiveness of HIV Interventions

Principal Investigator: Margaret Brandeau (Stanford subcontract), Douglas K. Owens (Co-Principal Investigator, Stanford subcontract)

Agency: NIDA

ID Number: 1-R01-DA09531

Term: 6/15/96 to 4/30/2001

18. Grant Title: Cost effectiveness: Vaccine Interventions for Prevention of Gastric Cancer

Principal Investigator: Douglas K. Owens; Julie Parsonnet (Co-Principal Investigator)

Agency: Centers for Disease Control and Prevention

ID Number: 97FED09763

Term: 9/5/97 to 9/30/00

19. Grant Title: 18-F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging in Patients with Solitary Pulmonary Nodules (economic sub-study)

Co-Investigator: Douglas K. Owens

Agency: VA

ID Number: VA Cooperative Study 327

Term: 6/1/98 to 12/31/2004

20. Grant Title: Valley Fever Vaccine Project

Principal Investigator: Douglas K. Owens

Agency: Cal State Bakersfield Foundation

ID Number: NA

Term: 6/1/99 to 10/1/99

21. Grant Title: Identification of HIV Infection among Veterans

Principal Investigator: Douglas K. Owens

Agency: Department of Veterans Affairs

ID Number: 99-047-1

Term: 10/1/99 to 3/31/04

22. Grant Title: Evaluation of the cost effectiveness of a PET-FDG strategy before hepatic resection for colorectal metastases, Subcontract to Stanford: Diagnostic Simulation Model
Principal Investigator: Gillian Sanders,
Agency: BFG Funding Agency, Guy's and St. Thomas Hospital Trust
Term: 4/1/99 to 9/30/00
Position: Co-investigator
23. Grant Title: Computer-based guidelines to prevent sudden cardiac death
Principal Investigator: Gillian Sanders; Co-Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: R01 HS10623-01A1
Term: 9/30/00 to 8/31/03
24. Contract Title: Bioterrorism: Use of decision support systems.
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: 290-97-0013
Term: 9/30/00 to 9/29/02
25. Grant Title: Economic Substudy Tri-National Trial 1: Options in Management with Anti-Retrovirals (TNT-1: OPTIMA) VA Cooperative Study No. 512:
Principal Investigator: Douglas K. Owens
Agency: Department of Veterans Affairs
ID Number: Cooperative Study 512
Term: 4/1/01 to 3/31/07
26. Contract title: Stanford-UCSF Evidence Based Practice Center (Master Agreement)
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: 290-02-0017
Term: 06/17/02-06/30/07
27. Grant Title: Making Better Decisions: Policy Modeling for AIDS and Drug Abuse
Principal Investigator: Douglas K. Owens
Agency: National Institutes of Health
ID Number: 1 R01 DA15612-01
Term: 9/25/02 to 6/30/07
28. Contract Title: Evidence Report on Regional Models for Bioterrorism Preparedness.
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: 290-97-0017
Term: 11/30/02 to 5/29/04
29. Grant Title: Cost Effectiveness of HIV Screening and Treatment in the Elderly. Supplement to Center on the Economics and Demography of Health and Aging
Principal Investigator: Douglas K. Owens (Supplement); Alan Garber, PI (Center on the Economics and Demography of Health and Aging)
Agency: National Institutes of Health
ID Number: 3 P30 AG17253-04S3
Term: 9/30/02 to 6/30/04
30. Contract Title: Evidence Report on Best Practices for Quality Health Care.
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality

ID Number: 290-02-0017, Task Order No. 3
Term: 5/30/03 to 5/30/07

31. Grant Title: Making Better Decisions: Policy Modeling for AIDS and Drug Abuse, Supplement 02 S1
Principal Investigator: Douglas K. Owens
Agency: National Institutes of Health
ID Number: 1 R01 DA15612-01
Term: 7/1/03 to 6/30/07

32. Grant Title: Improving HIV Screening with Nurse-Based Rapid Testing and Streamlined Counseling
Principal Investigator: Steven Asch; Co-Principal Investigator: Douglas K. Owens
Agency: Department of Veterans Affairs
ID Number: IIR 04-023-1
Term: 5/1/05 to 11/1/07

33. Contract title: Comparative effectiveness reviews for MMA Section 1013
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: 290-02-0017, Task Order No. 5
Term: 6/15/2005 to 9/30/08

34. Contract title: Diagnosis and Management of Pediatric Anthrax
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: 290-02-0017, Task Order No. 4
Term: 5/16/2005 to 3/15/06

35. Grant Title: VA Physician Post-Residency Fellowship in Health Services Research and Development
Principal Investigator: Douglas K. Owens (Program Director)
Agency: VA Office of Academic Affairs
Term: 7/1/2006 to 6/30/2011

36. Grant Title: VA Palo Alto Center for Translational Research in Chronic Viral Infections
Principal Investigator: Mark Holodniy
Agency: Department of Veterans Affairs
Term: 10/1/2006 to 9/30/2010
Role: Co-investigator

37. Grant Title: Making Better Decisions: Policy Modeling for AIDS and Drug Abuse
Principal Investigator: Douglas K. Owens
Agency: National Institutes of Health
ID Number: 2 R01 DA15612-016
Term: 7/9/07 to 6/30/13

38. Grant Title: Stanford Center for Clinical and Translational Education and Research (SCCTR)
Principal Investigator: Harry B. Greenberg
Agency: National Institutes of Health
ID Number: 2UL1 RR025744
Term: 5/19/08-4/30/2013
Role: Co-investigator, Community Engagement

39. Grant Title: Evaluation of Computerized Decision Support for Managing Lung Nodules
Principal Investigator: Michael Gould
Agency: National Institutes of Health
ID Number: 2R01CA117840
Term: 6/27/05-2/28/11

Role: Co-investigator

40. Grant Title: Comparative effectiveness of ART for HIV in patients with comorbidities
Principal Investigator: Douglas K. Owens
Agency: National Institutes of Health
ID Number: 1RC1A1086927-01
Term: 9/26/09 to 9/26/2012

41. Grant Title: Evaluation of the HSR&D Career Development Program
Principal Investigator: John w. Finney
Agency: VA HSR&D Service
ID Number: SDR 10-182
Term: 7/1/2010 to 12/31/2011
Role: Co-investigator

42. Grant title: Training Program in Health Services Research
Principal Investigator: Douglas K. Owens
Agency: Agency for Healthcare Research and Quality
ID Number: T32 HS 000028
Term: 6/30/2014

43. Grant Title: Management of HIV as chronic disease
Principal Investigator: Douglas K. Owens
Agency: VA HSR&D Service
ID Number: IIR 11-045-2
Term: 5/1/2012 to 4/31/2014

44. Grant title: Phase II Evaluation of the VA Health Services Research and Development Career Development Program
Principal Investigator: Ruth Cronkite
Agency: VA HSR&D Service
ID Number: SDR 11-439-1
Term: 1/1/2013 to 6/30/2015
Role: Co-investigator

45. Grant Title: Cost-effective Uses of New Hepatitis C Treatments and their VA Budgetary Impact
Principal Investigator: Douglas K. Owens
Agency: VA HSR&D Service
ID Number: IIR 12-059-2
Term: 6/1/2013 to 5/30/2016

46. Grant Title: Making Better Decisions: Policy Modeling for AIDS and Drug Abuse
Principal Investigator: Douglas K. Owens
Agency: National Institutes of Health
ID Number: 2 R01 DA015612-011
Term: 5/1/2013 to 1/31/2018

47. Grant Title: The handling of missing data induced by the inclusion of time-varying covariates in comparative effectiveness research involving HIV patients
Principal Investigator: Manisha Desai
Agency: Patient Centered Outcomes Research Institute
Term: 5/1/2013 to 1/31/2016

48. Grant Title: Developing capacity to assess health interventions and poverty reduction
Principal Investigator: Douglas K. Owens
Agency: Stanford Global Development and Poverty Initiative

Term: 7/1/2014 to 6/30/2019

49. Grant Title: Economic modeling for prevention of disease

Principal Investigator: James G. Kahn

Agency: Centers for Disease Control and Prevention

ID Number: 10/01/13-08/31/15

Term: 09/30/14-09/29/19

Role: Stanford Principal Investigator

50. Grant Title: Cost Effectiveness of Interventions to Reduce Morbidity from Opioid Dependency

Principal Investigator: Douglas K. Owens

Agency: VA HSR&D Service

ID Number: IIR

Term: 4/1/2018 to 12/31/2021

51. Grant Title: Stanford Health Services Research Training Program

Principal Investigator: Laurence C. Baker, Douglas K. Owens

Agency: Agency for Health Care Research and Quality

ID Number: 1T32HS026128-01

Term: 7/1/2018 to 6/30/2023

Role: Principal Investigator with Laurence C. Baker, and Co-Director

52. Grant Title: Making Better Decisions: Policy Modeling for AIDS and Drug Abuse

Principal Investigator: Douglas K. Owens

Agency: National Institutes of Health

ID Number: 2R37DA01561216

Term: 2/15/19 to 2/15/2028

53. Grant Title: Prevention Policy Modeling Lab

Principal Investigator: Joshua Salomon

Agency: Centers for Disease Control and Prevention

ID Number: 1NU38PS004651-01

Term: 9/30/19 to 9/29/24

Role: Co-investigator

54. Grant Title: Implicit Bias in the Evidence: An Evaluation of Female-Predominant Disease

Principal Investigator: Julia Simard

Agency: National Institutes of Health

ID Number: 1R01AI15453301

Term: 9/30/19 to 9/29/24

Role: Co-investigator

55. Grant Title: SARS-COV-2 Screening in dialysis facilities: Building an optimal strategy to protect high risk populations

Principal Investigator: Shuchi Anand, Glenn Chertow, Julie Parsonnet)

Agency: National Institutes of Health

ID Number: U01AI169477

Term: 1/11/22 to 12/31/22

Role: Co-investigator

56. Grant Title: Sexual harassment training of principal investigators

Principal Investigator: Arghavan Salles

Agency: National Institutes of Health

ID Number: 1R01GM147063-01

Term: 07/2022 – 06/2027

Role: Co-investigator

57. Grant Title: Pandemic preparedness for underserved persons in the US: Harnessing data from the RADx-UP consortium

Principal Investigator: Shuchi Anand

Agency: National Institutes of Health

ID Number: R21MD019394

Term: 4/01/2024 to 3/31/2026

Role: Co-investigator

BIBLIOGRAPHY

DOUGLAS K. OWENS, M.D., M.S.

Journal Articles

1. Coull BM, Owens DK and Cutler RW. Release of amino acids into the vitreous in the intact albino rat: Effect of photic stimulation, potassium and ouabain. *Brain Research* 1981; 210:301-309.
2. Cochi SL, Markowitz LE, Joshi DD, Owens RC Jr, Stenhouse DH, Regmi DN, Shrestha RPB, Acharya IL, Manandhar M, Gurubacharya VL, Owens D, Reingold AL. Control of epidemic group A meningococcal meningitis in Nepal. *International Journal of Epidemiology* 1987; 16:91-97.
3. Haponik EF, Sox HC, Lillington G, Owens DK, Gottlieb J, Reichman L, Jordan T, Colice G. Decision analysis for chest clinicians (Symposium). *American Review of Respiratory Disease* 1988; 138:1058-1060.
4. Owens, DK, Sox HC Jr, Inouye SK. Strategies for test selection in the staging of lung neoplasms. *Seminars in Respiratory Medicine* 1989; 10:195-202.
5. Nease RF Jr, Owens DK, Sox HC Jr. Threshold analysis using diagnostic tests with multiple results. *Medical Decision Making* 1989; 9:91-103.
6. Nease RF, Owens DK. Assessment and representation of prior beliefs: Unexpected implications of the uniform distribution. *Medical Decision Making* 1990; 10:112-114.
7. Brandeau ML, Lee HL, Owens DK, Sox CH, Wachter RM. Policy analysis of human immunodeficiency virus screening and intervention: An overview of modeling approaches. *AIDS Public Policy Journal* 1990; 5: 119-131.
8. Brandeau ML, Lee HL, Owens DK, Sox CH, Wachter RM. A policy model of human immunodeficiency virus screening and intervention. *Interfaces* 1991; 21: 5-25.
9. Owens DK, Nease RF. Occupational exposure to human immunodeficiency virus (HIV) and hepatitis B (HBV): A comparative analysis of risk. *American Journal of Medicine* 1992; 92: 503-512.
10. Albright CL, Farquhar JW, Fortmann SP, Dachs DPL, Owens DK, Gottlieb L, Stratos GA, Bergen MR, Skeff KM. Impact of a clinical preventive medicine curriculum for primary care faculty: results of a dissemination model. *Preventive Medicine* 1992; 21: 419-435.
11. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus infection: A cost-benefit analysis. *Archives of Internal Medicine* 1992; 152: 2229-2237.
12. Brandeau ML, Owens DK, Sox CH, Wachter RM. Screening women of childbearing age for human immunodeficiency virus infection: A model-based policy analysis. *Management Science* 1993; 39: 72-92.
13. Owens DK, Nease RF. Development of outcome-based practice guidelines: A method for structuring problems and synthesizing evidence. *Joint Commission Journal on Quality Improvement* 1993; 19: 248-263.
14. Nease RF, Owens DK. A method for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. *Medical Decision Making* 1994; 14: 382-392.
15. Sanders GD, Owens DK, Padian N, Cardinalli AB, Sullivan AN, Nease RF. A computer-based interview to identify HIV risk behaviors and to assess patient preferences for HIV-related health states. *Journal of the American Medical Informatics Association* 1994; Annual Supplement: 20-24.
16. El-Sadr W, Oleske JM, Agins BD, Bauman K, Brosgart C, Brown GM, Geaga JV, Greenspan D, Hein K, Holzemer WL, Jackson RE, Lindsay MK, Makadon HJ, Moon MW, Nease RF Jr, Owens DK, Rappoport CA, Scott

- G, Shervington WW, Shulman LC, Wofsy CB. Managing early HIV infection. *American Family Physician* 1994; 49: 801-814.
17. Owens DK, Harris RA, Scott PMcJ, Nease RF. Screening surgeons for HIV infection: a cost-effectiveness analysis. *Annals of Internal Medicine* 1995; 122: 641-652.
18. Mason JJ, Owens DK, Harris RA, Cooke JP, Hlatky MA. The role of coronary angiography and coronary revascularization before non-cardiac vascular surgery. *Journal of the American Medical Association* 1995; 273: 1919-1925.
19. Rotman BL, Sullivan AN, McDonald T, DeSmedt P, Goodnature D, Higgins MC, Suermondt HJ, Young C, Owens DK. A randomized evaluation of a computer-based physician workstation: Design considerations and baseline results. *Journal of the American Medical Informatics Association* 1995; Annual Supplement: 693-697.
20. Sanders GD, Harris RA, Hlatky MA, Owens DK. Prevention of sudden cardiac death: a probabilistic model for decision support. *Journal of the American Medical Informatics Association* 1995; Annual Supplement 258-262.
21. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. *Journal of the American Medical Association* 1995; 274: 1839-1845.
22. Sanders GD, Dembitzer AD, Heidenreich PA, McDonald KM, Owens DK. Presentation and explanation of medical decision models using the world wide web. *Journal of the American Medical Informatics Association* 1996; Annual Supplement: 60-64.
23. Owens DK, Nease RF, Harris RA. Cost-effectiveness of human immunodeficiency virus (HIV) screening in acute-care settings. *Archives of Internal Medicine* 1996; 156: 394-404.
24. Owens DK, Holodniy M, Garber AM, Scott J, Sonnad S, Moses L, Kinosian B, Schwartz JS. The polymerase chain reaction for the diagnosis of HIV infection in adults: A meta-analysis with recommendations for clinical practice and study design. *Annals of Internal Medicine* 1996; 124: 803-815.
25. Owens DK, Holodniy M, McDonald TW, Scott J, Sonnad S. A meta-analytic evaluation of the polymerase chain reaction (PCR) for diagnosis of human immunodeficiency virus (HIV) infection in infants. *Journal of the American Medical Association*. 1996; 275:1342-1348.
26. Parsonnet J, Harris RA, Hack HH, Owens DK. Modeling cost effectiveness of *Helicobacter pylori* screening to prevent gastric cancer: a mandate for clinical trials. *Lancet*. 1996; 348: 150-154.
27. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin therapy on quality of life. *Archives of Internal Medicine* 1996; 156: 1829-1836.
28. Rotman BL, Sullivan AN, McDonald T, Brown BW, DeSmedt P, Goodnature D, Higgins MC, Suermondt HJ, Young C, Owens DK. A randomized controlled trial of a computer-based physician workstation in an outpatient setting: Implementation barriers to outcome evaluation. *Journal of the American Medical Informatics Association* 1996; 3:340-348.
29. Owens DK, Sanders GD, Harris RA, McDonald KM, Heidenreich PA, Dembitzer AD, Hlatky MA. Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death. *Annals of Internal Medicine* 1997; 126:1-12.
30. Owens DK, Cardinalli AB, Nease RF. Physicians' assessments of the utility of health states associated with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. *Quality of Life Research* 1997; 6: 77-86.

31. Owens DK, Shachter RD, Nease RF. Representation and analysis of medical decision problems with influence diagrams. *Medical Decision Making* 1997; 17: 241-262.
32. Nease RF, Owens DK. Use of influence diagrams to structure medical decisions. *Medical Decision Making* 1997; 17: 263-275.
33. Stratos GA, Bergen MR, Albright CL, Skeff KM, Owens DK. Use of faculty development to improve ambulatory-care education. *Medical Teacher* 1997; 19: 285-292.
34. Owens DK, Nease RF. A normative analytic framework for development of practice guidelines for specific clinical populations. *Medical Decision Making* 1997; 17: 409-426.
35. Salpeter SR, Sanders GD, Salpeter EE, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis. *Annals of Internal Medicine* 1997; 127: 1051-1061.
36. Owens DK. Use of medical informatics to implement and develop practice guidelines. *Western Journal of Medicine* 1998; 168:166-175.
37. Owens DK. Patient preferences and the development of practice guidelines. *Spine* 1998; 23:1073-1079.
38. Edwards DM, Shachter RD, Owens DK. A dynamic HIV-transmission model for evaluating the costs and benefits of vaccine programs. *Interfaces* 1998; 28:144-166.
39. Owens DK, Brandeau ML, Sox CH. Effect of relapse to high-risk behavior on the costs and benefits of a program to screen women for human immunodeficiency virus (HIV). *Interfaces* 1998; 28:52-74.
40. Owens DK, Edwards DE, Shachter RD. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics. *AIDS* 1998; 12:1057-1066.
41. Gage BF, Cardinalli AB, Owens DK. Cost effectiveness of preference-based antithrombotic therapy for patients who have nonvalvular atrial fibrillation. *Stroke* 1998; 29:1083-1091.
42. Koenig BA, Greely HT, McConnell LM, Silverberg HL, Raffin TA, and the members of the Breast Cancer Working Group of the Stanford Program in Genomics, Ethics, and Society. Genetic testing for BRCA1 and BRCA2: Recommendations of the Stanford Program in Genomics, Ethics, and Society. *Journal of Women's Health* 1998; 7:531-545.
43. Cheng CHF, Sanders GD, McDonald KM, Heidenreich PA, Hlatky MA, Owens DK. Design of a modular, extensible decision support system for arrhythmia therapy. *Journal of the American Medical Informatics Association* 1998; Annual Supplement: 693-697.
44. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The effects of protease inhibitors on the spread of HIV and the development of drug-resistant HIV strains: a simulation study. *Simulation* 1998; 71:262-275.
45. McConnell LM, Sanders GD, Owens DK. Evaluation of genetic tests: APOE genotyping for the diagnosis of alzheimer disease. *Genetic Testing* 1999; 3: 47-53.
46. Sanders GD, Hagerty CG, Sonnenberg FA, Hlatky MA, Owens DK. Distributed decision support using a web-based interface: Prevention of sudden cardiac death. *Medical Decision Making* 1999; 19: 157-166.
47. Richter A, Brandeau ML, Owens DK. An analysis of optimal resource allocation for prevention of infection with human immunodeficiency virus (HIV) in injection drug users. *Medical Decision Making* 1999; 19: 167-179.
48. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Health-related quality of life after liver transplantation: a meta-analysis. *Liver Transplantation and Surgery* 1999; 5:1-15.

49. Harris RA, Owens DK, Witherell H, Parsonnet J. Helicobacter pylori and gastric cancer: What are the benefits of screening only for the CagA phenotype of H. pylori? Helicobacter 1999; 4: 69-76.
50. Heidenreich PA, Masoudi FA, Maini B, Chou TM, Foster E, Schiller NB, Owens DK. Echocardiography in patients with suspected endocarditis: A cost-effectiveness analysis. American Journal of Medicine 1999; 107:198-208.
51. Rupnow MF, Owens DK, Shachter R, Parsonnet J. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine methodology. Helicobacter 1999; 4: 272-280.
52. Vold-Pepper P, Owens DK. Cost effectiveness of the pneumococcal vaccine in the United States navy and marine corps. Clinical Infectious Diseases 2000; 30:157-164.
53. Sanders GD, Nease RF, Owens DK. Design and pilot evaluation of a system to develop computer-based site-specific practice guidelines from decision models. Medical Decision Making 2000; 20:145-159.
54. Rupnow MFT, Shachter RD, Owens DK, Parsonnet J. Using a dynamic transmission model to predict the future of H. pylori and associated diseases in the US. Emerging Infectious Diseases 2000; 6:228-37.
55. Sim I, Owens DK, Lavori PW, Rennels GD. Electronic trial banks: a complementary method for reporting randomized trials. Medical Decision Making 2000; 20:440-450.
56. Yock CA, Boothroyd DB, Owens DK, Winston C, Hlatky MA. Projected long-term costs of coronary stenting in multivessel coronary disease based on the experience of the Bypass Angioplasty Revascularization Investigation. American Heart Journal 2000; 140:556-564.
57. Gerson LB, Gage BF, Owens DK, Triadafilopoulos G. Effect and outcomes of the ASGE guidelines on the perendoscopic management of patients who take anticoagulants. American Journal of Gastroenterology 2000; 95:1717-24.
58. Cheng CHF, Sanders GD, Hlatky MA, Heidenreich PA, McDonald KM, Lee BK, Larson MS, Owens DK. Cost-effectiveness of radiofrequency ablation for supraventricular tachycardia. Annals of Internal Medicine 2000; 133: 864-876.
59. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States. Journal of Acquired Immune Deficiency Syndromes 2000; 25:403-416.
60. Bozzette SA, Phillips B, Asch S, Gifford AL, Lenert L, Menke T, Oritz E, Owens D, Deyton L. Quality Enhancement Research Initiative for human immunodeficiency virus/acquired immunodeficiency syndrome: framework and plan. HIV-QUERI Executive Committee. Medical Care. 2000; Jun;38(6 Suppl 1):I60-9.
61. Sanders GD, Nease RF, Owens DK. Publishing web-based guidelines using interactive decision models. Journal of Evaluation in Clinical Practice 2001; 7: 175-189.
62. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Employment and alcohol use after liver transplantation for alcoholic and nonalcoholic liver disease: A systematic review. Liver Transplantation 2001; 7:191-203.
63. Barnato AE, Sanders GD, Owens DK. Cost effectiveness of a potential vaccine for *Coccidioides immitis*. Emerging Infectious Diseases 2001; 7:797-806.
64. Gould MK, Maclean CC, Kushner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. Journal of the American Medical Association 2001; 285:914-924.

65. Sanders GD, Hlatky MA, Every NR, McDonald KM, Heidenreich PA, Parsons LS, Owens DK. Potential cost effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction. *Annals of Internal Medicine* 2001; 135: 870-883.
66. Rupnow MFT, Shachter RD, Owens DK, Parsonnet J. Quantifying the population impact of a prophylactic *Helicobacter pylori* vaccine. *Vaccine* 2001; 20:879-85.
67. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA. Effect of risk stratification on the cost effectiveness of the implantable cardioverter defibrillator. *American Heart Journal* 2002; 144:440-448.
68. Pepper PV, Owens DK. Cost effectiveness of the pneumococcal vaccine in healthy younger adults. *Medical Decision Making* 2002; 22(Suppl):S45-S57.
69. Owens DK. Analytic tools for public-health decision making. *Medical Decision Making* 2002; 22(Suppl):S3-S10.
70. Gould MK, Sanders GD, Barnett PG, Maclean CC, Rydzak CE, McClellan MB, Owens DK. Cost effectiveness of alternative management strategies for patients with solitary pulmonary nodules. *Annals of Internal Medicine* 2003; 138:724-735.
71. Snow V, Weiss KB, Mottur-Pilson C, Clinical Efficacy Assessment Subcommittee of the American College of Physicians. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. *Annals of Internal Medicine* 2003; 138: 587-592.
72. Yock CA, Boothroyd DB, Owens DK, Garber AM, Hlatky MA. Cost effectiveness of bypass surgery versus stenting in patients with multivessel coronary artery disease. *American Journal of Medicine* 2003; 115:382-389.
73. Gould MK, Kushner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, Chan JK, Owens DK. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta analysis. *Annals of Internal Medicine* 2003; 139:879-92.
74. Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, Michl K, Owens DK, Susman J, Allen DI, Mottur-Pilson C, the Joint AAFP/ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. *Annals of Internal Medicine* 2003; 139:1009-17.
75. Bravata DM, Sundaram V, McDonald KM, Smith WM, Szeto H, Schleinitz MD, Owens DK. Evaluating detection systems and diagnostic decision support systems for bioterrorism response. *Emerging Infectious Diseases* 2004; 10: 100-108.
76. Schleinitz MD, Socks DA, Weiss JP, Owens DK. Clopidogrel versus aspirin for secondary prophylaxis of thrombotic events: a cost-effectiveness analysis. *American Journal of Medicine* 2004; 116:797-806.
77. Bravata DM, McDonald KM, Szeto H, Smith WM, Rydzak C, Owens DK. A conceptual framework for evaluating information technologies and decision support systems for bioterrorism preparedness and response. *Medical Decision Making* 2004; 24:192-206.
78. Bravata DM, McDonald KM, Smith WM, Rydzak C, Szeto H, Buckeridge DL, Haberland C, Owens DK. Systematic review: surveillance systems for early detection of bioterrorism-related diseases. *Annals of Internal Medicine* 2004; 140:910-922.
79. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis secondary to chronic hepatitis C infection. *Alimentary Pharmacology and Therapeutics* 2004; 19:1159-72.

80. Snow V, Barry P, Fihn SD, Gibbons RJ, Owens DK, Williams SV, Weiss KB, Mottur-Pilson C. Evaluation of primary care patients with chronic stable angina: guidelines from the American College of Physicians. *Annals of Internal Medicine* 2004; 141:57-64.
81. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus. *Gastrointestinal Endoscopy* 2004; 60:739-56.
82. Snow V, Aronson MD, Hornbake ER, Mottur-Pilson C, Weiss KB, Clinical Efficacy Subcommittee of the American College of Physicians. Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2004; 140:644-649.
83. Snow V, Barry P, Fihn SD, Gibbons RJ, Owens DK, Williams SV, Mottur-Pilson C, Weiss KB; American College of Physicians and American College of Cardiology Chronic Stable Angina Panel. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2004; 141:562-7.
84. Groeneveld PW, Owens DK. Cost effectiveness of training unselected laypersons in cardiopulmonary resuscitation and defibrillation. *American Journal of Medicine* 2005; 118:58-67.
85. Hlatky MA, Sanders GD, Owens DK. Evidence-based medicine and policy: the case of the implantable cardioverter defibrillator. *Health Affairs* 2005; 24:42-51.
86. Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK. Cost effectiveness of screening for HIV in the era of highly active antiretroviral therapy. *New England Journal of Medicine* 2005; 352:570-585.
87. Fowler RA, Nouri B, Sanders GD, Bravata DM, Gastwirth JM, Peterson D, Broker AG, Garber AM, Owens DK. Cost effectiveness of defending against bioterrorism: a comparison of vaccination and antimicrobial prophylaxis against anthrax. *Annals of Internal Medicine* 2005; 142:601-610.
88. Bravata DM, McDonald KM, Shojania KG, Sundaram V, Owens DK. Challenges in systematic reviews: synthesis of topics related to the delivery, organization, and financing of healthcare. *Annals of Internal Medicine* 2005; 142: 1056-1065.
89. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K, the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2005; 142:525-531.
90. Buckeridge DL, Switzer P, Owens D, Siegrist D, Pavlin J, Musen M. An evaluation model for syndromic surveillance: assessing the performance of a temporal algorithm. In *Syndromic Surveillance: Reports from a National Conference, 2004*. *MMWR* 2005; 54(Suppl):109-115.
91. Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of the implantable cardioverters. *New England Journal of Medicine* 2005; 353:1471-8.
92. Qaseem A, Aronson M, Fitterman N, Snow V, Weiss KB, Owens DK, the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for hereditary hemochromatosis: A clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2005; 143:517-21.
93. Holty J-EC, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. *Annals of Internal Medicine* 2006; 144: 270-280.
94. Guyatt G, Baumann M, Pauker S, Halperin J, Maurer J, Owens DK, Tosteson ANA, Carlin B, Gutterman D, Prins M, Lewis SZ, Schünemann H. Addressing resource allocation issue in recommendations from clinical practice guideline panels. *Chest* 2006; 129:182-187.

95. Honiden S, Sundaram V, Nease RF, Holodniy M, Lazzeroni LC, Zolopa A, Owens DK. The effect of diagnosis with HIV infection on quality of life. *Quality of Life Research* 2006; 15:69-82.
96. Walsh JME, McDonald KM, Shojania KG, Sundaram V, Nayak S, Lewis R, Owens DK, Goldstein MK. Quality improvement strategies for hypertension management: a systematic review. *Medical Care* 2006; 44:646-57.
97. Liu H, Michaud K, Nayak S, Karpf DB, Owens DK, Garber AM. The cost effectiveness of parathyroid hormone and alendronate in high-risk osteoporotic women. *Archives of Internal Medicine* 2006; 166:1209-1217.
98. Nayak S, Olkin I, Liu H, Grabe M, Gould MK, Allen IA, Owens DK, Bravata DM. Accuracy of calcaneal quantitative ultrasound for identifying patients meeting the World Health Organization's diagnostic criteria for osteoporosis: a systematic review. *Annals of Internal Medicine* 2006; 144: 832-841.
99. Qaseem A, Snow V, Fitterman N, Hornbake ER, Lawrence VA, Smetana GW, Weiss K, and Owens DK for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing non-cardiothoracic surgery: a guideline from the American College of Physicians. *Annals of Internal Medicine* 2006; 144:575-580.
100. Long EF, Brandeau ML, Vinichenko T, Tole SP, Schwartz A, Sanders GD, Owens DK. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. *AIDS* 2006; 20:2207-2215.
101. Shojania KG, Ranji SR, McDonald KM, Grimshaw JM, Shaw LK, Rushakoff RJ, Owens DK. Effects of quality improvement strategies for type 2 diabetes on glycemic control: a meta-regression analysis. *Journal of the American Medical Association* 2006; 296:427-440.
102. Bravata DM, Zaric GS, Holty JEC, Brandeau ML, Wilhelm ER, McDonald KM, Owens DK. Reducing mortality from anthrax bioterrorism: strategies for stockpiling and dispensing medical and pharmaceutical supplies. *Biosecurity and Bioterrorism* 2006; 4:244-62.
103. Buckeridge DL, Owens DK, Switzer P, Frank J, Musen MA. Evaluating detection of an inhalational anthrax outbreak. *Emerging Infectious Diseases* 2006; 12:1942-1949.
104. Hlatky MA, Owens DK, Sanders GD. Cost effectiveness as an outcome in randomized clinical trials. *Clinical Trials (London, England)*. 2006; 3:543-51.
105. Bravata DM, Wang E, Holty JEC, Lewis R, Wise PH, McDonald KM, Owens DK. Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases from 1900 to 2005. *Archives of Pediatrics and Adolescent Medicine* 2007; 161:896-905.
106. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Tempio P, Holodniy M, Sanders GD, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Chavis D, Borowsky LH, Yano EM, Jensen P, Simberkoff M, Bozzette SA. HIV testing and screening in an integrated health care system. *Journal of General Internal Medicine* 2007; 22:315-320.
107. Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal J, Bass E, Weiss KB, Green L, Owens DK. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. *Annals of Family Medicine* 2007; 5:57-62.
- Also published as: Qaseem A, Snow V, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal J, Bass EB, Weiss KB, Green L, Owens DK, Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism.. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. *Annals of Internal Medicine* 2007; 146:454-458.

108. Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Weiss KB, Green L, Owens DK. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. *Annals of Internal Medicine* 2007; 146: 204-210.

Also published as: Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Weiss KB, Green L, Owens DK. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. *Annals of Family Medicine* 2007; 5:74-80.

109. Qaseem A, Snow V, Sherif K, Aronson M, Weiss KB, Owens DK for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening mammography for women between age 40 and 49: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2007; 146:511-515.

109. Chou R, Qaseem A, Snow V, Casey D, Cross T, Shekelle P, Owens DK. Diagnosis and treatment of lower back pain: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2007; 147:478-491.

110. Bravata DM, Gienger AL, McDonald KM, Sundaram V, Perez M, Varghese R, Kapoor JR, Ardehali R, Owens DK, Hlatky MA. The comparative effectiveness of percutaneous coronary interventions and coronary artery bypass surgery: a systematic review. *Annals of Internal Medicine* 2007; 147:703-716.

111. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Taylor K, VanGroningen R, Shadle VM, McWhorter VC, Agoncillo T, Haren N, Nyland J, Tempio P, Khayr W, Dietzen D, Jensen P, Simberkoff MS, Bozzette SA, Holodniy M. The prevalence of HIV-1 infection among inpatients and outpatients in Department of Veterans Affairs Health Care Systems: implications for screening programs for HIV. *American Journal of Public Health* 2007; 97:2173-2178.

112. Andersson KM, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual HIV epidemic in low- and middle-income countries: a South African example. *Journal of Acquired Immunity Deficiency Syndrome* 2007; 46:78-90. PMID: PMC3570247.

113. Qaseem A, Vijan S, Snow V, Cross T, Weiss KB, Owens DK. Glycemic control and type 2 diabetes mellitus: the optimal A1c targets. A guidance statement from the American College of Physicians. *Annals of Internal Medicine* 2007; 147:417-422.

114. Qaseem A, Snow V, Shekelle P, Sherif K, Wilt TJ, Weinberger S, Owens DK. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2007; 147:633-638.

115. Brandeau ML, Hutton DW, Owens DK, Bravata DM. Planning the bioterrorism response supply chain: learn and live. *American Journal of Disaster Medicine* 2007; 2: 231-247.

116. Schultz EM, Sanders GD, Trotter PR, Patz EF, Silvestri GA, Owens DK, Gould MK. Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. *Thorax* 2008; 63:335-341.

117. Zaric GS, Bravata DM, Holty JEC, McDonald KM, Owens DK, Brandeau ML. Modeling the logistics of response to anthrax bioterrorism. *Medical Decision Making* 2008; 28:332-350.

118. Qaseem A, Snow V, Shekelle P, Casey D, Cross T, Owens DK. Evidence-based Interventions to improve palliative care of pain, dyspnea, and depression at the end of life: A clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2008; 148:141-146.

119. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy (HAART) in men who have sex with men. *Medical Decision Making* 2008; 28: 359-376. PMID: PMC3243050.
121. Qaseem A, Snow V, Cross TJ, Forcica MA, Hopkins R, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Owens DK. Current pharmacologic treatment of dementia: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. *Annals of Internal Medicine* 2008; 148:370-378.
120. Bendavid E, Young SD, Bayoumi AM, Sanders GD, Katzenstein DA, Owens DK. Cost effectiveness of HIV monitoring strategies in resource-limited settings – a Southern African analysis. *Archives of Internal Medicine* 2008; 168:1910-1918. PMID: PMC2894578.
121. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost effectiveness of HIV screening in patients older than 55 years of age. *Annals of Internal Medicine* 2008; 148:889-903. PMID: PMC3428219.
122. Desai AA, Baras J, Berk BB, Nakajima A, Garber AM, Owens D, Chertow GM. Management of acute renal failure in the intensive care unit: a cost-effectiveness analysis of daily vs alternate-day hemodialysis. *Archives of Internal Medicine* 2008; 168:1761-1767.
123. Walsh JME, Sundaram V, McDonald K, Owens DK, Goldstein MK. Implementing effective hypertension quality improvement strategies: barriers and potential solutions. *Journal of Clinical Hypertension* 2008; 10:311-316.
124. Qaseem A, Snow V, Shekelle P, Hopkins R, Forcica MA, Owens DK, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for osteoporosis in men: A clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2008; 148:680-84.
125. Qaseem A, Snow V, Shekelle P, Denberg T, Forcica MA, Owens DK. Pharmacologic treatment of depressive disorders using second-generation antidepressants: A clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2008; 149:725-733.
126. Anaya HD, Hoang T, Golden JF, Goetz MB, Gifford A, Bowman C, Osborn T, Owens DK, Sanders GD, Asch SM. Improving HIV screening and receipt of results by nurse-initiated streamlined counseling and rapid testing. *Journal of General Internal Medicine* 2008; 23:800-807.
127. Kapoor JR, Gienger AL, Ardehali R, Varghese R, Perez MV, McDonald KM, Owens DK, Hlatky MA, Bravata DM. Isolated disease of the proximal left anterior descending artery: Comparing the effectiveness of percutaneous coronary interventions and coronary artery bypass surgery. *Journal of the American College of Cardiology Cardiovascular Interventions* 2008; 1: 483-491.
128. Qaseem A, Snow V, Shekelle P, Hopkins R, Forcica MA, Owens DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: A clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2008; 149:404-415.
129. Tole SP, Sanders GD, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, Owens DK. Cost effectiveness of voluntary HIV screening in Russia. *International Journal of STD and AIDS* 2009; 20(1):46-51. PMID: PMC2981087.
130. Qaseem A, Snow V, Shekelle P, Hopkins R, Owens DK, for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Screening for HIV in health care settings: A guidance statement from the American College of Physicians. *Annals of Internal Medicine* 2009; 150:125-131.
131. Bravata DM, Gienger AL, Holty JEC, Sundaram V, McDonald KM, Owens DK. Quality improvement strategies for children with asthma: a systematic review. *Archives of Pediatrics and Adolescent Medicine* 2009; 163:572-581.

132. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Kyriakides TC, Yu W, Sundaram V, Holodniy M, Brown ST, Cameron W, Youle M, Sculpher M, Anis AH, Owens DK. Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease. *Journal of the Acquired Immunodeficiency Syndrome* 2009; 50:27-36.
133. Sundaram V, Lazzeroni LC, Douglass LR, Sanders GD, Tempio P, Owens DK. A randomized trial of computer-based reminders and audit and feedback to improve HIV screening in a primary care setting. *International Journal of STD and AIDS* 2009; 20: 527-533.
134. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, Helfand M. AHRQ series paper 5: Grading the strength of a body of evidence when comparing medical interventions – Agency for Healthcare Research and Quality and the effective health care program. *Journal of Clinical Epidemiology* 2010; 63:513-523.
135. Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Carragee EJ, Grabois M, Murphy DR, Resnick DK, Stanos SP, Shaffer WO, Wall EM for the American Pain Society Low Back Pain Guideline Panel. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. *Spine* 2009; 34:1066-1077.
136. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrié D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009; 373:1190-1197.
137. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Expanding antiretroviral options in resource-limited settings – a cost-effectiveness analysis. *Journal of the Acquired Immunodeficiency Syndrome* 2009; 52:106-13. PMID: PMC2757100.
138. Young S, Monin B, Owens D. Opt-out testing for stigmatized diseases: a social psychological approach for understanding the potential effect of recommendations for routine HIV testing. *Health Psychology* 2009; 28:675-681.
139. Caughey AB, Sundaram V, Kaimal AJ, Gienger A, Cheng YW, McDonald KM, Shaffer BL, Owens DK, Bravata DM. Systematic review: elective induction of labor safe versus expectant management of pregnancy. *Annals of Internal Medicine* 2009; 151: 252-263.
140. Rupnow MFT, Chang AH, Shachter RD, Owens DK, Parsonnet J. Cost effectiveness of a potential prophylactic *Helicobacter pylori* vaccine. *Journal of Infectious Diseases* 2009; 200:1311-1317.
141. Nosyk B, Sun H, Bansback N, Guh D, Li X, Barnett P, Bayoumi A, Griffin S, Joyce V, Holodniy M, Owens DK, Anis AH. The validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. *Quality of Life Research* 2009; 18: 815-824.
142. Long EF, Brandeau ML, Owens DK. Potential population health outcomes and expenditures of HIV vaccination strategies in the United States. *Vaccine* 2009; 27:5402-5410. PMID: PMC2757634.
143. Qaseem A, Snow V, Denberg T, Casey D, Forcica MA, Owens DK, Shekelle P for the Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Hormonal testing and pharmacologic treatment of erectile dysfunction: a clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2009; 151:639-649.
144. Khazeni N, Hutton DW, Garber AM, Hupert N, Owens DK. Effectiveness and cost effectiveness of vaccination against pandemic H1N1 influenza 2009. *Annals of Internal Medicine* 2009; 151(12):829-839. PMID: PMC3250217.

145. Khazeni N, Hutton DW, Garber AM, Owens DK. Effectiveness and cost effectiveness of antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic. *Annals of Internal Medicine* 2009; 151:840-853.
146. Levesque BG, Cipriano LE, Chang SL, Lee KK, Owens DK, Garber AM. Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease. *Clinical Gastroenterology and Hepatology* 2010; 8:261-267.
147. Perloth DJ, Glass RJ, Davey VJ, Cannon D, Garber AM, Owens DK. Health outcomes and costs of community mitigation strategies for an influenza pandemic in the U.S. *Clinical Infectious Disease* 2010; 50:165-174.
148. Smith-Spangler C, Juusola J, Enns E, Owens DK, Garber AM. Desalination of the American diet: population strategies to decrease sodium intake and the burden of cardiovascular disease. *Annals of Internal Medicine* 2010; 152:481-487.
149. Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, Owens DK. Cost effectiveness of strategies to improve HIV testing and receipt of results: Economic analysis of a randomized trial. *Journal of General Internal Medicine* 2010; 25:556-563.
150. Bendavid E, Brandeau ML, Wood R, Owens DK. Comparative effectiveness of HIV testing and treatment strategies in highly endemic regions. *Archives of Internal Medicine* 2010; 170:1347-1354. PMID: PMC2921232.
151. Long EF, Brandeau ML, Owens DK. The cost effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. *Annals of Internal Medicine* 2010; 153:778-789. PMID: PMC3173812.
152. Andersson KM, Owens DK, Paltiel AD. Scaling up circumcision programs in Southern Africa: the potential impact of gender disparities and changes in condom use behavior on heterosexual HIV transmission. *AIDS and Behavior* 2010; September 11 [Epub ahead of print]. PMID: PMC3112296.
153. Qaseem A, Snow V, Owens DK, Shekelle P. The development of clinical practice guidelines and guidance statements of the American College of Physicians: summary of methods. *Annals of Internal Medicine* 2010; 153:194-199.
154. Lee KL, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost effectiveness of using high-sensitivity C-reactive protein to identify intermediate- and low-cardiovascular risk individuals for statin therapy. *Circulation* 2010; 122:1478-1487.
155. Kaimal AJ, Little SE, Odibo AO, Stamilio D, Grobman W, Long E, Owens DK, Caughey AB. Cost effectiveness of elective induction of labor at 41 weeks in nulliparous women. *American Journal of Obstetrics and Gynecology* 2011; 204:137.e1-9. Epub 2010 Oct 20.
156. Bendavid E, Grant P, Talbot A, Owens DK, Zolopa A. Effectiveness and cost-effectiveness of HIV antiretroviral regimens recommended in the World Health Organization's guidelines for resource-limited settings. *AIDS* 2011;25:211-220. PMID: PMC3071983.
157. Freeman JV, Zhu RP, Owens DK, Garber AM, Go AS, Wang PJ, Turakhia MP. Cost effectiveness of dabigatran compared with warfarin for stroke prevention in nonvalvular atrial fibrillation. *Annals of Internal Medicine* 2011;154-1-11.
158. Owens DK, Qaseem A, Chou R, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians. High-value, cost-conscious health care: concepts for clinicians to evaluate benefits, harms, and costs of medical interventions. *Annals of Internal Medicine* 2011; 154:174-80.

159. Chou R, Qaseem A, Owens DK, Shekelle P, for the Clinical Guidelines Committee of the American College of Physicians. Diagnostic imaging for low back pain: Advice for high-value health care from the American College of Physicians. *Annals of Internal Medicine* 2011; 154:181-189.
160. Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost effectiveness of genetic testing in family members of patients with long QT syndrome. *Circulation: Cardiovascular Quality and Outcomes* 2011 4:76-84.
161. Joyce VR, Barnett PG, Chow A, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron DW, Youle M, Sculpher M, Anis AH, Owens DK. Effect of treatment interruption and intensification of antiretroviral therapy on health-related quality of life in patients with advanced HIV: a randomized controlled trial. *Medical Decision Making*; 2012; 32:70-82. DOI: 10.1177/0272989X10397615. PMID: 21383086
162. Holodniy M, Brown ST, Cameron DW, Kyriakides TC, Angus B, Babiker A, Singer J, Owens DK, Anis A, Goodall R, Hudson F, Piaseczny M, Russo J, Shechter M, Deyton L, Darbyshire J, for the OPTIMA team. Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial. *PLOS One*; 2011 6(3): e14764. doi:10.1371/journal.pone.0014764.
163. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction programs and HIV antiretroviral therapy in a mixed HIV epidemic: an analysis for Ukraine. *PLOS Medicine*; 2011 8(3): e1000423. doi:10.1371/journal.pmed.1000423. PMCID: PMC3046988.
164. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. Comparative effectiveness review: benefits and harms of in-hospital use of recombinant factor VIIa for off-label indications. *Annals of Internal Medicine* 2011; 154:529-540.
165. Long EF, Owens DK. The cost effectiveness of a modestly effective HIV vaccine in the United States. *Vaccine* 2011 Aug 18;29(36):6113-24. Epub 2011 Apr 19. PMCID: PMC3156325.
166. Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the United States. *AIDS* 2011; 25:1779-87. PMCID: PMC3657607.
167. Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Nosyk B, Sun H, Holodniy M, Brown ST, Cameron DW, Sculpher M, Anis AH, Owens DK. Determinants of the cost of health services used by patients with HIV. *Medical Care* 2011; 49:848-856.
168. Andersson KM, Paltiel AD, Owens DK. The potential impact of an HIV vaccine with rapidly waning protection on the epidemic in Southern Africa: Examining the RV144 trial results. *Vaccine* 2011 Aug 18;29(36):6107-12. Epub 2011 Jul 5. PMCID: PMC3164284.
169. Moyer VA, U.S. Preventive Services Task Force. Screening for hearing loss in older adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157:655-661. PMID: 22893115
170. Qaseem A, Fihn SD, Williams S, Dallas P, Owens DK, Shekelle P; for the Clinical Guidelines Committee of the American College of Physicians. Diagnosis of stable ischemic heart disease: Summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Annals of Internal Medicine* 2012; 157:729-734.
171. Qaseem A, Fihn SD, Dallas P, Williams S, Owens DK, Shekelle P for the Clinical Guidelines Committee of the American College of Physicians. Management of stable ischemic heart disease: Summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. *Annals of Internal Medicine* 2012; 157:735-743.

172. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. *Annals of Internal Medicine* 2012; 156:279-290.

173. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost effectiveness of pre-exposure prophylaxis for HIV prevention in the United States in men who have sex with men. *Annals of Internal Medicine* 2012;156(8):541-550. PMID: PMC3690921.

174. Moyer VA, U.S. Preventive Services Task Force. Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157:59-65.

175. Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: A report from the ISPOR-SMDM modeling good research practices task force working group 3. *Medical Decision Making* 2012; 32(5):690-700.

Also published as:

Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, Kuntz KM; ISPOR-SMDM Modeling Good Research Practices Task Force. State-transition modeling: A report from the ISPOR-SMDM modeling good research practices task force working group 3. *Value in Health*. 2012 15(6):812-20. doi: 10.1016/j.jval.2012.06.014.

176. Moyer VA, U.S. Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157(5):367-71. PMID: 22733153.

177. Moyer VA, U.S. Preventive Services Task Force. Screening for and management of obesity in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157(5):373-378. PMID: 22733087.

178. Moyer VA, U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157(2):120-134. PMID: 22801674.

179. Moyer VA, U.S. Preventive Services Task Force. Prevention of falls in community-dwelling older adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157(3):197-204. PMID: 22868837.

180. Cipriano LE, Zaric GS, Holodniy H, Bendavid E, Owens DK, Brandeau ML. Cost effectiveness of screening strategies for HIV and HCV infection in injection drug users. *PLoS ONE* 2012; 7(9):e45176. doi: 10.1371/journal.pone.0045176. Epub 2012 Sep 18. PMID: 23028828. PMID: PMC3445468.

181. Negoescu DM, Owens DK, Brandeau ML, Bendavid E. Balancing immunological benefits and cardiovascular risks of antiretroviral therapy: When is immediate treatment optimal? *Clinical Infectious Diseases* 2012; 55:1392-9. doi: 10.1093/cid/cis731. PMID: 22942203.

182. Winetsky DE, Negoescu DM, Almukhamedova O, DeMarchis E, Dooronbekova A, Pulatov D, Vezhnina N, Zhussupov B, Owens DK, Goldhaber-Fiebert JD. Screening and rapid molecular diagnosis of tuberculosis in prisons in Russia and eastern Europe: a cost-effectiveness analysis. *PLoS Medicine* 2012; Nov;9(11):e1001348. doi: 10.1371/journal.pmed.1001348. Epub 2012 Nov 27. PMID: 23209384. PMID: PMC3507963.

183. Moyer VA, U.S. Preventive Services Task Force. Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157(1):59-65. PMID: 22751761.

184. Melynk BM, Grossman DC, Chou R, Mabry-Hernandez I, Nicholson W, DeWitt TG, Cantu AG, Flores G, US Preventive Services Task Force. USPSTF perspective on evidence-based preventive recommendations for children. *Pediatrics* 2012; 130:e399-407. Epub 2012 Jul 2. PMID: 22753558.

185. Moyer VA, U.S. Preventive Services Task Force. Screening for coronary heart disease with electrocardiography: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012; 157:512-518. PMID: 22847227.
186. Moyer VA, U.S. Preventive Services Task Force. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Annals of Internal Medicine* 2012; 157:900-904. PMID: 22964825
187. Moyer VA, U.S. Preventive Services Task Force. Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2012;157:567-570. PMID: 22928170.
188. Qaseem A, Barry MJ, Denberg T, Owens DK Shekelle P. for the Clinical Guideline Committee of the American College of Physicians. Screening for prostate cancer: a guidance statement from the clinical guidelines committee of the American College of Physicians. *Annals of Internal Medicine* 2013; May 21;158(10):761-9. doi: 10.7326/0003-4819-158-10-201305210-00633. PMID: 23567643.
189. Moyer VA, U.S. Preventive Services Task Force. Menopausal hormone therapy for primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; 158(1):47-54. PMID: 23090711.
190. Delgado MK, Staudenmayer KL, Wang NE, Spain DA, Weir S, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. *Annals of Emergency Medicine* 2013; Oct;6 2(4):351-364.e19. doi: 10.1016/j.annemergmed.2013.02.025. Epub 2013 Apr 9. PMID: 23582619,
191. Bavinger C, Bendavid E, Niehaus K, Olshen RA, Olkin I, Sundaram V, Wein N, Holodniy M, Owens DK, Desai M. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review. *PLoS One* 2013 *PLoS ONE* 8(3): e59551. doi:10.1371/journal.pone.0059551. PMCID: PMC3608726.
192. Erickson KF, Japa S, Owens DK, Chertow GM, Garber A, Goldhaber-Fiebert JD. A cost effectiveness analysis of statins for preventing cardiovascular disease in patients with chronic kidney disease. *Journal of the American College of Cardiology* 2013; 61(12):1250-1258.
193. Moyer VA, U.S. Preventive Services Task Force. Screening for intimate partner violence and abuse of elderly and vulnerable adults: A U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; 158(6):478-86doi: 10.7326/0003-4819-158-6-201303190-00588. PMID: 23338828.
194. Moyer VA, U.S. Preventive Services Task Force. Vitamin D and calcium supplementation to prevent fractures in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013 Feb 26. 158(9):691-6. doi: 10.7326/0003-4819-158-9-201305070-00603. PMID: 23440163.
195. Chernew ME, McKellar R, Aubry W, Beck R, Benner J, Berger JE, Fendrick AM, Forma F, Goldman D, Peters-Harmel A, Killion R, Owens DK, Stahl J. Comparative effectiveness research and formulary placement: the case of diabetes. *American Journal of Managed Care* 2013; 19:93-96.
196. Delgado KM, Meng LJ, Mercer MP, Pines JM, Owens DK, Zaric GS. Reducing ambulance diversion at the hospital and regional level: a systematic review of insights from simulation models. *Western Journal of Emergency Medicine* 2013; 14:489-498.
197. Simons CT, Cipriano LE, Shah RU, Garber AM, Owens DK, Hlatky MA. Transcatheter aortic valve replacement in non-surgical candidates with severe, symptomatic aortic stenosis: a cost-effectiveness analysis. *Circulation: Cardiovascular Quality and Outcomes* 2013; 6:419-428.
198. Owens DK, Aubry W, Beck R, Brenner J, Berger JE, Chernew ME, Forma F, Goldman DP, Herman WH, Killion R, Lakdawalla D, Mittman B, Peters A. Improving patient-centered care in diabetes with comparative effectiveness research. *American Journal of Managed Care*. 2013;19(SP7):SP239-41. Epub 9/30/13.

199. Moyer VA, U.S. Preventive Services Task Force. Screening for HIV: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; Apr 30 159(1):51-60. doi: 10.7326/0003-4819-159-1-201307020-00645. PMID:23698354.
200. Moyer VA, U.S. Preventive Services Task Force. Screening and behavioral counseling interventions in primary care to reduce alcohol misuse: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; May 14. 159(3):210-8/ doi: 10.7326/0003-4819-159-3-201308060-00652. PMID: 23698791.
201. Moyer VA, U.S. Preventive Services Task Force. Primary care interventions to prevent child maltreatment: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; Jun 11. 159(4):289-95. doi: 10.7326/0003-4819-159-4-201308200-00667. PMID:23752681.
202. Qaseem A, Holty JE, Owens DK, Dallas P, Starkey M, Shekelle P and the Clinical Guidelines Committee of the American College of Physicians. Management of Obstructive Sleep Apnea: A Clinical Practice Guideline from the American College of Physicians. *Annals of Internal Medicine* 2013; Sep 24. doi: 10.7326/0003-4819-159-7-201310010-00704.
203. Moyer VA, U.S. Preventive Services Task Force. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; Jun 25. 159(5):349-57 doi: 10.7326/0003-4819-159-5-201309030-00672. PMID: 23798026.
204. Moyer VA, U.S. Preventive Services Task Force. Screening for glaucoma: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; 159:484-489.
205. Kastenbergs ZJ, Hurley MP, Luan A, Vasu-Devan V, Spain DA, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of preoperative imaging for appendicitis after indeterminate ultrasonography in the second or third trimester of pregnancy. *Obstetrics and Gynecology* 2013; 122:821-829.
206. Moyer VA, U.S. Preventive Services Task Force. Primary care interventions to prevent tobacco use in children and adolescents: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; 159(8):552-7. PMID: 23974083.
- Also published as:
- Moyer VA, U.S. Preventive Services Task Force. Primary care interventions to prevent tobacco use in children and adolescents: U.S. Preventive Services Task Force recommendation statement. *Pediatrics*. 2013 Sep;132(3):560-5. doi: 10.1542/peds.2013-2079. Epub 2013 Aug 26. PMID: 23979083.
207. Moyer VA, U.S. Preventive Services Task Force. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; Sep 3;159(5):342-8. doi: 10.7326/0003-4819-159-5-201309030-00008. PMID: 24026320.
208. Moyer VA, U.S. Preventive Services Task Force. Medications to decrease the risk for breast cancer in women: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2013; 159:698-708. PMID: 24061412.
209. Bayoumi AM, Barnett PG, Joyce VR, Griffin SC, Sun H, Bansback NJ, Holodniy M, Brown ST, Sculpher M, Anis AH, Owens DK. Cost effectiveness of new antiretroviral drugs in treatment-experienced patients with multi-drug resistant HIV disease. *Journal of Acquired Immunodeficiency Syndrome (JAIDS)*. 2013; 64:382-391. PMCID: PMC3932156.

210. Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron DW, Sculpher M, Youle M, Anis AH, Owens DK. Effect of management strategies and clinical status on costs of care for advanced HIV. *Am J Managed Care* 2014; 0(5):e129-e137.
211. Kazi DS, Garber AM, Shah RU, Dudley RA, Mell M, Rhee C, Moshkevich S, Boothroyd DB, Owens DK, Hlatky MA. Cost-effectiveness analysis of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. *Annals of Internal Medicine* 2014; 160:221-232.
212. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. *PLoS One* 2014; Jan 28;9(1):e86584. doi: 10.1371/journal.pone.0086584. eCollection 2014. PMID: 24489747.
213. Khazeni N, Hutton DW, Collins I, Garber AM, Owens DK. Health and economic benefits of early vaccination for a human influenza A(H7N9) pandemic. *Annals of Internal Medicine* 2014 160:684-694. PMID: PMC4053659.
214. Moyer VA, U.S. Preventive Services Task Force. Screening for primary hypertension in children and adolescents: U.S. Preventive Services Task Force recommendation statement. *Pediatrics* 2013; Nov;132(5):907-14. doi: 10.1542/peds.2013-2864. Epub 2013 Oct 7. PMID: 24101758.
215. Shluzas LA, Cronkite RC, Chambers D, Hoffman BB, Breeling J, Musen MA, Owens DK, Goldstein MK. Organizational factors affecting implementation of the ATHENA-Hypertension clinical decision support system during the VA's nation-wide information technology restructuring: a case study. *Health Systems* 2014; (in press).
216. Pershing S, Enns EA, Matesic B, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of treatment for diabetic macular edema. *Annals of Internal Medicine* 2014; 160: 18-29. PMID: 24573663.
217. Moyer VA, U.S. Preventive Services Task Force. Screening for oral cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; 160(1):55-60. doi: 10.7326/M13-2568. PMID: 24276469.
218. Moyer VA, U.S. Preventive Services Task Force. Vitamin, mineral, and multivitamin supplement for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014 Apr 15;160(8):558-64. doi: 10.7326/M14-0198. PMID: 24566474.
219. Moyer VA, U.S. Preventive Services Task Force. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; 160:330-338.
220. Qaseem A, Dallas P, Owens DK, Starkey M, Holty JE, Shekelle P and the Clinical Guidelines Committee of the American College of Physicians. Diagnosis of obstructive sleep apnea in adults: A clinical practice guideline from the American College of Physicians. *Annals of Internal Medicine* 2014; 161:210-220. PMID: 25089864.
221. Halvorsen MA, Finlay AK, Cronkite RC, Bi X, Hayashi K, Maisel NC, Amundson EO, Weitlauf JC, Litt IF, Owens DK, Timko C, Cuciare MA, Finney JW. Ten-year publication trajectories of health services research career development award recipients: collaboration, awardee characteristics, and productivity correlates. *Evaluation & the Health Professions*. 2014 Jul 11. pii: 0163278714542848 [Epub ahead of print].
222. Moyer VA, U.S. Preventive Services Task Force. Screening for cognitive impairment in older adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; Jun 3;160(11):791-7. doi: 10.7326/M14-0496. PMID: 24663815.
223. LeFevre ML, U.S. Preventive Services Task Force. Screening for suicide risk in adolescents, adults, and older people in primary care: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; May 20;160(10):719-26. doi: 10.7326/M14-0589. PMID: 24842417.

224. Habbema JDF, Wilt TJ, Etzioni R, Nelson HD, Schechter CB, Lawrence WF, Melnikow J, Kuntz KM, Owens DK, Feuer EJ. Models in the development of clinical practice guidelines. *Annals of Internal Medicine* 2014 Dec 2;161(11):812-8. doi: 10.7326/M14-0845. PMID:25437409.
225. LeFevre ML, U.S. Preventive Services Task Force. Screening for chlamydia and gonorrhea: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; *Annals of Internal Medicine* 2014 Dec 16;161(12):902-10. doi: 10.7326/M14-1981. PMID: 25243785.
226. LeFevre ML, U.S. Preventive Services Task Force. Screening for asymptomatic carotid artery stenosis: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; 161(5):356-62. doi: 10.7326/M14-1333. PMID: 25003392.
227. LeFevre ML, U.S. Preventive Services Task Force. Screening for abdominal aortic aneurysm: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; Aug 19;161(4):281-90. doi: 10.7326/M14-1204. PMID: 24957320.
228. LeFevre ML, U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; Jul 1;161(1):58-66. doi: 10.7326/M14-1018 PMID: 24863637.
229. LeFevre ML, U.S. Preventive Services Task Force. Behavioral counseling interventions to prevent sexually transmitted infections: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; *Annals of Internal Medicine* 2014 Dec 16;161(12):894-901. doi: 10.7326/M14-1965. PMID: 25244227.
230. LeFevre ML, U.S. Preventive Services Task Force. Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; *Annals of Internal Medicine* 2014 Oct 21;161(8):587-93. doi: 10.7326/M14-1796.PMID: 25155419.
231. LeFevre ML, U.S. Preventive Services Task Force. Low-dose aspirin for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2014; *Annals of Internal Medicine* 2014 Dec 2;161(11):819-26. doi: 10.7326/M14-1884. PMID:25200125.
232. Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, Owens DK. Uptake and utilization of directly-acting antiviral medications for hepatitis C infection in U.S. veterans. *Journal of Viral Hepatitis* 2015 22(5):489-95 doi: 10.1111/jvh.12344. [Epub ahead of print] PMID:25417805.
233. Leung TI, Jalal H, Zulman DM, Dumontier M, Owens DK, Musen MA, Goldstein MK. Automating identification of multiple chronic conditions in clinical practice guidelines. *American Medical Informatics Joint Summits on Translational Science Proceedings*; 2015 Mar 25;2015:456-60. eCollection 2015. PMID: 26306285.
234. LeFevre ML, U.S. Preventive Services Task Force. Screening for Vitamin D deficiency in adults: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2015 Jan 20;162(2):133-40. doi: 10.7326/M14-2450. PMID: 25419853.
235. Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky MA, Chow A, Holodniy M, Barnett P, Owens DK. Risk of cardiovascular events associates with current exposure to HIV antiretroviral therapies in a US veteran population. *Clinical Infectious Diseases* 2015 2015 Aug 1;61(3):445-52. doi: 10.1093/cid/civ316. Epub 2015 Apr 22. PMID: 25908684.
236. Woo CY, Strandberg EJ, Schmiegelow MD, Pitt AL, Hlatky MA, Owens DK, Goldhaber-Fiebert JD. Cost-Effectiveness of adding cardiac resynchronization therapy to an implantable cardioverter-defibrillator among patients with mild heart failure. *Annals of Internal Medicine* 2015 2015 Sep 15;163(6):417-26. doi: 10.7326/M14-1804. PMID: 26301323.

237. LeFevre ML, U.S. Preventive Services Task Force. Screening for thyroid dysfunction: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2015 May 5;162(9):641-50. doi: 10.7326/M15-0483. PMID: 25798805.
238. Richman I, Asch SM, Bhattacharya J, Owens DK. Colorectal cancer screening in the era of the affordable care act. *Journal of General Internal Medicine* 2015 Sept 8 [Epub ahead of print]. PMID: 26306285.
239. Siu AL, U.S. Preventive Services Task Force. Screening for speech and language delay and disorders in children age 5 years or younger: U.S. Preventive Services Task Force recommendation statement. *Pediatrics*. 2015 Aug;136(2):e474-81. doi: 10.1542/peds.2015-1711. Epub 2015 Jul 7. PMID: 26152670.
240. Finney JW, Amundson EO, Xiaoyu B, Cucciare MA, Eisen SA, Finlay AK, Halvorson MA, Hayashi K, Owens DK, Maisel NC, Timko C, Weitlauf JC, Cronkite RC. Evaluating the productivity of VA, HHS, and AHRQ health services research development awardees. *Academic Medicine* 2015 Nov 9. [Epub ahead of print] PMID: 26556291.
241. Siu AL, U.S. Preventive Services Task Force. Screening for iron deficiency anemia in young children: U.S. Preventive Services Task Force recommendation statement. *Pediatrics*. 2015 Oct;136(4):746-52. doi: 10.1542/peds.2015-2567. Epub 2015 Sep 7. PMID: 26347426.
242. Siu AL, U.S. Preventive Services Task Force. Screening for iron deficiency anemia and iron supplementation in pregnant women to improve maternal health and birth outcomes: U.S. Preventive Services Task Force recommendation statement. *Annals of Internal Medicine* 2015 Oct 6;163(7):529-36. doi: 10.7326/M15-1707. PMID: 26344176.
243. Sandhu AT, Goldhaber-Fiebert JD, Owens DK, Turakhia MP, Kaiser DW, Heidenreich PA. Cost effectiveness of implantable pulmonary artery pressure monitoring in chronic heart failure. *Journal of the American College of Cardiology Heart Failure* 2016 May;4(5):368-75. doi: 10.1016/j.jchf.2015.12.015. Epub 2016 Feb 10. PMID: 26874380/
244. Siu AL, U.S. Preventive Services Task Force. Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2015 Oct 20;163(8):622-34. doi: 10.7326/M15-2023. Epub 2015 Sep 22. PMID: 26389730.
245. Siu AL, U.S. Preventive Services Task Force. Screening for high blood pressure in adults: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2015 Nov 17;163(10):778-86. doi: 10.7326/M15-2223. Epub 2015 Oct 13. PMID: 26458123.
246. Siu AL, U.S. Preventive Services Task Force. Screening for abnormal blood glucose and type 2 diabetes mellitus: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2015 Dec 1;163(11):861-8. doi: 10.7326/M15-2345. Epub 2015 Oct 27. PMID: 26501513.
247. Siu AL, U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2016 Feb 16;164(4):279-96. doi: 10.7326/M15-2886. Erratum in: *Ann Intern Med*. 2016 Mar 15;164(6):448. PMID: 26757170.
248. Siu AL; US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, Ebell M, Garcia FA, Gillman M, Herzstein J, Kemper AR, Krist AH, Kurth AE, Owens DK, Phillips WR, Phipps MG, Pignone MP. Screening for depression in adults. U.S. Preventive Services Task Force recommendation statement. *Journal of the American Medical Association (JAMA)*. 2016 Jan 26;315(4):380-7. doi: 10.1001/jama.2015.18392. PMID: 26813211.
249. Siu AL, US Preventive Services Task Force (USPSTF), , Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, Ebell M, Garcia FA, Gilman M, Herzstein J, Kemper AR, Krist AH, Kurth AE, Owens DK, Phillips WR, Phipps MG, Pignone MP. Screening for autism spectrum disorder in young children: U.S. Preventive Services

Task Force Recommendation Statement. *Journal of the American Medical Association (JAMA)* 2016 Feb 16;315(7):691-6. doi: 10.1001/jama.2016.0018. PMID: 26881372.

250. US Preventive Services Task Force (USPSTF), Siu AL, Bibbins-Domingo K, Grossman DC, Baumann LC, Davidson KW, Ebell M, Garcia FA, Gilman M, Herzstein J, Kemper AR, Krist AH, Kurth AE, Owens DK, Phillips WR, Phipps MG, Pignone MP. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force Recommendation Statement. *Journal of the American Medical Association (JAMA)* 2016 Mar 1;315(9):908-14. doi: 10.1001/jama.2016.0763. PMID: 26934260.

251. Bernard CL, Brandeau ML, Humphreys K, Bendavid E, Holodniy M, Weyant C, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of HIV pre-exposure prophylaxis for people who inject drugs in the United States. *Annals of Internal Medicine* 2016; 165:10-19. doi: 10.7326/M15-2634. PMID:27110953.

252. Owens DK, Whitlock EP, Henderson J, Pignone MP, Krist AH, Bibbins-Domingo K, Curry SJ, Davidson KW, Ebell M, Gilman MW, Grossman DC, Kemper AR, Kurth AE, Maciosek M, Siu AL, LeFevre ML, for the U.S. Preventive Services Task Force. Use of decision models in the development of evidence-based clinical preventive services recommendations: Methods of the U.S. Preventive Services Task Force. *Annals of Internal Medicine* 2016 Oct 4;165(7):501-508. doi: 10.7326/M15-2531 PMID: 27379742.

253. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Recommendations of the Second Panel on cost effectiveness in health and medicine. *Journal of the American Medical Association (JAMA)* 2016 Sep 13;316(10):1093-103. doi: 10.1001/jama.2016.12195 PMID:27623463.

254. Freeman JV, Hutton DW, Barnes GD, Zhu RP, Owens DK, Garber AM, Go AS, Hlatky MA, Heidenreich PA, Wang PJ, Al-Ahmad A, Turakhia MP. Cost effectiveness of percutaneous closure of the left atrial appendage in atrial fibrillation based on results from PROTECT AF versus PREVAIL. *Circulation: Arrhythmia and Electrophysiology. Circulation Arrhythmia and Electrophysiology* 2016 Jun;9(6). pii: e003407. doi: 10.1161/CIRCEP.115.003407. PMID: 27307517.

255. US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, Gilman MW, Herzstein J, Harper DM, Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Journal of the American Medical Association (JAMA)* 2016 Jun 21;315(23):2564-75. doi: 10.1001/jama.2016.5989. PMID: 27304597.

256. Siu AL, US Preventive Services Task Force (USPSTF). Screening for depression in children and adolescents: U.S. Preventive Services Task Force Recommendation Statement. *Pediatrics* 2016 Mar;137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8. PMID: 26908686.

Also published as:

Siu AL, US Preventive Services Task Force (USPSTF). Screening for depression in children and adolescents: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine* 2016 Mar 1;164(5):360-6. doi: 10.7326/M15-2957. Epub 2016 Feb 9. PMID: 26858097.

257. Liu S, Barnett PG, Holodniy M, Lo J, Joyce VR, Gidwani R, Asch SM, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of treatment for genotype 1 hepatitis c virus infection in non-VA and VA populations. *Medical Decision Making Policy and Practice* 2016 1:1-12.

258. Richman I, Fairley M, Joergensen M, Schuler A, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of intensive blood pressure management. *Journal of the American Medical Association (JAMA) Cardiology* 2016 Nov 1;1(8):872-879. doi: 10.1001/jamacardio.2016.3517. PMID:27627731.

259. US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, Gilman MW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, LeFevre M, Mangione CM, Owens DK, Phillips WR, Phipps MG, Pignone MP, Siu AL. Screening for lipid disorders in children and adolescents: U.S. Preventive Services Task Force Recommendation Statement. *Journal of the American Medical Association (JAMA)* 2016 Aug 9;316(6):625-33. doi: 10.1001/jama.2016.9852. Erratum in: *JAMA*. 2016 Sep 13;316(10):1116. PMID: 27532917.
260. US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW Jr, Garcia FA, Gilman MW, Kemper AR, Krist AH, Kurth AE, Landefeld CS, LeFevre M, Mangione CM, Phillips WR, Owens DK, Phipps MG, Pignone MP. Statin use for the primary prevention of cardiovascular disease in adults: U.S. Preventive Services Task Force Recommendation Statement. *Journal of the American Medical Association (JAMA)* 2016 Nov 15;316(19):1997-2007. doi: 10.1001/jama.2016.15450. PMID: 27838723.
261. Bibbins-Domingo K, U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine* 2016 Jun 21;164(12):836-45. [PMID: 27064677](#)
262. Richman I, Asch SM, Bendavid E, Bhattacharya J, Owens DK. Breast density notification legislation and breast cancer stage at diagnosis: early evidence from the SEER registry. *Journal of General Internal Medicine* 2017 Jun;32(6):603-609. doi: 10.1007/s11606-016-3904-y. Epub 2016 Nov 14. PMID: 27844260.
263. Baras Shreibati J, Goldhaber-Fiebert JD, Banerjee D, Owens DK, Hlatky M. Cost effectiveness of left ventricular assist devices in ambulatory patients with advanced heart failure. *Journal of the American College of Cardiology Heart Failure (JACC Heart Failure)* 2017 Feb;5(2):110-119. doi: 10.1016/j.jchf.2016.09.008. PMID: 28017351.
264. Pollom EL, Lee K, Durkee BY, Grade M, Mokhtari DA, Wahl DR, Feng M, Kothary N, Koong AC, Owens DK, Goldhaber-Fiebert J, Chang DT. Cost effectiveness of stereotactic body radiation therapy versus radiofrequency ablation for hepatocellular carcinoma: a Markov modeling study. *Radiology*. 2017 May;283(2):460-468. doi: 10.1148/radiol.2016161509. [Epub ahead of print]. PMID: 28045603
265. Bernard CL, Owens DK, Goldhaber-Fiebert JD, Brandeau ML. Cost effectiveness of HIV prevention portfolios for people who inject drugs in the United States. *PLoS Medicine* 2017 May 24;14(5):e1002312. doi: 10.1371/journal.pmed.1002312. eCollection 2017 May. PMID: 28542184.
266. Richman I, Owens DK. Aspirin for the prevention of cardiovascular disease and colorectal cancer. *Medical Clinics of North America* 2017 101(4):713-724. PMID: 28577622.
267. Qian Y, Maruyama S, Kim H, Pollom EL, Kumar KA, Chin AL, Harris JP, Chang DT, Pitt A, Bendavid E, Owens DK, Durkee BY, Soltys SG. Cost effectiveness of radiation and chemotherapy for high-risk low-grade glioma. *Neuro-Oncology* 2017 DOI: 10.1093/neuonc/nox121 PMID: 28666368.
268. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Vision screening in children aged 6 months to 5 years: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2017 Sep 5;318(9):836-844. doi: 10.1001/jama.2017.11260. PMID: 28873168.
269. Li K, Cannon JGD, Jiang SY, Sambare T, Owens DK, Bendavid E, Poultsides GA. Diagnostic staging laparoscopy in gastric cancer treatment: a cost effectiveness. *Journal of Surgical Oncology* 2017 Dec 4. doi: 10.1002/jso.24942. [Epub ahead of print] PMID: 29205366.
270. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force Recommendation Statement. Dec 12;318(22):2224-2233. doi: 10.1001/jama.2017.18261. PMID: 29234814.

271. Joyce VR, Sun H, Barnett PG, Bansback N, Griffin SC, Bayoumi AM, Anis AH, Sculpher M, Cameron W, Brown ST, Holodniy M, Owens DK. Mapping MOS-HIV to HUI3 and EQ-5D-3L in patients with HIV. *Medical Decision Making Policy and Practice* 2017; 2(2):1-13.
272. Wolff T, Krist AH, LeFevre M, Jonas DE, Harris RP, Siu A, Owens DK, Gillman MW, Ebell MH, Herzstein J, Chou R, Whitlock E, Bibbins-Domingo K. Update on the methods of the U.S. Preventive Services Task Force: linking intermediate outcomes and health outcomes in prevention. *American Journal of Preventive Medicine* 2018 Jan;54(1S1):S4-S10. doi: 10.1016/j.amepre.2017.08.032. PMID: 29254525.
273. Petitti DB, Lin JS, Owens DK, Croswell JM, Feuer EJ. Collaborative modeling: experience of the United States Preventive Services Task Force. *American Journal of Preventive Medicine* 2018 Jan;54(1S1):S53-S62. doi: 10.1016/j.amepre.2017.07.003. PMID: 29254526.
274. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for adolescent idiopathic scoliosis: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Jan 9;319(2):165-172. doi: 10.1001/jama.2017.19342. PMID: 29318284.
275. Barnett PG, Joyce VR, Lo J, Gidwani-Marszowski R, Goldhaber-Fiebert JD, Desai M, Asch SM, Holodniy M, Owens DK. Effect of interferon-free regimens on disparities in hepatitis C treatment of U.S. veterans. *Value in Health* 2018 219(8):921-930 doi: 10.1016/j.jval.2017.12.025. Epub 2018 Mar 7. PMID: 30098669.
276. Fu R, Owens DK, Brandeau ML. Cost effectiveness of alternative strategies for provision of HIV Pre-exposure prophylaxis for people who inject drugs in the United States. *2018 AIDS* 2018 Mar 13;32(5):663-672. doi: 10.1097/QAD.0000000000001747. PMID: 29334549.
277. Itoga NK, Minami HR, Chelvakumar M, Pearson K, Mell MM, Bendavid E, Owens DK. Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. *Vasc Med*. 2018 Jan 1:1358863X17745371. doi: 10.1177/1358863X17745371. [Epub ahead of print]. PMID: 29345540.
278. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW. Screening for ovarian cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Feb 13;319(6):588-594. doi: 10.1001/jama.2017.21926. PMID: 29450531.
279. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW. Behavioral counseling to prevent skin cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Mar 20;319(11):1134-1142. doi: 10.1001/jama.2018.1623. PMID: 29558558.
280. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Apr 17;319(15):1592-1599. doi: 10.1001/jama.2018.3185. PMID: 29677309.
281. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione CM, Pignone M, Silverstein M, Simon MA, Tseng CW. Interventions to prevent falls in community-dwelling older adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Apr 24;319(16):1696-1704. doi: 10.1001/jama.2018.3097. PMID: 29710141.
282. US Preventive Services Task Force, Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, Davidson KW, Doubeni CA, Ebel M, Epling JW Jr., Kemper AR, Krist AH, Kubik M, Landefeld CS, Mangione

CM, Silverstein M, Simon MA, Siu AL, Tseng C. Screening for prostate cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 May 8;319(18):1901-13. doi: 10.1001/jama.2018.3710. PMID: 29801017.

283. Alsan M, Kammili N, Lakshmi J, Xing A, Khan A, Rani M, Kolli P, Relman DA, Owens DK. Poverty and community-acquired antimicrobial resistance with extended-spectrum beta-lactamsase producing organisms, Hyderabad, India. *Emerging Infectious Diseases*. 2018 Aug;24(8):1490-1496. doi: 10.3201/eid2408.171030. PMID: 30014842.

284. Barnes JI, Divi V, Begaye A, Wong R, Coutre S, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. *Blood Advances* 2018 Aug 14;2(15):1946-1956. doi: 10.1182/bloodadvances.2017015461. PMID: 30097461.

285. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for cardiovascular disease risk with electrocardiography: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Jun 12;319(22):2308-2314. doi: 10.1001/jama.2018.6848. PMID: 29896632.

286. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Phipps MG, Pignone M, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for osteoporosis to prevent fractures: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Jun 26;319(24):2521-2531. doi: 10.1001/jama.2018.7498. PMID: 29946735.

287. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Risk assessment for cardiovascular disease with nontraditional risk factors: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Jul 17;320(3):272-280. doi: 10.1001/jama.2018.8359. PMID: 29998297.

288. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for peripheral artery disease and cardiovascular disease risk with the ankle-brachial index: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Jul 10;320(2):177-183. doi: 10.1001/jama.2018.8357. PMID: 29998344.

289. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for atrial fibrillation with electrocardiography: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2018 Aug 7;320(5):478-484. doi: 10.1001/jama.2018.10321. PMID: 30088016.

290. Lin JK, Lerman BJ, Barnes JI, Bourisquot BC, Tan YJ, Robinson AQL, Davis KL, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. *Journal of Clinical Oncology* 2018 Sep 13; 36:3192-3202 JCO2018790642. doi: 10.1200/JCO.2018.79.0642. PMID: 30212291.

291. Neumann PJ, Kim DD, Trikalinos TA, Sculpher MJ, Salomon JA, Prosser LA, Owens DK, Meltzer DO, Kuntz KM, Krahn M, Feeny D, Basu A, Russell LB, Siegel JE, Ganiats TG, Sanders GD. Future directions for cost-effectiveness analysis in health and medicine. *Medical Decision Making* 2018 Oct;38(7):767-777. doi: 10.1177/0272989X18798833. PMID: 30248277.

292. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for cervical cancer: US Preventive Services Task Force

Recommendation Statement. JAMA. 2018 Aug 21;320(7):674-686. doi: 10.1001/jama.2018.10897. PMID: 30140884.

293. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Kurth AE, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for syphilis infection in pregnant women: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Sep 4;320(9):911-917. doi: 10.1001/jama.2018.11785. PMID: 30193283.

294. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Grossman DC, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Phipps MG, Silverstein M, Simon MA, Tseng CW, Wong JB. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Sep 18;320(11):1163-1171. doi: 10.1001/jama.2018.13022. PMID: 30326502.

295. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Grossman DC, Kemper AR, Kubik M, Kurth A, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Oct 23;320(16):1678-1687. doi: 10.1001/jama.2018.14741. PMID: 30357305.

296. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening and behavioral counseling interventions to reduce unhealthy alcohol use in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Nov 13;320(18):1899-1909. doi: 10.1001/jama.2018.16789. PMID: 30422199.

297. Sehested TSG, Bjerre J, Chang A, Ku S, Jahansouz A, Owens DK, Hlatky MA, Goldhaber-Fiebert JD. Cost effectiveness of canakinumab for prevention of recurrent cardiovascular events. JAMA Cardiology 2019 Jan 16. doi: 10.1001/jamacardio.2018.4566. [Epub ahead of print] PMID: 30649147.

298. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Grossman DC, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Interventions to prevent child maltreatment: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 Nov 27;320(20):2122-2128. doi: 10.1001/jama.2018.17772. PMID: 30480735.

299. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Ocular prophylaxis for gonococcal ophthalmia neonatorum: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Jan 29;321(4):394-398. doi: 10.1001/jama.2018.21367. PMID: 30694327.

300. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, Doubeni CA, Epling JW Jr., Grossman DC, Kemper AR, Kubik M, Landefeld CS, Mangione CM, Silverstein M, Simon MA, Tseng CW, Wong JB. Interventions to prevent perinatal depression: US Preventive Services Task Force Recommendation Statement. JAMA. 2019 Feb 12;321(6):580-587. doi: 10.1001/jama.2019.0007. PMID: 30747971.

301. Harris JP, Saraswathula A, Kaplun B, Qian Y, Chan KCA, Chan ATC, Le QT, Owens DK, Goldhaber-Fiebert JD, Pollom E. Cost effectiveness of screening for nasopharyngeal carcinoma for Asian-American men in the U.S. Otolaryngology-Head and Neck Surgery. 2019 Mar 5:194599819832593. doi: 10.1177/0194599819832593. [Epub ahead of print] PMID: 30832545.

302. Burns RB, Olumi AF, Owens DK, Smetana GW. Would you recommend PSA screening for this patient? Grand Round discussion from Beth Israel Deaconess Medical Center. Annals of Internal Medicine 2019 Jun 4;170(11):770-778. doi: 10.7326/M19-1072. PMID: 31158876.

303. Desai M, Montez-Ruth ME, Kapphahn K, Joyce VR, Mathur MB, Garcia A, Purington N, Owens DK. Missing data strategies for time-varying confounders in comparative effectiveness studies of non-missing time-varying exposures and right-censored outcomes. *Statistics in Medicine* 2019 Stat Med. 2019 May 17. doi: 10.1002/sim.8174. [Epub ahead of print] PMID: 31099433.
304. Lin JK, Muffly LS, Spinner MA, Barnes JI, Owens DK, Goldhaber-Fiebert J. Cost effectiveness of chimeric antigen receptor T-cell therapy in multiply relapsed or refractory adult large B-cell lymphoma. *Journal of Clinical Oncology* 2019 Jun 3;JCO1802079. doi: 10.1200/JCO.18.02079. [Epub ahead of print] PMID: 31157579.
305. Yu JX, Russell WA, Ching JH, Kin N Bendavid E, Owens DK, Kaitenbach T. Cost effectiveness of endoscopic resection vs transanal resection of complex benign rectal polyps. *Clinical Gastroenterology and Hepatology*. 2019 Mar 5. pii: S1542-3565(19)30247-2. doi: 10.1016/j.cgh.2019.02.041. [Epub ahead of print] PMID: 30849517.
306. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for elevated blood lead levels in children and pregnant women: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019 Apr 16;321(15):1502-1509. doi: 10.1001/jama.2019.3326. PMID: 30990556.
307. Gidwani-Marszowski R, Owens DK, Lo J, Goldhaber-Fiebert JD, Asch SM, Barnett PG. The costs of hepatitis C by liver disease stage: estimates from the Veterans Health Administration. *Appl Health Econ Health Policy*. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print] PMID: 31030359.
308. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Preexposure prophylaxis for the prevention of HIV infection: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019 Jun 11;321(22):2203-2213. doi: 10.1001/jama.2019.6390. PMID: 31184747.
309. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for HIV infection: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019 Jun 11; doi: 10.1001/jama.2019.6587. [Epub ahead of print] PMID: 31184701.
310. Sceats LA, Ku S, Coughran A, Barnes B, Grimm E, Muffly M, Spain DA, Kin C, Owens DK, Goldhaber-Fiebert JD. Operative versus non-operative management of appendicitis: a long-term cost-effectiveness analysis. *Medical Decision Making Policy and Practice* 2019 Aug 17;4(2):2381468319866448. doi: 10.1177/2381468319866448. eCollection 2019 Jul-Dec. PMID: 31453362.
311. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2019 Jul 23;322(4):349-354. doi: 10.1001/jama.2019.9365. PMID: 31334800.
312. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kemper AR, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for pancreatic cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2019 Aug 6;322(5):438-444. doi: 10.1001/jama.2019.10232. PMID: 31386141.
313. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive

Services Task Force Recommendation Statement. *JAMA*. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987. PMID: 31429903.

314. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Tseng CW, Wong JB. Medication use to reduce risk of breast cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019 Sep 3;322(9):857-867. doi: 10.1001/jama.2019.11885. PMID: 31479144.

315. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for asymptomatic bacteriuria in adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2019 Sep 24;322(12):1188-1194. doi: 10.1001/jama.2019.13069. PMID: 31550038.

316. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for abdominal aortic aneurysm: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2019 Dec 10;322(22):2211-2218. doi: 10.1001/jama.2019.18928. PMID: 31821437.

317. Lin JL, Tawfik DS, Gupta R, Imrie M, Bendavid E, Owens DK. Health and economic outcomes of posterior spinal fusion for children with neuromuscular scoliosis. *Hospital pediatrics*. 2020 Mar;10(3):257-265. doi: 10.1542/hpeds.2019-0153. PMID: 32079619.

318. Blum MR, Øien H, Carmichael HL, Heidenreich P, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of transitional care services after hospitalization with heart failure. *Annals of Internal Medicine* 2020 Jan 28. doi: 10.7326/M19-1980. [Epub ahead of print] PMID: 31986526.

319. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr., Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for cognitive impairment in older adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2020 Feb 25;323(8):757-763. doi: 10.1001/jama.2020.0435. PMID: 32096858.

320. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr., Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Reaffirmation Recommendation Statement. *JAMA*. 2020 Mar 2. doi: 10.1001/jama.2020.1123. [Epub ahead of print] PMID: 32119076.

321. Barnes JI, Lin JK, Gupta D, Owens DK, Goldhaber-Fiebert JD, Kunz PL. Cost effectiveness of initial versus delayed lanreotide for treatment of metastatic enteropancreatic neuroendocrine tumors. *Journal of the National Comprehensive Cancer Network*. 2020 Sep;18(9):1200-1209. doi: 10.6004/jnccn.2020.7563. PMID: 32886901.

322. Ryckman T, Luby S, Owens DK, Bendavid E, Goldhaber-Fiebert JD. Methods for model calibration under high uncertainty: modeling cholera in Bangladesh. *Medical Decision Making* 2020 Jul;40(5):693-709. doi: 10.1177/0272989X20938683. Epub 2020 Jul 8. PMID: 32639859.

323. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Curry SJ, Donahue K, Doubeni CA, Epling JW Jr., Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Primary care interventions for prevention and cessation of tobacco use in children and adolescents: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2020 Apr 28;323(16):1590-1598. doi: 10.1001/jama.2020.4679. PMID: 32343336.

324. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr., Kubik M, Ogedegbe G, Pbert L, Silverstein M, Simon MA, Tseng CW,

Wong JB. Screening for bacterial vaginosis in pregnant persons to prevent preterm delivery: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2020 Apr 7;323(13):1286-1292. doi: 10.1001/jama.2020.2684. PMID: 32259236.

325. US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Donahue K, Doubeni CA, Epling JW Jr., Kubik M, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB. Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2020 Dec 15;324(23):2415-2422. doi: 10.1001/jama.2020.22980. PMID: 33320230.

326. US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Kubik M, Landefeld CS, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for lung cancer: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021 Mar 9;325(10):962-970. doi: 10.1001/jama.2021.1117. PMID: 33687470.

327. Lin JL, Rigdon J, Van Haren K, Buu M, Saynina O, Bhattacharya J, Owens DK, Sanders LM. Gastrostomy tubes placed in children with neurologic impairment: associated morbidity and mortality *J Child Neurol*. 2021 Mar 22;8830738211000179. doi: 10.1177/08830738211000179. Online ahead of print. PMID: 33750232.

328. Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, Oliva EM, Goldhaber-Fiebert JD, Asch SM, Brandeau ML, Owens DK. Cost-effectiveness of treatments for opioid use disorder. *JAMA Psychiatry* 2021 Mar 31. doi: 10.1001/jamapsychiatry.2021.0247. Online ahead of print. PMID: 33787832.

329. 326. US Preventive Services Task Force, Krist AH, Davidson KW, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for vitamin D deficiency in adults: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2021 Apr 13;325(14):1436-1442. doi: 10.1001/jama.2021.3069. PMID: 33847711.

330. Ching JH, Owens DK, Trafton JA, Goldhaber-Fiebert JD, Salomon JA. Impact of treatment duration on mortality among Veterans with opioid use disorder in the United States Veterans Health Administration. *Addiction*. 2021 May 17. doi: 10.1111/add.15574. Online ahead of print. PMID: 33999485.

331. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement *JAMA*. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238. PMID: 34003218.

332. US Preventive Services Task Force, Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM, Donahue KE, Doubeni CA, Krist AH, Kubik M, Li L, Ogedegbe G, Owens DK, Pbert L, Silverstein M, Stevermer J, Tseng CW, Wong JB. Screening for prediabetes and Type 2 diabetes: US Preventive Services Task Force Recommendation Statement *JAMA*. 2021 Aug 24;326(8):736-743. doi: 10.1001/jama.2021.12531. PMID: 34427594.

333. Caughey AB, Krist AH, Wolff TA, Barry MJ, Henderson JT, Owens DK, Davidson KW, Simon MA, Mangione CM. USPTF approach to addressing sex and gender when making recommendations for clinical preventive services. *JAMA*. 2021 Nov 16;326(19):1953-1961. doi: 10.1001/jama.2021.15731. PMID: 34694343.

334. Qaseem A, Ikobaltzeta IE, Lin JS, Fitterman N, Shamliyan T, Wilt TJ, and Clinical Guideline Committee of the American College of Physicians. Diagnosis and management of acute left-sided colonic diverticulitis: A clinical guideline from the American College of Physicians. *Annals of Internal Medicine* 2022 Mar;175(3):399-415. doi: 10.7326/M21-2710. Epub 2022 Jan 18. PMID: 35038273.

335. Qaseem A, Ikobaltzeta IE, Lin JS, Fitterman N, Shamliyan T, Wilt TJ, and Clinical Guideline Committee of the American College of Physicians. Evaluation and management after acute left-sided colonic diverticulitis: A clinical

- guideline from the American College of Physicians. *Annals of Internal Medicine* 2022 Mar;175(3):416-431. doi: 10.7326/M21-2711. Epub 2022 Jan 18. PMID: 35038270.
336. Tisdale RL, Cusick MM, Aluri KZ, Handley TJ, Joyner AKC, Salomon JA, Chertow GM, Goldhaber-Fiebert JD, Owens DK. Cost effectiveness of dapagliflozin for non-diabetic kidney disease. *Journal of General Internal Medicine* 2022 Oct;37(13):3380-3387. doi: 10.1007/s11606-021-07311-5. Epub 2022 Feb 8. PMID: 35137296.
337. Ho VT, Nguyen AT, Stern JR, Asch SM, Owens DK, Salomon JA, Dalman RL, Lee JT. Cost effectiveness of computed tomography versus ultrasound-based surveillance following endovascular aortic repair of intact infrarenal abdominal aortic aneurysms. *J Vasc Surg.* 2022 Sep;76(3):707-713.e1. doi: 10.1016/j.jvs.2022.02.057. Epub 2022 Mar 9. PMID: 35278655.
338. Calonge N, Shekelle GP, Owens DK, Teutsch MS, Downey A, Brown L, Noyes J. A framework for synthesizing intervention evidence from multiple sources into a single certainty of evidence rating: Methodological developments from a US National Academies of Science, Engineering and Medicine committee. *Research Synthesis Methods* 2023 Jan;14(1):36-51. doi: 10.1002/jrsm.1582. Epub 2022 Jul 4. PMID: 35722864.
339. Karam S, Darzi AJ, Bognanni A, Morsi RZ, Tannous EE, Charide R, Choe SI, Stalteri R, Lee Y, Piggott T, Jewell L, Schünemann F, Langendam M, Parmelli E, Saz-Parkinson Z, Roi A, Vilahur N, Vali Y, Waffenschmidt S, Owens DK, Leontiadis GI, Moayyedi P, Brozek JL, Schünemann HJ. Analytical frameworks in colorectal cancer guidelines: development of methods for systematic review, their application and practical guidance for their use. *Journal of Clinical Epidemiology.* 2022 Jun 17:S0895-4356(22)00151-2. doi: 10.1016/j.jclinepi.2022.06.005. Online ahead of print. PMID: 35724863
340. Qaseem A, Owens DK, Etzeandia-Ikobaltzeta I, Tuftte J, Cross T, Wilt TJ, and the Clinical Guideline Committee of the American College of Physicians. Nonpharmacologic and pharmacologic treatment of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. *Annals of Internal Medicine* 2023 Jan 24. doi: 10.7326/M22-2056. Online ahead of print. PMID: 36689752.
341. Barry MJ, Wolff TA, Pbert L, Davidson KW, Fan TM, Krist AH, Lin JS, Mabry-Hernandez IR, Mangione CM, Mills J, Owens DK, Nicholson WK. Putting evidence into practice: an update on the US Preventive Services Task Force methods for developing recommendations for preventive services. *Annals of Family Medicine* 2023 Mar-Apr;21(2):165-171. doi: 10.1370/afm.2946. PMID: 36973047.
342. Qian G, Rao I, Humphreys K, Owens DK, Brandeau ML. Cost effectiveness of office-based buprenorphine treatment for opioid use disorder. *Drug and Alcohol Dependence* 2023 Feb 1;243:109762. doi: 10.1016/j.drugalcdep.2022.109762. Epub 2022 Dec 30. PMID: 36621198.
343. Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-wide screening for chronic kidney disease: a cost effectiveness analysis. *Annals of Internal Medicine* 2023 Jun;176(6):788-797. doi: 10.7326/M22-3228. Epub 2023 May 23. PMID: 37216661.
344. Varkila M, Montez-Rath M, Salomon J, Yu X, Block G, Owens DK, Chertow GM, Parsonnet J, Anand S. Use of wastewater metrics to track Covid-19 in the US: a national time-series analysis over the first three quarters of 2022. *JAMA Network Open* 2023 Jul 3;6(7):e2325591. doi: 10.1001/jamanetworkopen.2023.25591. PMID: 37494040.
346. Anand S, Montez-Rath M, Varkila M, Yu X, Block M, Leppink A, Brillhart S, Hunsader P, Owens DK, Chertow GM, Parsonnet J, Block G. Feasibility and acceptability of SARS-CoV-2 screening among patients receiving hemodialysis: a pilot study. *Clin J Am Soc Nephrol.* 2023 Apr 24. doi: 10.2215/CJN.000000000000137. Online ahead of print. PMID: 36976655.
345. Joyce VR, Oliva EM, Garcia C, Trafton J, Asch SM, Humphreys K, Owens DK, Bounthavong M. Healthcare costs and utilization before and after opioid overdose in Veterans Health Administration patients with opioid use disorder. *Addiction* 2023 Nov;118(11):2203-2214. doi: 10.1111/add.16289. Epub 2023 Jul 19. PMID: 37465971.

346. Guan G, Joshi NS, Frymoyer A, Achepohl GD, Dang R, Taylor NK, Salomon JA, Goldhaber-Fiebert JD, Owens DK. Resource utilization and costs associated with approaches to identify infants with early onset sepsis. *Medical Decision Making Policy and Practice* 2024 (in press).

347. Dossabhoy SS, Fisher AT, Chang TI, Owens DK, Arya S, Stern JR, Lee JT. Preoperative proteinuria is an independent predictor of mortality after fenestrated endovascular aneurysm repair. *Journal of Vascular Surgery* 2024 (in press).

Publications with trainees: 176 (1-9-24)

Journal Articles Under Review or In Preparation

1. Cusick M, Chertow G, Owens DK, Goldhaber-Fiebert JD, Salomon JA. When to start population-wide screening for chronic kidney disease: a cost-effectiveness analysis. (in preparation).

2. Barnes JI, Frosch Z, Garfall A, Vogl D, Schinke C, Owens DK, Goldhaber-Fiebert J, Lin JK. Cost effectiveness of BMCA-directed CAR-T-Cell therapy in triple-class refractory multiple myeloma. (under review).

3. Cusick M, Chertow G, Owens DK, Williams M, Rose S. Effects of removing race-adjustment from the estimated glomerular filtration rate formula on referral to nephrology for chronic kidney disease evaluation and management. (in preparation).

4. Qaseem A, Shamliyan T, Tice JA, Owens DK, Crandall CJ, for the Clinical Guidelines Committee of the American College of Physicians (in preparation).

Other Research Articles

1. Richter A, Brandeau ML, Owens DK. Policy analysis of preventive HIV interventions targeted to adolescents. In: *Simulation in the Medical Sciences Conference: Proceedings of the 1996 Western Multiconference*, Society for Computer Simulation, San Diego, CA, January 14-17, 1996; 55-63.

2. Zaric GS, Brandeau ML, Bayoumi AM, Owens DK. Simulating the effects of protease inhibitors on the HIV epidemic: Treatment, compliance, and drug resistance. In: Anderson JG, Katzper M, Eds. *Proceedings of the 1998 Medical Sciences Simulation Conference. 1998 Western Multiconference*, San Diego, CA, January 11-14, 1998; 65-72.

3. Hlatky MA, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. *Cardiac Electrophysiology Review* 1998; 2:319-321.

4. Hlatky MA, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. *Cardiac Electrophysiology Review* 2001; 5: 105-107.

5. Bravata DM, Keeffe EB, Owens DK. Quality of life, employment, and alcohol use after liver transplantation. *Current Opinions in Organ Transplantation* 2001; 6:130-141.

6. Heidenreich PA, Cheng CHF, Sander GD, Hlatky MA, McDonald KM, Lee BK, Larson MS, Owens DK. Radiofrequency ablation for supraventricular tachycardia. *Cardiology Review* 2001; 18:8-13.

7. Hlatky MA, Sanders GD, Owens DK. Cost-effectiveness of the implantable cardioverter defibrillator. *Cardiac Electrophysiology Review* 2003; 7:479-482.

Books, Book Chapters, and Monographs

1. Sox H, Stern S, Owens D, Abrams HL. Assessment of Diagnostic Technology in Health Care. Monograph of the Council on Health Care Technology, Institute of Medicine. Washington D.C.: National Academy Press, 1989.
2. Owens DK, Sox HC Jr. Medical Decision Making: Probabilistic Medical Reasoning. In: Shortliffe EH, Perreault LE, Fagan LM, Wiederhold G, eds. Medical Informatics: Computer Applications in Health Care. Reading, MA: Addison-Wesley, 1990:70-116.
3. Owens DK, Nease RF. Transmission of human immunodeficiency virus (HIV) infection between provider and patient: A quantitative analysis of risk. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy and Prediction. New York: Raven Press, 1994:153-177.
4. Brandeau ML, Owens DK. When women return to risk: Costs and benefits of HIV screening in the presence of relapse. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy and Prediction. New York: Raven Press, 1994:121-136.
5. Garber AM, Owens DK. Paying for evaluative research. In: Gelijns AC, Dawkins HV, eds. Medical Innovations at the Crossroads, Volume IV: Adopting New Medical Technology. Washington, D.C.: National Academy Press, 1994:172-192.
6. Owens DK. Economic evaluations of HIV screening. In: Holtgrave DR, ed. Handbook of HIV Prevention Policy Analysis. New York: Plenum, 1998: 81-101.
7. Owens DK, Sox HC. Medical decision making: Probabilistic medical reasoning. In: Shortliffe EH, Perreault LE, Wiederhold G, Fagan LM, eds. Medical Informatics: Computer Applications in Health Care and Biomedicine. New York: Springer-Verlag 2000: 76-131.
8. Friedman CP, Owens DK, Wyatt J. Evaluation and technology assessment. In: Shortliffe EH, Perreault LE, Wiederhold G, Fagan LM, eds. Medical Informatics: Computer Applications in Health Care and Biomedicine. New York: Springer-Verlag 2000: 282-325.
9. Owens DK, Edwards DM, Shachter RD. Costs and benefits of imperfect HIV vaccines: Implications for vaccine development and use. In: Kaplan EH, Brookmeyer R, eds. Quantitative Evaluation of HIV Prevention Programs. Yale Press, 2001: 143-171.
10. Bravata DM, McDonald K, Owens DK, Buckeridge D, Haberland C, Rydzak C, Schleinitz M, Smith WM, Szeto H, Wilkening D, Musen M, Duncan BW, Nouri B, Dangiolo MB, Liu H, Shofer S, Graham J, Davies S. Bioterrorism Preparedness and Response: Use of Information Technologies and Decision Support Systems (Evidence Report/Technology Assessment No. 59, Prepared by University of California San Francisco-Stanford University Evidence-based Practice Center under Contract No. 290-97-0013). AHRQ Publication No. 02-E028. Rockville, MD: Agency for Healthcare Research and Quality. June 2002.
11. Owens DK, Edwards DM, Cavallaro JF, Shachter RD. The cost effectiveness of partially effective HIV vaccines. In: Brandeau ML, Sainfort F, and Pierskalla WP, Eds. *Operations Research and Health Care: A Handbook of Methods and Applications*, Kluwer Academic Publishers, 2004:403-418.
12. Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies, Volume 1—Series Overview and Methodology. Technical Review 9 (Contract No. 290-02-0017 to the Stanford University—UCSF Evidence-based Practice Center). AHRQ Publication No. 04-0051-1. Rockville, MD: Agency for Healthcare Research and Quality. August 2004.
13. Wachter RM, Owens DK. Chapter 1: An introduction to the report. In: Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies, Volume 1—

Series Overview and Methodology. Technical Review 9 (Contract No. 290-02-0017 to the Stanford University–University of California San Francisco Evidence-based Practice Center). AHRQ Publication No. 04-0051-1. Rockville, MD: Agency for Healthcare Research and Quality. August 2004.

14. Shojania KG, McDonald KM, Owens DK. Chapter 2: Evidence-based review methodology for the closing the quality gap series. In: Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies, Volume 1–Series Overview and Methodology. Technical Review 9 (Contract No. 290-02-0017 to the Stanford University–University of California San Francisco Evidence-based Practice Center). AHRQ Publication No. 04-0051-1. Rockville, MD: Agency for Healthcare Research and Quality. August 2004.

15. Shojania KG, Ranji S, Shaw LK, Charo LN, Lai JC, Rushakoff RJ, McDonald KM, Owens DK. Diabetes mellitus care. Vol 2 of: Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Contract No. 290-02-0017 to the Stanford University - University of California San Francisco Evidence-based Practice Center). AHRQ Publication No. 04-0051-2. Rockville, MD: Agency for Healthcare Research and Quality. September 2004.

16. Bravata DM, McDonald KM, Owens DK, Wilhelm ER, Brandeau ML, Zaric GS, Holty JEC, Liu H, Sundaram V. Regionalization of Bioterrorism Preparedness and Response. Evidence Report/Technology Assessment No. 96. (Prepared by the Stanford University—University of California San Francisco Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 04-E016-2. Rockville, MD: Agency for Healthcare Research and Quality. April 2004.

17. Walsh J, McDonald KM, Shojania KG, Sundaram V, Nayak S, Davies S, Lewis R, Mechanic J, Sharp C, Henne M, Shah B, Chan JK, Owens DK, Goldstein MK. Hypertension care. Volume 3 of: Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by the Stanford University—UCSF Evidence-based Practice Center, under Contract No. 290-02-0017). AHRQ Publication No. 04-0051-3. Rockville, MD: Agency for Healthcare Research and Quality. January 2005.

18. Owens DK, Sox HC. Biomedical decision making: probabilistic reasoning. In: Shortliffe EH, Cimino JJ. Biomedical Informatics: Computer Applications in Health Care and Biomedicine, New York: Springer-Verlag 2006: 80-132.

19. Friedman CP, Wyatt JC, Owens DK. Evaluation and technology assessment. In: Shortliffe EH, Cimino JJ. Biomedical Informatics: Computer Applications in Health Care and Biomedicine, New York: Springer-Verlag 2006: 403-443.

20. Ranji SR, Steinman MA, Shojania KG, Sundaram V, Lewis R, Arnold S, Gonzales R. Antibiotic Prescribing Behavior. Vol 4 of: Shojania KG, McDonald KM, Wachter RM, Owens DK. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies, Technical Review 9 (Prepared by the Stanford University - UCSF Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 04(06)-0051-4. Rockville, MD: Agency for Healthcare Research and Quality. January 2006.

22. Bravata DM, Wang E, Holty J-E, Lewis R, Wise PH, Nayak S, Liu H, McDonald KM, Owens DK. Pediatric Anthrax: Implications for Bioterrorism Preparedness. Evidence Report/Technology Assessment No. 141 (Prepared by Stanford University-UCSF Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 06-E013. Rockville, MD: Agency for Healthcare Research and Quality. August 2006.

23. Bravata DM, Sundaram V, Lewis R, Gienger A, Gould MK, McDonald KM, Wise PH, Holty J-EC, Hertz K, Paguntalan H, Sharp C, Kim J, Wang E, Chamberlain L, Shieh L, Owens DK. Asthma Care. Vol 5 of: Shojania KG, McDonald KM, Wachter RM, Owens DK, editors. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by the Stanford University-UCSF Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 04(07)-0051-5. Rockville, MD: Agency for Healthcare Research and Quality. January 2007.

24. Ranji SR, Shetty K, Posley KA, Lewis R, Sundaram V, Galvin CM, Winston LG. Prevention of Healthcare-Associated Infections. Vol 6 of: Shojania KG, McDonald KM, Wachter RM, Owens DK, editors. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by the Stanford University-UCSF Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 04(07)-0051-6. Rockville, MD: Agency for Healthcare Research and Quality. January 2007.
25. McDonald KM, Sundaram V, Bravata DM, Lewis R, Lin N, Kraft S, McKinnon M, Paguntalan H, Owens DK. Care Coordination. Vol 7 of: Shojania KG, McDonald KM, Wachter RM, Owens DK, editors. Closing the Quality Gap: A Critical Analysis of Quality Improvement Strategies. Technical Review 9 (Prepared by the Stanford University-UCSF Evidence-based Practice Center under Contract No. 290-02-0017). AHRQ Publication No. 04(07)-0051-7. Rockville, MD: Agency for Healthcare Research and Quality. June 2007.
26. Bravata DM, McDonald KM, Gienger AL, Sundaram V, Perez MV, Varghese R, Kapoor JR, Ardehali R, McKinnon MC, Stave CD, Owens DK, Hlatky MA. Comparative Effectiveness of Percutaneous Coronary Interventions and Coronary Artery Bypass Grafting for Coronary Artery Disease. Comparative Effectiveness Review No. 9. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. #290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. October 2007. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm
27. Brandeau ML, Long EF, Hutton DW, Owens DK. Optimal spending on HIV prevention and treatment: A framework for evaluating the cost effectiveness of HIV prevention and treatment programs with example applications to The India AIDS Initiative. In: Lim GJ, Lee EK (Eds.) Optimization in Medicine and Biology. Taylor and Francis Publishers, Boca Raton, Florida, 2008 147-175.
28. Caughey AB, Sundaram V, Kaimal AJ, Cheng YW, Gienger A, Little SE, Lee JF, Wong L, Shaffer BL, Tran SH, Padula A, McDonald KM, Long EF, Owens DK, Bravata DM. Maternal and Neonatal Outcomes of Elective Induction of Labor. Evidence Review/Technical Assessment No. 176. (Prepared by the Stanford University—UCSF Evidence-based Practice Center under contract No. 290-02-0017) AHRQ Publication No. 09-E005. Rockville, MD.: Agency for Healthcare Research and Quality. March 2009. Available at: <http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat1b.chapter.146430>
29. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, Chang S, Helfand M. Grading the strength of a body of evidence when comparing medical interventions. In: Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews [posted July 2009]. Rockville, MD. Available at: <http://effectivehealthcare.ahrq.gov/healthInfo.cfm?infotype=rr&ProcessID=60>
30. Yank V, Tuohy V, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Stave CD, Zehnder JL, Olkin I, McDonald KM, Owens DK, Stafford R. Comparative effectiveness of recombinant factor VIIa for off-label indications versus usual care. Comparative Effectiveness Review No. 21. (Prepared by Stanford-UCSF Evidence-based Practice Center under Contract No. # 290-02-0017.) Rockville, MD: Agency for Healthcare Research and Quality. May 2010. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm
31. IOM (Institute of Medicine) and NRC (National Research Council). (Committee: Goldstein BD, DeSimone JM, Ascher MS, Buehler JW, Cook KS, Crouch NA, Doyle FJ, Foldy S, Gursky EA, Hoffman S, Johnson CB, Keim P, Kellerman AL, Kleinman KP, Layton M, Lee EK, Mayor SD, Moshier TF, Murphy FA, Murray RW, Owens DK, Pollock SM, Resnick IG, Schaudies RP, Schultz JS). 2011. Biowatch and public health surveillance: Evaluation systems for the early detection of biological threats. Abbreviated version. Washington DC: The National Academies Press.
32. Sox HC, Higgins MC and Owens DK. Medical Decision Making, Second Edition. Chichester: John Wiley & Sons Ltd; 2013.
33. Owens DK, Sox HC. Biomedical decision making: probabilistic clinical reasoning. In: Shortliffe EH, Cimino JJ. Biomedical Informatics: Computer Applications in Health Care and Biomedicine, New York: Springer-Verlag 2014: 67-108.

34. Owens DK, Siegel JE, Sculpher MJ, Salomon JA. Chapter 4: Designing a cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (Eds.) *Cost-Effectiveness in Health and Medicine*, 2nd edition. New York: Oxford University Press, 2016.
35. Kuntz KM, Russell LB, Owens DK, Sanders GD, Trikalinos TA, Salomon JA. Chapter 5: Decision models in cost-effectiveness analysis. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (Eds.) *Cost-Effectiveness in Health and Medicine*, 2nd edition. New York: Oxford University Press, 2016.
36. Neumann PJ, Sanders GD, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Chapter 3: Recommendations on perspectives for the reference case. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (Eds.) *Cost-Effectiveness in Health and Medicine*, 2nd edition. New York: Oxford University Press, 2016.
37. Neumann PJ, Sanders GD, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, Salomon JA, Sculpher MJ, Trikalinos TA, Russell LB, Siegel JE, Ganiats TG. Overview of the book. In: Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG (Eds.) *Cost-Effectiveness in Health and Medicine*, 2nd edition. New York: Oxford University Press, 2016.
38. Owens DK, Goldhaber-Fiebert JD, Sox HC. Biomedical decision making: probabilistic clinical reasoning. In: Shortliffe EH, Cimino JJ. *Biomedical Informatics: Computer Applications in Health Care and Biomedicine* 5th edition. Switzerland: Springer Nature 2021: 77-120. <https://doi.org/10.1007/978-3-030-58721-5>.
39. Sox HC, Higgins MC, Owens DK, Sanders Schmidler G. *Medical Decision Making*, Third Edition. Chichester: Wiley Blackwell 2024 (in press).

Editorials, Commentaries, and Letters

1. Wachter RM, Cooke M, Brandeau ML, Owens DK. HIV testing of pregnant women and newborns [Letter]. *JAMA* 1991; 265: 1525.
2. Owens DK. Commentary on "Clinical guidelines and medical practice: A review." *ACP Journal Club* 1994 May-June: 85 (Ann Intern Med vol 120, suppl 3). Comment on Grimshaw JM, Russell IT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. *Lancet* 1993; 342: 1317-22.
3. Owens DK. Commentary — Guidelines for the evaluation and management of early HIV infection. *Abstracts of Clinical Care Guidelines* 1994; 6: 7.
4. Owens DK, Harris RA, Nease RF. Screening surgeons for HIV infection [Letter]. *Annals of Internal Medicine* 1995; 123: 812-813.
5. Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of stroke prophylaxis for nonvalvular atrial fibrillation [Letter]. *Journal of the American Medical Association* 1996; 275: 909-910.
6. Owens DK. Commentary on "Screening and treatment of diabetic retinopathy was cost-effective". *Evidence-Based Medicine* 1996 Jul-Aug;1:158. Comment on Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. *Annals of Internal Medicine* 1996: 124:164-169.
7. Owens DK. Commentary on "Low-molecular-weight heparin was cost effective for perioperative prevention of DVT" *ACP Journal Club* 1997 March-April; 126:51. Comment on Bergqvist D, Lindgren B, Matsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. *British Journal of Surgery* 1996; 83: 1548-1552.

8. Owens DK, Holodniy M, Garber AM. The polymerase chain reaction for the diagnosis of HIV infection in adults [Letter]. *Annals of Internal Medicine* 1997; 126:739-740.
9. Owens DK. Defensive diagnostic testing: A case of stolen utility? [Editorial] *Medical Decision Making* 1998; 18: 33-34.
10. Owens DK. In the eye of the beholder: Assessment of health-related quality of life [Editorial]. *Hepatology* 1998; 27: 292-293.
11. Hlatky MA, Owens DK. Cost effectiveness of tests to assess the risk of sudden death after acute myocardial infarction [Editorial]. *Journal of the American College of Cardiology* 1998; 31:1490-1492.
12. Salpeter SR, Sanders GD, Owens DK. Monitored isoniazid prophylaxis for low-risk tuberculin reactors [Letter]. *Annals of Internal Medicine* 1998; 128:1048.
13. Owens DK. Interpretation of cost-effectiveness analyses [Editorial]. *Journal of General Internal Medicine* 1998; 13: 716-717.
14. Owens DK. Commentary — ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmic devices. *Abstracts of Clinical Care Guidelines* 1998; 10: 1-5.
15. Owens DK. Does the emperor have clothes? Assessing medical technology [Commentary]. *The Pharos* 2000(Winter) 63: 29-30.
16. Owens DK, Bravata DM. Computer-based decision support: Wishing on a star? [Editorial] *Effective Clinical Practice* 2001; 4:34-38.
17. Gould MK, Owens DK. Positron emission tomography to evaluate lung lesions [Letter]. *Journal of the American Medical Association* 2001; 285:2711-2712.
18. Schleinitz MD, Owens DK. The reply [Letter]. (Response to a letter regarding the cost effectiveness of clopidogrel versus aspirin for secondary prophylaxis of thrombotic events.) *American Journal of Medicine* 2005; 118:200.
19. Schleinitz MD, Owens DK. The reply [Letter]. (Response to a letter regarding the cost effectiveness of clopidogrel versus aspirin for secondary prophylaxis of thrombotic events.) *American Journal of Medicine* 2005; 118:199.
20. Owens DK, Black M. Assessing the benefits and costs of new therapies for Hepatitis B virus infection [Editorial]. *Annals of Internal Medicine* 2005; 142:863-864.
21. Sanders GD, Bayoumi AM, Owens DK. Cost-effectiveness of screening for HIV [Letter]. *New England Journal of Medicine* 2005; 352:2138.
22. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of ICDs [Letter]. *New England Journal of Medicine* 2006; 354:206-207.
23. Shojania KG, Ranji SR, McDonald KM, Grimshaw JM, Rushakoff RJ, Owens DK. Quality Improvement strategies for type 2 diabetes [Letter]. *JAMA* 2006; 296:2680-2681.
24. Chou R, Shekelle P, Qaseem A, Owens DK. Correction: Diagnosis and treatment of low back pain. *Annals of Internal Medicine* 2008; 148:247-248.
25. Qaseem A, Shekelle P, Owens DK. Is too much intervention recommended in the ACP osteoporosis treatment guideline? [Letter] Response. *Annals of Internal Medicine* 2009; 150: 285-287.

26. O'Neil C, Owens DK. Lumbar facet joint pain: time to hit the reset button [Editorial]. *The Spine Journal* 2009; 9: 6-19-622.
27. O'Neil C, Owens DK. The role of single photon emission computed tomography in the diagnosis of chronic low back pain [Editorial]. *The Spine Journal* 2010; 10:70-72.
28. Owens DK. Improving practice guidelines with patient-specific recommendations [Editorial]. *Annals of Internal Medicine* 2011 154:638-639.
29. Owens DK, Shekelle P. Quality of life, utilities, quality-adjusted life years, and health care decision making [Editorial]. *JAMA Internal Medicine* 2013; 173(12):1073-4. doi: 10.1001/jamainternmed.2013.7396.
30. Owens DK, Goldhaber-Fiebert JD. Prioritizing guideline-recommended interventions [Editorial]. *Annals of Internal Medicine* 2013; 159:223-224.
31. Chang TI, Owens DK, Chertow GM. Lowering blood pressure to lower the risk of cardiovascular events in chronic kidney disease [Commentary]. *American Journal of Kidney Disease* 2014; 63(6):900-902. doi: 10.1053/j.ajkd.2014.03.001.
32. Shekelle P, Holty JE, Owens DK, Qaseem A. Management of obstructive sleep apnea: a clinical practice guideline from the American College of Physicians [Letter]. *Annals of Internal Medicine* 2014; Mar 4;160(5):367-8. doi: 10.7326/L14-5005-2. PMID: 24737275.
33. Kazi DS, Owens DK, Hlatky MA. Cost effectiveness of genotype-guided and dual antiplatelet therapies [Letter]. *Annals of Internal Medicine* 2014; 161: 378-379.
34. Desai M, Joyce V, Bendavid E, Olshen RA, Hlatky M, Chow A, Holodniy M, Owens DK. Reply to Young et al. *Clinical Infectious Disease* 2015; June 29 pii: civ517. [Epub ahead of print] No abstract available. PMID: 26123931
35. Siu AL, Bibbins-Domingo K, Grossman DC, LeFevre ML; U.S. Preventive Services Task Force. Convergence and divergence around breast cancer screening [Commentary]. *Ann Intern Med.* 2016 Jan 12. doi: 10.7326/M15-3065. [Epub ahead of print] PMID: 26756136.
36. Owens DK. Aspirin for the prevention of cardiovascular disease and colorectal cancer: new recommendations from the U.S. Preventive Services Task Force [Commentary]. *American Family Physician* 2017 Feb 15;95(4):222-223. PMID: 28290628.
37. Richman IB, Owens DK, Goldhaber-Fiebert J. Cost effectiveness of intensive blood pressure management – is there an additional price to pay? – Reply [Letter]. *JAMA Cardiology* 2017 May 1;2(5):581-582. doi: 10.1001/jamacardio.2016.5837. PMID: 28199457.
38. Grossman DC, Curry SJ, Owens DK. Guideline recommendations for statin therapy [Letter]. *JAMA.* 2017 Sep 12;318(10):963-964. doi: 10.1001/jama.2017.11375. PMID: 28898373.
39. Grossman DC, Curry SJ, Owens DK. Studies omitted from the US Preventive Services Task Force recommendations for child vision screening [Letter]. *JAMA Ophthalmol.* 2018 Apr 12. doi: 10.1001/jamaophthalmol.2018.0624. [Epub ahead of print] No abstract available. PMID: 29677236.
40. Curry SJ, Kirst AH, Owens DK. Skin self-examination for skin cancer prevention-reply [Letter]. *JAMA.* 2018 Aug 21;320(7):721-722. doi: 10.1001/jama.2018.8024. No abstract available. PMID: 30140873.
41. Curry SJ, Kirst AH, Owens DK. Annual Report to the Nation on the Status of Cancer, Part II: Recent Change in Prostate Cancer Trends and Disease Characteristics. *Cancer* 2018 2018 Nov 14. doi: 10.1002/cncr.31846. [Epub ahead of print] No abstract available. PMID: 30427532.

42. Curry SJ, Krist AH, Owens DK. Electrocardiography screening for atrial fibrillation – reply. *JAMA*. 2018 Dec 25;320(24):2598-2599. doi: 10.1001/jama.2018.17768. No abstract available. PMID: 30575872.
43. Curry SJ, Kirst AH, Owens DK. Age of initiation of cervical cancer screening – reply. *JAMA*. 2019 Feb 12;321(6):612. doi: 10.1001/jama.2018.19089. No abstract available. PMID: 30747962.
44. Curry SJ, Owens DK, Krist AH. Weight loss interventions in adults – reply. *JAMA*. 2019 Mar 5;321(9):900-901. doi: 10.1001/jama.2018.20291. No abstract available. PMID: 30835304.
45. Krist AH, Owens DK, Mangione CM. Recommends related to genetic testing for breast cancer [Letter]. *JAMA*. 2020 Jan 14;323(2):188-189. doi: 10.1001/jama.2019.18222. PMID: 31935025.
46. Krist AH, Barry MJ, Woff TA, Owens DK, Fan TM, Davidson KW. Evolution of the U.S. Preventive Services Task Force’s Methods. *American Journal of Preventive Medicine* 2020 Mar;58(3):332-335. doi: 10.1016/j.amepre.2019.11.003. No abstract available. PMID: 32087861.
47. Yelorda KL, Fu SJ, Owens DK. Commentary on analysis of survival among adults with early-onset colorectal cancer. *JAMA Network Open* 2021 Jun 1;4(6):e2112878. doi: 10.1001/jamanetworkopen.2021.12878. PMID: 34132797.
48. Qaseem A, Owens DK, Etzeandia-Ikoaltzeta I, Tuftte J, Cross JT, Wilt TJ, for the Clinical Guidelines Committee of the American College of Physicians. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: A living clinical guideline from the American College of Physicians (Version 1: Update Alert 1). *Annals of Internal Medicine* 2024 (in press).
49. Qaseem A, for the Clinical Guidelines Committee of the American College of Physicians. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians (Version 1: update alert 1). *Annals of Internal Medicine* 2024 (in press).

Reports

1. Yano EM, Phillips B, McWhorter V, Asch S, Owens D, Menke T, Chang S, Bozzette S. VHA Survey of HIV/AIDS Programs and Practices: Results of a National Survey. HIV/AIDS Quality Enhancement Research Initiative, Health Services Research and Development Section, VA San Diego Healthcare System, 3350 La Jolla Village Drive, 111 N-1, San Diego California 92161. July 2001.
2. Goldhaber-Fiebert JD, Barnett PG, Dally S, Asch SM, Liu S, Cipriano L, Owens DK, Miake-Lye IM, Beroes JB, Shekelle PG. Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C. VA Evidence-based Synthesis Program (ESP) Project #05-226, 2012. Washington (DC): Department of Veterans Affairs; 2013 March. PMID: 23833804.
3. Grossman DC, Curry SJ, Owens DK for the U.S. Preventive Services Task Force. Seventh annual report to Congress on high-priority evidence gaps for clinical preventive services. December 2017. <https://www.uspreventiveservicestaskforce.org/Page/Name/seventh-annual-report-to-congress-on-high-priority-evidence-gaps-for-clinical-preventive-services>.
4. Curry SJ, Owens DK, Kris AH, for the U.S. Preventive Services Task Force. Eighth annual report to Congress on high-priority evidence gaps for clinical preventive services. November 2018.

<https://www.uspreventiveservicestaskforce.org/Page/Name/eighth-annual-report-to-congress-on-high-priority-evidence-gaps-for-clinical-preventive-services>.

5. Owens DK, Davidson KW, Kris AH, for the U.S. Preventive Services Task Force. Ninth annual report to Congress on high-priority evidence gaps for clinical preventive services. November 2019.

<https://www.uspreventiveservicestaskforce.org/uspstf/sites/default/files/inline-files/uspstf-annual-report-to-congress-2019.pdf>.

6. National Academies of Sciences, Engineering, and Medicine. 2020. Evidence-based practice for public health emergency preparedness and response. Washington, DC: The National Academies Press. <https://doi.org/10.17226/25650>.

Other Publications

1. Owens DK. How good is good enough? Even seemingly imperfect HIV vaccines are worth testing for efficacy. *Stanford Medicine* 1998; 16(1):30, 40.

2. Owens DK. The effectiveness and cost effectiveness of screening for HIV. In: *Forum: translating research into quality health care for veterans*. VA Health Services Research and Development Service. May 2006: 5.

3. Owens DK. Opinion: Who you gonna call? The role of public health departments. *The Silicon Valley Mercury News*, May 4, 2009. http://www.mercurynews.com/opinion/ci_12293435?nlick_check=1.

Abstracts

1. Nease RF Jr, Bonduelle YF, Owens DK. Threshold analysis using diagnostic tests with multiple results. *Medical Decision Making* 1987; 7:284.

2. Owens DK, Nease RF Jr, Sox HC Jr. Decision analytic approach to staging non-small cell (T1) lung cancer. *Medical Decision Making* 1988; 8:348.

3. Nease RF, Owens DK. The magnitude of risks imposed on providers treating HIV positive patients. *Medical Decision Making* 1988; 8:349.

4. Owens DK, Nease RF, Sox HC Jr. Invasive versus non-invasive tests for staging non-small lung cancer of unknown extent: A decision analytic model. *Clinical Research* 1989; 37:780A.

5. Nease RF, Owens DK. Methodologic implications of aggregation in measuring test performance. *Clinical Research* 1989; 37:322A.

6. Nease RF Jr, Owens DK. Prophylaxis with zidovudine after occupational exposure: Analysis of risks and benefits. *Medical Decision Making* 1989; 9:319.

7. Owens DK, Nease RF. Physician beliefs about occupational risk and severity of health states associated with HIV and hepatitis infection. In: *Proceedings and Abstracts of the Sixth International Conference on AIDS*; June 20-24, 1990; San Francisco, CA. 3: 308.

8. Brandeau ML, Lee HL, Owens DK, Sox CH, Wachter RM. An analytic decision model of HIV screening and intervention, with an example application: analysis of screening policies to reduce HIV transmission to newborns. In: *Proceedings and Abstracts of the Sixth International Conference on AIDS*; June 20-24, 1990; San Francisco, CA. 3: 120.

9. Owens DK, Nease RF. Occupational exposure to HIV and hepatitis B virus (HBV): a comparative analysis of risk. In: Proceedings and Abstracts of the Sixth International Conference on AIDS; June 20-24, 1990; San Francisco, CA. 3: 310.
10. Owens DK, Nease RF. Morbidity and mortality in the analysis of risk: Effect of incorporation of preferences for diminished health states. *Medical Decision Making* 1990; 10:323.
11. Owens DK, Nease RF. Identifying test alternatives with value of information calculations: Analysis of the timing of thoracotomy after myocardial infarction. *Medical Decision Making* 1990; 10:328.
12. Bonduelle Y, Call H, Owens DK. DPL: A new tool for analyzing medical decision analysis problems. *Medical Decision Making* 1990; 10:325.
13. Owens DK, Nease RF, Sox HC. Optimal test strategy for staging peripheral non-small cell lung cancer with potential chest wall invasion. *Clinical Research* 1991; 39: 160A.
14. Owens DK, Nease RF. A model-based approach for prioritizing information acquisition during guideline development. *Medical Decision Making* 1991; 11: 330.
15. Nease RF, Owens DK. Decision models as an aid to short-term evaluation of clinical guidelines. *Medical Decision Making* 1991; 11: 325.
16. Nease RF, Owens DK. Estimating the risk posed to patients of HIV-infected surgeons and dentists performing invasive procedures. *Medical Decision Making* 1991; 11:325.
17. Owens DK, Nease RF. Evaluating the impact of variation in clinical circumstance on optimal guideline development: the expected value of customization. *Medical Decision Making* 1991; 11: 330.
18. Owens DK, Holodniy M, Garber AM, Sonnad S, Scott J, Kinoshian B, Schwartz JS. Use of the polymerase chain reaction for the diagnosis of HIV infection in adults: A meta-analytic evaluation of test performance. *Clinical Research* 1992; 40: 588A.
19. Owens DK, Holodniy M, McDonald T, Scott J. Diagnosis of pediatric HIV infection with the polymerase chain reaction: A meta-analytic evaluation of test performance. *Medical Decision Making* 1992; 12: 346.
20. Nease RF, Sumner W, Owens DK. A methodology for estimating the cost-effectiveness of incorporating patient preferences into practice guidelines. *Medical Decision Making* 1992; 12: 346.
21. Flam R, El-Sadr W, Oleske J, Nease RF, Owens DK. The challenge of developing guidelines for clinical care of individuals with HIV. In: Proceedings and Abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. 1: 507.
22. Agins B, El-Sadr W, Owens DK, Flam R, Oleske J, the HIV Panel. Guidelines for the management of M.T.B. infection in early HIV infection. In: Proceedings and Abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. 2: 734.
23. Owens DK, Nease RF, Flam R, El Sadr W, Oleske J. A preliminary analysis of clinical content of published guidelines for antiretroviral therapy and PCP prophylaxis. In: Proceedings and Abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. 2: 778.
24. Agins B, El-Sadr W, Flam R, Owens DK, Oleske J. Guidelines for general medical management of early HIV infection in adults. In: Proceedings and Abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. 1: 510.

25. Nease RF, Owens DK, Flam R, El-Sadr W, Oleske J, the HIV Panel. Development of graphical algorithms for the management of individuals with early HIV infection. In: Proceedings and Abstracts of the Ninth International Conference on AIDS; June 6-11, 1993; Berlin, Germany. 2: 777.
26. Gage BF, Scott JD, Owens DK. Marginal cost-utility of warfarin and aspirin in elderly patients with non-valvular atrial fibrillation. *Medical Decision Making* 1993; 13: 386.
27. Owens DK, Nease RF, Harris RA. Screening for HIV infection in acute-care settings: Determinants of cost-effectiveness. *Medical Decision Making* 1993; 13: 395.
28. Owens DK, Nease RF, Harris RA. Use of cost-effectiveness and value of information analyses to customize guidelines for specific clinical practice settings. *Medical Decision Making* 1993; 13: 395.
29. Owens DK, Nease RF, Harris RA. An evaluation of the cost-effectiveness of screening physicians for HIV infection to prevent transmission to patients. *Medical Decision Making* 1993; 13: 395.
30. Sonnad S, McDonald TW, Nease RF, Oleske J, Owens DK. An evaluation of the methodology of guidelines for zidovudine therapy in HIV disease. *Medical Decision Making* 1993; 13: 398.
31. Mason JJ, Owens DK, Harris RA, Cooke JP, Hlatky MA. Should coronary revascularization be performed prior to vascular surgery? *Circulation (Supplement 1)* 1993; 88: I11.
32. Nease R, Hynes L, Tosteson A, Littenberg B, Sumner W, Owens DK. The cost-effectiveness of incorporating patient preferences into practice guidelines for mild hypertension. *Clinical Research* 1994; 42: 226A.
33. Hack HM, Harris RA, Owens DK, Parsonnet J. Prevention of gastric cancer: A cost-effectiveness analysis of screening for helicobacter pylori. *Clinical Research* 1994; 42: 226A.
34. Owens DK, Brandeau ML. Model-based cost benefit analysis of HIV interventions. In: Proceedings of the Eleventh Annual Investigators Meeting of the Universitywide AIDS Research Program; March 29-30, 1994; San Francisco, CA. 1: Owens.
35. Sonnad SS, Owens DK, Nease RF, McDonald TW, Oleske J. Measurement of variability in guidelines for ZDV therapy in HIV-positive adults: relationship to guideline development methodology. In: Proceedings of the Eleventh Annual Meeting of the Association for Health Services Research; June 12-14, 1994; San Diego, CA. 1: 26.
36. Nease RF, Hynes L, Littenberg B, Tosteson A, Sumner W, Owens DK. Variation in patient preferences for outcomes associated with the management of mild hypertension: implications for practice guidelines. In: Proceedings of the Eleventh Annual Meeting of the Association for Health Services Research; June 12-14, 1994; San Diego, CA. 1: 25.
37. Rotman BL, McDonald TW, Suermondt HJ, De Smedt P, Strong PC, Young CY, Owens DK. Computer-based detection of drug interactions in an ambulatory care practice. *Medical Decision Making* 1994; 14: 440.
38. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of incorporating patient-specific utilities for the prevention of stroke in patients with non-valvular atrial fibrillation. *Medical Decision Making* 1994; 14: 431.
39. Owens DK, Sanders GD, Harris RA, McDonald KM, Hlatky MA. Cost-effectiveness of third-generation implantable cardioverter-defibrillators for prevention of sudden cardiac death. *Medical Decision Making* 1995; 15: 420.
40. Edwards DM, Shachter RD, Owens DK. Cost-effectiveness of preventive and therapeutic HIV vaccines: implications for vaccine development. *Medical Decision Making* 1995; 15: 420.

41. Edwards DM, Shachter RD, Owens DK. Comparison of methods for valuing health and economic effects of interventions with delayed outcomes: application to HIV vaccine programs. *Medical Decision Making* 1995; 15: 420.
42. Sonnad S, Owens DK. A comparison of meta-analytic methods for estimating the accuracy of the polymerase chain reaction for HIV diagnosis. *Medical Decision Making* 1995; 15: 433.
43. Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Dembitzer AD, Hlatky MA. Identification of patients at high risk for sudden cardiac death. *Medical Decision Making* 1996; 16: 456.
44. Heidenreich PA, Owens DK, Garber AM. The management of chronic coronary occlusions: a decision analysis. *Medical Decision Making* 1996; 16: 469.
45. Sim I, Rennels GD, Owens DK. Design of a sharable, clinical trials knowledge base for computer-supported evidence-based medicine. *Medical Decision Making* 1996; 16: 468.
46. Heidenreich PA, Owens DK. Echocardiography in the diagnosis of endocarditis: Evaluating uncertainty in the results of a cost-effective analysis. *Medical Decision Making* 1996; 16: 468.
47. Dembitzer AD, Sanders GD, Owens DK. Medical management of BRCA-1 mutation carriers: a decision analysis of breast cancer detection and prevention strategies. *Medical Decision Making* 1996; 16: 456.
48. Sim I, Owens DK, Lavori PW, Rennels GD. A sharable knowledge base of randomized clinical trials for evidence-based decision support. In: *Proceedings of the Fifteenth Annual Health Services Research and Development Service Meeting*; February 12-14, 1997; Washington DC; HSR&D Service, Department of Veterans Affairs 1:26.
49. Richter A, Brandeau ML, Owens DK. HIV-prevention resource allocation: A case study of the Menlo Park/Palo Alto VA. In: *Proceedings of the Fifteenth Annual Health Services Research and Development Service Meeting*; February 12-14, 1997; Washington DC; HSR&D Service, Department of Veterans Affairs. 1:22.
50. Dembitzer AD, Goldstein MK, Owens DK. Effect of genetic testing on expenditures related to breast cancer screening and treatment. *Journal of General Internal Medicine* 1997; 12 (suppl 1): 60.
51. Gould MK, Nease RF, Sox HC, Owens DK. A decision model for mediastinal staging in non-small cell lung cancer. *Journal of General Internal Medicine* 1997; 12 (suppl 1): 61.
52. Salpeter S, Sanders GD, Salpeter EE, Owens DK. Cost effectiveness of monitored isoniazid prophylaxis for low risk tuberculin reactors over age 35. *Medical Decision Making* 1997; 17: 520.
53. Sanders GD, Every NR, McDonald KM, Parsons LS, Heidenreich PA, Hlatky MA, Owens DK. Cost effectiveness of implantable cardiac defibrillators (ICDs) after myocardial infarction (MI). *Medical Decision Making* 1997; 17: 531.
54. Sanders GD, Hagerty CG, Sonnenberg FA, Hlatky MA, Owens DK. Distributed dynamic decision support using a web-based interface for prevention of sudden cardiac death. *Medical Decision Making* 1997; 17: 524.
55. Harris RA, Owens DK, Witherell H, Parsonnet J. *Helicobacter pylori* and gastric cancer: What are the benefits of screening only for the CagA phenotype of *H. pylori*. *Medical Decision Making* 1997; 17: 531.
56. Dembitzer AD, Sanders GD, Owens DK. Cost-effectiveness of screening for breast cancer with BRCA1/BRCA2. *Medical Decision Making* 1997; 17: 531.
57. Sim I, Owens DK, Rennels GD. Pilot evaluation of a randomized-trial knowledge base. *Medical Decision Making* 1997; 17: 540.

58. Zaric G, Bayoumi AM, Brandeau ML, Owens DK. Routine HIV screening of newborns: A cost-effectiveness analysis. *Medical Decision Making* 1997; 17: 531.
59. Bayoumi AM, Holodniy M, Owens DK. Cost effectiveness of human immunodeficiency virus (HIV) treatment with protease inhibitors and viral load testing. *Medical Decision Making* 1997; 17: 527.
60. Bradford ES, Owens DK. Cost-effectiveness of postexposure prophylaxis for prevention of non-occupational transmission of HIV. *Medical Decision Making* 1997; 17: 523.
61. Sim I, Owens DK, Lavori PW, Rennels GD. The design of sharable, randomized-clinical-trial knowledge bases for evidence-based decision support. American Medical Informatics Association Spring Congress, San Jose, California. 1997; 1:91.
62. Sim I, Owens DK, Rennels GD. Computer-based structured reporting of randomized trials. Third International Congress on Biomedical Peer Review. Prague, Czech Republic. 1997; 1:47.
63. Sim I, Owens DK, Lavori PW, Rennels GD. A Sharable Knowledge Base of Randomized Clinical Trials for Evidence-Based Decision Support. In: Proceedings of the Fifteenth Annual Health Services Research and Development Service Meeting. February, 1997; Washington, DC. HSR&D Service, Department of Veterans Affairs 1:26.
64. Tsugawa M, Shachter R, Owens DK, and Parsonnet J. Cost-effectiveness of vaccine development for H. pylori using the Institute-of-Medicine (IOM) Model. *Gastroenterology* 1998; 114(#4/part 2):G1279.
65. Gould MK, Owens DK. Positron emission tomography for mediastinal staging in non-small cell lung cancer: a meta-analysis. *American Journal of Respiratory and Critical Care Medicine* 1998; 157:A256.
66. Heidenreich PA, Owens DK. Should all fen-phen patients have an echocardiogram? A cost-effectiveness analysis. *Journal of the American Society of Echocardiography* 1998; 11:510.
67. Pepper PV, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the Navy and Marine Corps. *Journal of General Internal Medicine* 1998; 13(supplement 1): 32.
68. Gage BF, Cardinalli AB, Owens DK. Meta-analysis of the optimal INR in nonvalvular atrial fibrillation. *Journal of General Internal Medicine* 1998; 13(supplement 1): 25.
69. Gage BF, Gage BF, Wood K, Wiemer C, Reuter D, Owens DK. Selection of patients with atrial fibrillation for a trial of the implantable atrial defibrillator vs amiodarone. *Medical Decision Making* 1998; 18: 486.
70. Sanders GD, Nease RF, Owens DK. Development and pilot evaluation of automated computer-based creation of site-specific clinical-practice guidelines from decision models. *Medical Decision Making* 1998; 18:462.
71. Sanders GD, Nease RF, Owens DK. Design and implementation of a computer-based system to annotate decision models for use in guideline development. *Medical Decision Making* 1998; 18:469.
72. Pepper PV, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the health young adult population. *Medical Decision Making* 1998; 18:471.
73. Cheng CHF, Sanders GD, Heidenreich PA, McDonald KM, Lee BK, Larson MS, Hlatky MA, Owens DK. Cost effectiveness of radiofrequency ablation for treatment of paroxysmal supraventricular tachycardias. *Medical Decision Making* 1998; 18:458.
74. Sanders GD, Every NR, McDonald KM, Parson LS, Heidenreich PA, Hlatky MA, Owens DK. Cost effectiveness of implantable cardioverter defibrillators and amiodarone after myocardial infarction. *Journal of the American College of Cardiology* 1999; 33(2) Supplement A:307A.

75. Fredrickson JO, Young H, Napel S, Beaulieu CF, Jeffrey RB, and Owens, DK. Cost-effectiveness of virtual colonoscopy in colorectal cancer screening. Proceedings of the First International Symposium on Virtual Colonoscopy, Boston MA. 1998; 1:100.
76. Tsugawa MF, Shachter R, Owens DK, Parsonnet J. Predicting the next century of *H. pylori* prevalence and associated diseases in the United States. Gastroenterology 1999; 116(4, Part2): A339.
77. Tsugawa MF, Shachter R, Owens DK, Parsonnet J. Learning about *H. pylori* transmission dynamics from the distinct patterns of duodenal ulcer and gastric cancer. Gastroenterology 1999; 116(4, Part2): A338.
78. Gerson LB, Gage BF, Owens DK, Triadafilopoulos G. Management of patients on anticoagulants prior to endoscopy: a retrospective analysis. Gastrointestinal Endoscopy 1999; 4 (Part II); 353.
79. Alloggiamento T, Khalessi A, Lin O, Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of intracoronary brachytherapy for the prevention of restenosis in single-vessel coronary artery disease. Medical Decision Making 1999; 19:539.
80. Haug CJ, Sanders GD, Luu V, Cody SH, Barnato AE, Owens DK. Cost effectiveness of screening women for *Chlamydia trachomatis* infection. Medical Decision Making 1999; 19:539.
81. Heidenreich PA, Sanders GD, Hlatky MA, McDonald KM, Owens DK. Cost effectiveness of screening survivors of myocardial infarction for prophylactic defibrillator implantation. Medical Decision Making 1999; 19:519.
82. Dembitzer AD, Sanders GD, Goldstein MK, Owens DK. Cost effectiveness of programs that screen for BRCA mutations in women. Medical Decision Making 1999; 19:526.
83. Szeto HC, Gould MK, Owens DK. Cost effectiveness of strategies to diagnose and treat pulmonary embolism. Medical Decision Making 1999; 19:539.
84. Sanders GD, Hlatky MA, Heidenreich PA, McDonald KM, Owens DK. Use of decision models to extrapolate results from clinical trials: cost effectiveness of the implantable defibrillator. Medical Decision Making 1999; 19:519.
85. Rupnow MFT, Shachter RD, Owens DK, Parsonnet J. The cost effectiveness of *H. pylori* vaccine to prevent gastric cancer. Medical Decision Making 1999; 19:523.
86. Payne M, Owens DK, Lamb EJ. The use of frozen semen to avoid HIV transmission by donor insemination: a cost-effectiveness analysis. Fertility and Sterility 1999; 71(4), Supplement 1:8S.
87. Gould MK, Maclean C, Owens DK. A comparison of methods for summarizing studies of diagnostic test performance. Proceedings of the Eighteenth Annual Health Services Research and Development Service Meeting. March 2000; Washington, DC. HSR&D Service, Department of Veterans Affairs, Abstract 146, pp. 163-164.
88. Alloggiamento T, Sanders GD, Khalessi A, Lin O, Hlatky MA, Yeung AC, Owens DK. Cost effectiveness of emerging antiproliferative therapies that reduce restenosis after coronary angioplasty. Journal of the American College of Cardiology 2000 35(2): Supplement A: 550.
89. Heidenreich PA, Sanders GD, Hlatky MA, McDonald KM, Owens DK. Should survivors of myocardial infarction be screened for risk of sudden death? A cost-effectiveness analysis. Journal of the American College of Cardiology 2000 35(2): Supplement A: 550.
90. Szeto HC, Gould MK, Owens DK. Cost effectiveness of management strategies for pulmonary embolism in patients with intermediate pretest probability. American Journal of Respiratory and Critical Care Medicine 2000; 161(3): part 2, A639.

91. Szeto HC, Gould MK, Owens DK. Factors favoring the use of spiral CT in patients suspected of pulmonary embolism: a cost-effectiveness analysis. *American Journal of Respiratory and Critical Care Medicine* 2000; 161(3): part 2, A757.
92. Sanders GD, Nease RF, Hlatky MA, Owens DK. Development of interactive web-based guidelines for prevention of sudden cardiac death. *PACE* 2000; 23(4 part II): 749.
93. Bravata DM, Olkin I, Barnato AE, Keeffe EB, Owens DK. Quality of life, employment and alcohol use after liver transplantation: a meta-analysis. *Journal of General Internal Medicine*, 2000; 15(April[S1]): 55.
94. Barnato AE, Sanders GD, Owens DK. Cost-effectiveness of a potential vaccine against *Coccidioides immitis* (Abstract p48). In: *Proceedings of the Third Annual Conference on Vaccine Research*. April 30-May 2, 2000, Washington D.C., National Foundation for Infectious Diseases 2000: 64.
95. Lin OS, Gerson LB, Keeffe EB, Owens DK. Serum des-gamma-carboxyprothrombin for the screening of hepatocellular carcinoma in cirrhotic patients: A meta-analysis. *Gastroenterology* 2000; 118(4)Supp2:A262.
96. Sanders GD, Nease RF, Owens DK. Publishing Web-Based Guidelines Using Interactive Decision Models. *Proceedings AMIA Symposium* 2000: 1129.
97. Bayoumi AM, Holodniy M, Owens DK. Cost effectiveness of resistance testing for patients with HIV failing highly active antiretroviral therapy. *Medical Decision Making* 2000; 20:486.
98. Bayoumi AM, Holodniy M, Owens DK. Health benefits and costs of early treatment of HIV. *Medical Decision Making* 2000; 20:486.
99. Heidenreich PA, Sanders GD, Hlatky MA, Buxton AE, Hafley GE, Lee KL, McDonald KM, Owens DK. Cost effectiveness of screening patients with low ejection fraction for prophylactic defibrillator implantation. *Medical Decision Making* 2000; 20:484.
100. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost effectiveness of screening strategies for hepatocellular carcinoma in cirrhotic patients. *Medical Decision Making* 2000; 20:477.
101. Barnato AE, Sanders GD, Owens DK. A markov model to assess the cost effectiveness of *C. immitis* vaccination. *Medical Decision Making* 2000; 20:487.
102. Gould MK, Maclean CC, Kuschner WK, Owens DK. Methods for summarizing studies of diagnostic test performance. *Medical Decision Making* 2000; 20:500.
103. Schleinitz M, Socks DA, Weiss JP, Owens DK. Clopidogrel for secondary prophylaxis of thrombotic events: a cost-effectiveness analysis. *Medical Decision Making* 2000; 20:484.
104. Gould MK, Maclean CC, Kuschner WK, Owens DK. A meta-analysis of studies of positron emission tomography for the diagnosis of pulmonary nodules and mass lesions. *Chest* 2000; 118: 105S.
105. Owens DK, Edwards D, Shachter R. Cost effectiveness of potential HIV vaccines. *Program Book of the National Institute on Drug Abuse Community Epidemiology Work Group Conference*, San Francisco, California, December 12-15, 2000; p. II-14.
106. Owens DK, Sanders GD, Sundaram V, Lazzeroni LC, Yano EM, Tempio P, Phillips B, McWhorter V, Douglass LR, Bozzette SA. Policies for human immunodeficiency virus screening in Department of Veterans Affairs hospitals. *Journal of General Internal Medicine* 2001; 16 (Supplement 1): 211.

107. Gould MK, Sanders GD, Maclean CC, Rydzak CE, McClellan MB, Barnett PG, Owens DK. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. *Am J Respir Crit Care Med* 2001;163:A72.
108. Gould MK, Sanders GD, Maclean CC, Rydzak CE, McClellan MB, Barnett PG, Owens DK. Optimal use of surgical biopsy and observation in patients with solitary pulmonary nodules. *Chest* 2001; 120:167S.
109. Gould MK, Sanders GD, Barnett PG, Maclean CC, Rydzak CE, McClellan MB, Owens DK. Cost-effectiveness of positron emission tomography for diagnosis of solitary pulmonary nodules. *Medical Decision Making* 2001; 21: 528.
110. Bayoumi AM, Owens DK. Using Weibull survival methods to model long-term outcomes from short-term data: a new DEALE? *Medical Decision Making* 2001; 21:538.
111. Sanders GD, Bilir SP, Lin D, Rydzak CE, Douglass L, Sundaram V, Owens DK. Automated and evidence-based site-specific guidelines for HIV screening. *Medical Decision Making* 2002; 22:549.
112. Sanders GD, Bilir SP, Lin D, Rydzak CE, Owens DK, Gould MK. Automated customization of recommended strategies for management of solitary pulmonary nodules. *Medical Decision Making* 2002; 22:535
113. Fowler R, Nouri B, Sanders GD, Gastwirth J, Peterson D, Broker A, Bravata D, Owens DK. Cost-effectiveness of the human anthrax vaccine and antimicrobial therapy for urban populations at risk for bioterror attacks. *Medical Decision Making* 2002; 22:554.
114. Sanders GD, Owens DK, Bilir SP, Sinaiko AD, Valk P, Maisey MN. Cost effectiveness of positron emission tomography (PET) before hepatic resection for colorectal metastases. *Medical Decision Making* 2002; 22:543.
115. Sanders GD, Bayoumi A, Sundaram V, Bilir SP, Rydzak CE, Douglass L, Holodniy M, Owens DK. Cost effectiveness of HIV screening in acute care settings in the era of highly active antiretroviral (HAART) therapy. *Medical Decision Making* 2002; 22:562.
116. Owens DK, Sundaram V, Lazzeroni LC, Douglass LR, Tempio P, Sanders GD, Holodniy M. HIV testing appropriateness and predictors of HIV infection in department of veterans affairs health care systems. *Medical Decision Making* 2002; 22:534.
117. Honiden S, Nease RF, Sundaram V, Holodniy M, Owens DK. The effect of diagnosis with HIV infection on quality of life. *Medical Decision Making* 2002; 22:560.
118. Sundaram V, Douglass LR, Lazzeroni LC, Sanders GD, Tempio P, Bergen MR, Owens DK. A randomized trial of an intervention to improve HIV screening. *Medical Decision Making* 2002; 22:542.
119. Silverman J, Bundorf MK, Rydzak CE, Dembitzer A, Enthoven A, Owens DK, Sanders GD. Cost effectiveness of assessing patient preferences for treatment of breast and ovarian cancer susceptibility. *Medical Decision Making* 2002; 22:554.
120. Groeneveld PW, Owens DK. Cost-effectiveness of widespread, non-selective training of laypersons in cardiopulmonary resuscitation. *Medical Decision Making* 2002; 22:544.
121. Bravata DM, Szeto H, McDonald K, Smith WM, Owens DK. Development of a Conceptual Framework for the Evaluation of Decision Support Systems to Respond to Bioterrorism. *Medical Decision Making* 2002; 22:554.
122. Bravata DM, McDonald K, Smith WM, Rydzak C, Szeto H, Buckeridge D, Haberland C, Owens DK. Surveillance systems for bioterrorism: A systematic review. *Journal of Urban Health: Bulletin of The New York Academy of Medicine* 2003; 80: i135.

123. Munakata J, Woolcott J, Anis A, Sculpher M, Yu W, Sanders G, Bayoumi A, Gulbinas V, Philips Z, Owens D. Design of a prospective economic evaluation for a tri-national clinical trial in HIV patients (OPTIMA). *Controlled Clinical Trials* 2003; 24: 173S.
124. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost-effectiveness analysis of photodynamic therapy for treatment of high grade dysplasia in Barrett's esophagus. *Gastrointestinal Endoscopy* 2003; 57(5): AB79.
125. Zaric GS, Bayoumi A, Brandeau ML, Owens DK. The cost effectiveness of improved adherence to antiretroviral therapy. *Value in Health* 2003; 6:266.
126. Tuli K, Hu D, Vanichseni S, Edwards D, Shachter R, Mock P, van Griensven G, Owens D, Choopanya K, Tappero J. Potential program to vaccinate injection drug users in Bangkok, Thailand with a partially effective HIV vaccine: a cost-effectiveness analysis. *AIDS Vaccine Conference* September 18-21, 2003, New York City.
127. Owens DK, Sundaram V, Douglass LR, Lazzeroni LC, Holodniy M, Margolis D, Sanders GD, Taylor K, VonGronigen R, Shadle VM, Gyuricza D, McWhorter VC, Agoncillo T, Paulk P, Haren N, Tuen M, Dwyer A, Nyland J, Tempio T, Khayr W, Dietzen D, Jensen P, Simberkoff M, Bozzette SA. Seroprevalence of HIV infection at VA health care systems. *Medical Decision Making* 2003; 23:569.
128. Munakata J, Sanders GD, Owens DK, Bayoumi AM. Cost effectiveness of enfuvirtide in the treatment of drug-resistant HIV infection. *Medical Decision Making* 2003; 23:569.
129. Zaric GS, Bravata D, Holty JC, Brandeau ML, Willhelm E, Sundaram V, Macdonald K, Owens DK. Modeling the logistics of response to a large anthrax attack in the United States. *Medical Decision Making* 2003; 23:570.
130. Vij R, Triadafilopoulos G, Owens DK, Kunz P, Sanders GD. Cost effectiveness of photodynamic therapy for high grade dysplasia in Barrett's esophagus. *Medical Decision Making* 2003; 23:585.
131. Sanders GD, Bayoumi AM, Sundaram V, Neukermans CP, Holodniy M, Owens DK. Effect of transmission on the cost effectiveness of screening for HIV. *Medical Decision Making* 2003; 23:585.
132. Sanders GD, Nouri B, Choudhry K, Owens DK, Hlatky MA. Potential cost effectiveness of genetic screening for sudden cardiac death. *Medical Decision Making* 2003; 23:579.
133. Zaric, GS, Bayoumi AM, Brandeau ML, Owens DK, The cost effectiveness of counseling to improve adherence to HAART. *Medical Decision Making* 2003; 23:582.
134. Mesesan K, Owens DK, Paltiel AD. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the HIV epidemic in developing countries: a South African example. *Medical Decision Making* 2005; 25(1):E1.
135. Walsh JME, McDonald KM, Shojanian KG, Sundaram V, Lewis R, Nayak S, Mechanic J, Owens DK, Goldstein MK. Provider adherence with quality improvement strategies for management of hypertension: a systematic review. *Medical Decision Making* 2005; 25 (1):E41.
136. Joyce V, Aalfs SSA, Sundaram V, Hill AK, Baker F, Munakata J, Kyriakides TC, Sanders GD, Holodniy M, Schulpher M, Anis A, Yu W, Brown S, Owens DK. Utility-based assessments of quality of life in a randomized trial of antiretroviral therapy in advanced HIV disease. *Medical Decision Making* 2005; 25 (1):E8.
137. Walsh JME, McDonald KM, Shojanian KG, Sundaram V, Lewis R, Nayak S, Mechanic J, Owens DK, Goldstein MK. Quality improvement strategies for hypertension: a systematic review. *Medical Decision Making* 2005; 25 (1):E49.

138. Bravata DM, Zaric GS, Holty JE, Brandeau ML, Wilhelm ER, McDonald KM, Owens DK. The cost effectiveness of alternative strategies for stockpiling and dispensing medical and pharmaceutical supplies during a response to anthrax bioterrorism. *Medical Decision Making* 2005; 25 (1):E5.
139. Aalfs SSA, Guh DP, Singer J, Sundaram V, Joyce V, Hill AK, Sun H, Griffin S, Sanders GD, Bayoumi AM, Holodniy M, Brown S, Schulpher M, Yu W, Owens DK, Anis AH. The impact of AIDS-related events and non-AIDS serious adverse events on health-related quality of life in a multinational trial of antiretroviral therapy. *Medical Decision Making* 2005; 25 (1):E52.
140. Holty JE, Bravata DM, Liu H, Wilhelm ER, Zaric GS, McDonald KM, Owens DK. 100 years of inhalational anthrax: a systematic review of cases from 1900 to 2001. *Medical Decision Making* 2005; 25 (1):E25.
141. Owens DK, Cavallaro JF, Edwards D, Shachter R. Cost effectiveness of partially effective HIV vaccines in the era of highly active antiretroviral therapy. *Medical Decision Making* 2005; 25 (1):E4.
142. Sanders GD, Hlatky MA, Owens DK. Cost effectiveness of the implantable cardioverter defibrillator in the MADIT-II population. *Medical Decision Making* 2005; 25 (1):E38.
143. Sanders GD, Sundaram V, Bayoumi AM, Owens DK. Cost effectiveness of HIV screening in the elderly. *Medical Decision Making* 2005; 25 (1):E15.
144. Bayoumi AM, Sanders GD, Munakata J, Owens DK. Potential cost effectiveness of aggressively treating multi-drug experienced HIV-positive patients. *Medical Decision Making* 2005; 25 (1):E35.
145. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole S, Owens DK. The cost effectiveness of highly active antiretroviral therapy for injection drug users in Russia. *Russian Journal of AIDS, Cancer and Public Health* 2005; 9(2):117.
146. Owens DK, Sanders G, Bayoumi A, Holodniy M. Cost effectiveness of screening for HIV in the United States in the era of highly active antiretroviral therapy. *Russian Journal of AIDS, Cancer and Public Health* 2005; 9(2):120.
147. Vinichenko T, Brandeau ML, Galvin CM, Long EF, Tole S, Owens DK. Policy options for addressing issues of injection drug use in the context of HIV/AIDS. *Russian Journal of AIDS, Cancer and Public Health* 2005; 9(2):133.
148. Sanders GD, Bayoumi AM, Sundaram V, Lazzeroni L, Holodniy M, Owens DK. Cost effectiveness of screening for HIV. Abstract Book, 2005 National HIV Prevention Conference, June 12-15, 2005, Atlanta, Georgia, p. 24-25.
149. Long EF, Brandeau ML, Galvin CM, Vinichenko TN, Tole SP, Schwartz A, Sanders GD, Owens DK. Treating injection drug users with antiretroviral therapy: effect on the HIV epidemic in Russia. *Medical Decision Making* 2006; 26: E7.
150. Long EF, Brandeau ML, Vinichenko TN, Galvin CM, Tole SP, Schwartz A, Sanders GD, Owens DK. The cost effectiveness of antiretroviral therapy for injection drug users in Russia. *Medical Decision Making* 2006; 26: E3.
151. Tole SP, Sanders GD, Bayoumi A, Galvin CM, Vinichenko TN, Long EF, Brandeau ML, Owens DK. The cost effectiveness of HIV screening in a resource-limited country: A model of screening in Russia. *Medical Decision Making* 2006; 26: E6.
152. Dembitzer AD, Sanders GD, Carter EH, Owens DK. Evaluation of the effectiveness and cost effectiveness of proband testing for BRCA1/2 mutations. *Medical Decision Making* 2006; 26: E28.
153. Sanders GD, Dembitzer AD, Carter EH, Goldstein MK, Bravata DM, Owens DK. Preference-based decision making to guide testing for breast cancer genes. *Medical Decision Making* 2006; 26: E10.

154. Liu H, Michaud K, Nayak S, Owens DK, Garber AM. The cost effectiveness of parathyroid hormone and alendronate in high-risk osteoporotic women. *Medical Decision Making* 2006; 26: E4.
155. Nayak S, Olkin I, Liu H, Grabe M, Gould MK, Allen EI, Owens DK, Bravata DM. Meta-analytic evaluation of the accuracy of calcaneal quantitative ultrasound for identifying patients with osteoporosis. *Medical Decision Making* 2006; 26: E40.
156. Mesesan K, Owens DK, Vardas E, Gray GE, McIntyre JA, Paltiel AD. Predicting the impact of a partially effective HIV vaccine and subsequent risk behavior change on the heterosexual epidemic in developing countries: a South African example. *Proceedings of the 13th Conference on Retroviruses and Opportunistic Infections*, Denver, February 5-9, 2006. Abstract Number 479, page 210.
157. Sanders GD, Hlatky MA, Owens DK. Inappropriate Shocks Reduce Implantable Cardioverter Defibrillator Cost Effectiveness (AB4-2). *Heart Rhythm Journal*. 2006; 3 (5) Supplement S: S7.
158. Mesesan K, Owens DK, Paltiel AD. The potential benefits of expanded male circumcision programs in Africa: Predicting the population-level impact on heterosexual HIV transmission in Soweto. *Proceedings of the XVI International AIDS Conference*, August 13-18, 2006, Toronto, Canada. 2006.
159. Sanders GD, Bayoumi AM, Owens DK. Cost effectiveness of HIV screening with streamlined counseling. *Society for Medical Decision Making Annual Meeting*, Boston, Massachusetts October 15-18, 2006 See: <http://smdm.confex.com/smdm/2006ma/techprogram/MEETING.HTM>.
160. Nayak S, Liu H, Michaud K, Owens DK. Cost effectiveness of alternative screening strategies for osteoporosis in postmenopausal women. *Society for Medical Decision Making Annual Meeting*, Boston, Massachusetts October 15-18, 2006 See: <http://smdm.confex.com/smdm/2006ma/techprogram/MEETING.HTM>.
161. Sun H, Guh DP, Bansback NJ, Nosyk B, Li X, Cameron W, Brown S, Gazzard B, Owens DK, Sculpher M, Singer J, Schechter M, Anis AH. Designing economic evaluations in late-stage HIV: what health states should be included? *Society for Medical Decision Making Annual Meeting*, Boston, Massachusetts October 15-18, 2006 See: <http://smdm.confex.com/smdm/2006ma/techprogram/MEETING.HTM>.
162. Liu H, Nayak S, Michaud K, Karpf D, Owens DK, Garber A. Generic fosamax: the effect of price reduction on the cost effectiveness of aledronate therapy. *Society for Medical Decision Making Annual Meeting*, Boston, Massachusetts October 15-18, 2006 See: <http://smdm.confex.com/smdm/2006ma/techprogram/MEETING.HTM>.
163. Bravata DM, McDonald KM, Gienger A, Owens DK. Comparative effectiveness of percutaneous coronary interventions and coronary artery bypass grafting for coronary artery disease. *Journal of General Internal Medicine* 2007; 22 supplement 1, p. 47, April 2007.
164. Sanders GD, Anaya H, Asch S, Hoang T, Golden J, Gifford A, Bowman C, Owens DK. Cost effectiveness of rapid HIV testing with streamlined counseling. *Proceedings of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention*, Sydney Australia, July 22-25, 2007.
165. Bendavid E, Young SD, Sanders GD, Owens DK. Cost effectiveness of HIV monitoring in resource-constrained settings. *Proceedings of the 16th International Conference on AIDS, Cancer and Public Health*, St Petersburg, Russia, May 28-June 1, 2007.
166. Tole SP, Sanders GD, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, Owens DK. The cost effectiveness of HIV screening in Russia. *Proceedings of the 16th International Conference on AIDS, Cancer and Public Health*, St Petersburg, Russia, May 28-June 1, 2007. *Russian Journal of AIDS, Cancer, and Public Health* 2007; 11: 129.
167. Long EF, Brandeau ML, Galvin CM, Vinichenko TN, Tole SP, Sanders GD, Owens DK. Evaluating the cost effectiveness of expanding antiretroviral therapy (ARV) in Russia and the effect of reduced ARV Price. *Proceedings of the 16th International Conference on AIDS, Cancer and Public Health*, St Petersburg, Russia, May 28-June 1, 2007. *Russian Journal of AIDS, Cancer, and Public Health* 2007; 11: 119.

168. Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost effectiveness of screening for HIV in older patients in the U.S. Proceedings of the 16th International Conference on AIDS, Cancer and Public Health, St Petersburg, Russia, May 28-June 1, 2007.
169. Thompson EM, Sanders GD, Trotter PR, Patz EF, Owens DK, Gould MK. Validation of two models to estimate the pre-test probability of malignancy in patients with solitary pulmonary nodules. *American Journal of Respiratory and Critical Care Medicine* 2007;175:A870.
170. Thompson EM, Sanders GD, Trotter PR, Patz EF, Owens DK, Gould MK. Validation of a decision model for managing solitary pulmonary nodules. *American Journal of Respiratory and Critical Care Medicine* 2007;175:A869.
171. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Sanders GD, Owens DK. Cost-effectiveness of expanded use of antiretroviral treatment (ARV) for injection drug users (IDUs) and non-IDUs in Russia: Impact of reduced ARV price. *American Public Health Association 135th Annual Meeting* 2007.
172. Bendavid E, Rajwade A, Young SD, Owens DK. Cost effectiveness of diagnostic monitoring for HIV care in resource poor settings. *American Public Health Association 135th Annual Meeting* 2007.
173. Long EF, Brandeau ML, Owens DK. The cost effectiveness of general versus targeted HIV vaccination strategies in the U.S. *Medical Decision Making* 2008; 28; E39.
174. Long EF, Brandeau ML, Owens DK. A framework for allocating resources for HIV among prevention and treatment interventions. *Medical Decision Making* 2008; 28; E77.
175. Sanders GD, Anaya H, Asch S, Goetz M, Hoang T, Golden J, Gifford A, Bowman C, Owens DK. Cost effectiveness of strategies to improve HIV testing and receipt of results. *Medical Decision Making* 2008; 28; E21-22.
176. Bendavid E, Young SD, Katzenstein DA, Bayoumi AM, Sanders GD, Owens DK. Cost effectiveness of HIV monitoring strategies in resource-limited settings. *Medical Decision Making* 2008; 28; E42.
177. Desai AA, Baras J, Berk BB, Nakajima A, Owens DK, Garber AM, Chertow GM. Management of acute renal failure (ARF) in the ICU: a cost-effectiveness analysis of competing strategies. *2007 Proceedings of the American Society of Nephrology*.
178. Khazeni N, Hutton D, Garber AM, Owens DK. Preventive strategies for an avian influenza pandemic. *Proceedings of the American Thoracic Society International Conference, Toronto, Ontario, Canada*.
179. Nayak S, Liu H, Michaud K, Owens DK. The cost effectiveness of osteoporosis screening strategies for postmenopausal women. *Annual Meeting, Society for General Internal Medicine* 2008.
180. Andersson KM, Owens DK, Paltiel AD. Risk compensation in partially-effective HIV prevention programs in the African setting: the impact of vaccination versus circumcision on HIV transmission in Soweto, South Africa. *Proceedings of the AIDS Vaccine 2008 Meeting, Cape Town, South Africa, October 13-16, 2008*.
181. Brown S, The OPTIMA Study Team. Clinical outcomes from OPTIMA: A randomized controlled trial of antiretroviral treatment interruption or intensification in advanced multi-drug resistant HIV infection. *Proceedings of the XVII International AIDS Conference, Mexico City, Mexico, August 3-8, 2008*.
182. Khazeni N, Hutton DW, Garber AM, Owens DK. Cost effectiveness of antiviral prophylaxis and adjuvanted prime boost vaccination strategies for an influenza pandemic. *Annual Meeting Society for Medical Decision Making Philadelphia, Pennsylvania, October 19-22, 2008*. <http://smdm.confex.com/smdm/2008pa/webprogram/start.html>
183. Long EF, Brandeau ML, Owens DK. To prevent or treat: the cost effectiveness of expanded HIV screening or antiretroviral therapy. *Annual Meeting Society for Medical Decision Making Philadelphia, Pennsylvania, October 19-22, 2008*. <http://smdm.confex.com/smdm/2008pa/webprogram/start.html>

184. Bendavid E, Wood R, Katzenstein DA, Bayoumi AM, Owens DK. Antiretroviral Strategies and Treatment Monitoring in Resource-Limited Settings – A Cost-Effectiveness Analysis. Annual Meeting Society for Medical Decision Making Philadelphia, Pennsylvania, October 19-22, 2008. <http://smdm.confex.com/smdm/2008pa/webprogram/start.html>
185. Bendavid E, Sanders GD, Owens DK. Cost-Effectiveness of Expanded Testing for HIV in Highly Endemic Regions. Annual Meeting Society for Medical Decision Making Philadelphia, Pennsylvania, October 19-22, 2008. <http://smdm.confex.com/smdm/2008pa/webprogram/start.html>
186. Perez MV, Kumarasamy NA, Owens DK, Wang PJ, Hlatky MA. Cost effectiveness of genetic testing in family members of patients with long QT syndrome. Proceedings of the American Heart Association, New Orleans, November 2008.
187. Andersson KM, Owens DK, Paltiel AD. Gender-related effects of expanded adult male circumcision programs in southern Africa: the impact of relationship dynamics and potential risk compensation on heterosexual HIV transmission. Proceedings of the 16th Conference on Retroviruses and Opportunistic Infections (CROI). Montreal, Canada, February 8-11, 2009.
188. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Holodniy M, Brown ST, Cameron W, Sculpher M, Anis AH, Owens DK. Impact of structured treatment interruptions and mega-HAART on health-related quality of life in patients with advanced HIV. 18th Annual Canadian Conference on HIV/AIDS Research, Canadian Association for HIV Research (CAHR), April 23-26, 2009.
189. Khazeni N, Hutton D, Garber AM, Owens DK. Effectiveness and cost-effectiveness of surgical masks and N-95 respirators for the next influenza pandemic. Proceedings of the American Thoracic Society International Conference, San Diego, California, May 15-20, 2009.
190. Levesque BG, Cipriano LE, Chang SL, Lee KL, Owens DK, Garber AM. Cost effectiveness of alternative diagnostic strategies for patients with suspected small-bowel Crohn's disease. *Gastroenterology* 2009 (in press).
191. Andersson KM, Owens DK, Paltiel AD. Gender differences in risk behavior and the power to negotiate safe sex: potential complications in scaling up adult male circumcision programs in Southern Africa. Proceedings of the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa, July 19-22, 2009.
192. Anis A, Barnett P, Owens DK. A multinational comparison of the costs of treatment of late-stage HIV/AIDS in the OPTIMA trial. Proceedings of the 5th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment, and Prevention, Cape Town, South Africa, July 19-22, 2009.
193. Smith-Spangler CM, Jusuola J, Enns E, Owens DK, Garber AM. Desalination of the American diet: population strategies to decrease sodium intake and the burden of cardiovascular disease. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
194. Barnett PG, Chow A, Joyce VR, Bayoumi AM, Griffin SC, Sun H, Holodniy M, Brown ST, Cameron DW, Sculpher M, Youle M, Anis AH, Sanders GD, Owens DK. Effect of management strategies and clinical status on costs of care for multi-drug resistant HIV. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
195. Joyce VR, Barnett PG, Bayoumi AM, Griffin SC, Sanders GD, Sun H, Holodniy M, Brown ST, Cameron DW, Sculpher M, Youle M, Anis AH, Owens DK. Impact of treatment interruptions and mega-ART on health-related quality of life in the OPTIMA trial. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
196. Griffin SC, Bayoumi AM, Owens DK, Sun H, Barnett PG, Sanders GD, Anis AH, Holodniy M, Brown ST, Cameron DW, Sculpher MJ. Analysing clinical trial data to provide inputs to decision models. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.

197. Bendavid E, Wood R, Brandeau ML, Owens DK. HIV testing and treatment: implications for epidemic control in South Africa. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
198. Khazeni N, Hutton DW, Garber A, Owens DK. Minimal required effectiveness and compliance of surgical masks and respirators to mitigate an influenza pandemic. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
199. Hutton DW, Khazeni N, Garber A, Hupert N, Owens DK. Effectiveness and cost-effectiveness of vaccination for novel influenza A(H1N1). Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
200. Schneider JJ, Foo P, Owens DK. Cost-effectiveness analysis of universal TB screening for children—facing up to complexity in high burden countries. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009..
201. Yank V, Tuohy CV, Logan A, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. The safety and efficacy of recombinant activated factor VIIa for cardiac surgery: a survey of use and comparative effectiveness review. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
202. Perlothro DJ, Glass RJ, Davey VJ, Garber A, Owens DK. Health outcomes and costs of community mitigation strategies for pandemic influenza in the U.S. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
203. Yank V, Tuohy CV, Logan A, Bravata DM, Staudenmayer K, Eisenhut R, Sundaram V, McMahon D, Olkin I, McDonald KM, Owens DK, Stafford RS. The safety and efficacy of recombinant activated factor VIIa for non-traumatic intracranial hemorrhage: patterns of use and comparative effectiveness review. Annual Meeting Society for Medical Decision Making, Hollywood, California, October 18-21, 2009.
204. Freeman JV, Zhu RP, Bobulsky SC, Owens, DK, Garber AM, Turakhia MP. Cost-effectiveness of Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation. Proceedings of the Heart Rhythm Society Scientific Sessions (Denver, CO). May 14, 2010.
205. Turakhia MP, Zhu RP, Bobulsky SC, Owens, DK, Garber AM, Freeman JV. Cost-effectiveness of Percutaneous Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation. Heart Rhythm Society Scientific Sessions (Denver, CO). May 13, 2010.
206. McDonald KM, Sundaram V, Smith-Spangler C, Albin L, Bravata DM, Owens DK. Care coordination: what works? Harnessing a vast literature through a systematic review of systematic reviews. European Society for Medical Decision Making, 2010.
207. Lee KK, Cipriano LE, Owens DK, Go AS, Hlatky MA. Cost effectiveness of using high sensitivity c-reactive protein to identify intermediate and low cardiovascular risk individuals for statin therapy. American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke Scientific Sessions, Washington D.C. May 19-21, 2010.
208. Cipriano LE, Zaric GS, Owens DK, Brandeau ML. Cost effectiveness of screening for acute HIV and HCV infection in injection drug users. Society for Medical Decision Making Annual Meeting 2010, Toronto, Canada, October 23-27, 2011. Abstracts available at: <http://smdm.confex.com/smdm/2010on/webprogram/meeting.html>
209. Smith-Spangler CM, Sundaram V, Albin L, Owens DK, McDonald KM. Care coordination: what works? Making sense of a vast literature via a systematic review of reviews. Society for Medical Decision Making Annual Meeting 2010, Toronto, Canada, October 23-27, 2010. Abstracts available at: <http://smdm.confex.com/smdm/2010on/webprogram/meeting.html>

210. Bayoumi AM, Joyce VR, Barnett PG, Griffin SC, Sun H, Sanders GD, Bansback NJ, Holodniy M, Brown ST, Kyriakides TC, Sculpher M, Anis AH, Owens DK. Cost effectiveness of novel antiretrovirals for human immunodeficiency virus infection. Society for Medical Decision Making Annual Meeting 2010, Toronto, Canada, October 23-27, 2010. Abstracts available at: <http://smdm.confex.com/smdm/2010on/webprogram/meeting.html>
211. Hutton DW, Khazeni N, Garber AM, Owens DK. Cost effectiveness of stockpiling protective facewear for an influenza pandemic. Society for Medical Decision Making Annual Meeting 2010, Toronto, Canada, October 23-27, 2010. Abstracts available at: <http://smdm.confex.com/smdm/2010on/webprogram/meeting.html>.
212. Freeman JV, Zhu RP, Bobulsky SC, Owens DK, Garber AM, Turakhia MP. Cost-effectiveness of Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation. Oral presentation at Heart Rhythm Society Scientific Sessions, May 14, 2010.
213. Turakhia MP, Zhu RP, Bobulsky SC, Owens, DK, Garber AM, Al-Ahmad A, Wang PJ, Freeman JV. Cost-effectiveness of percutaneous left atrial appendage occlusion for atrial fibrillation. Poster presentation at CARDIOSTIM Scientific Sessions, Nice, France, June 14, 2010.
214. Negoescu DM, Owens DK, Brandeau ML, Bendavid E. Balancing cardiac risk and immunologic benefits in decisions on HIV antiretroviral treatment initiation. Society for Medical Decision Making Annual Meeting 2011, Chicago, Illinois, October 23-26, 2011. Abstract available at: <http://smdm.confex.com/smdm/2011ch/webprogram/Paper6341.html>
215. Juusola JL, Brandeau ML, Long EF, Owens DK, Bendavid E. The cost effectiveness of symptom-based testing and routine screening for acute HIV infection in men who have sex with men in the United States. Society for Medical Decision Making Annual Meeting 2011, Chicago, Illinois, October 23-26, 2011. Abstract available at: <http://smdm.confex.com/smdm/2011ch/webprogram/Paper6399.html>
216. Juusola JL, Brandeau ML, Owens DK, Bendavid E. The cost effectiveness of preexposure prophylaxis for HIV prevention in men who have sex with men in the United States. Society for Medical Decision Making Annual Meeting 2011, Chicago, Illinois, October 23-26, 2011. Abstract available at: <http://smdm.confex.com/smdm/2011ch/webprogram/Paper6597.html>
217. Simons CT, Cipriano LE, Shah UR, Hlatky MA, Garber AM, Owens DK. Transcatheter aortic valve implantation should change the management of non-surgical aortic stenosis candidates. Society for Medical Decision Making Annual Meeting 2011, Chicago, Illinois, October 23-26, 2011. Abstract available at: <http://smdm.confex.com/smdm/2011ch/webprogram/Paper6391.html>
218. Shluzas LA, Cronkite RC, Chambers D, Owens DK, Goldstein MK. Implementation of the ATHENA-HTN Clinical Decision Support System [Abstract]. In: 2012 Proceedings of AMIA Summit on Clinical Research Informatics, San Francisco, CA, March 21-23, 2012.
219. Long EF, Andersson KM, Chen RT, Glasser JW, Hankins CA, Owens DK. A model-based consensus on the impact of an RV144-like HIV vaccine in diverse epidemic settings. Proceedings of the XIX International AIDS Conference, July 22-27, Washington DC, USA. (under review).
220. Niehaus K, Bavinger C, Desai M, Bendavid E, Joyce V, Olshen RA, Olkin I, Holodniy M, Bayoumi A, Owens DK. The Effectiveness of New HIV Antiretroviral Drugs in Treatment- Experienced Patients: A Meta-analysis of Randomized, Controlled Trials. Proceedings of the XIX International AIDS Conference, July 22-27, Washington DC, USA.
221. Shluzas, L.A., M.K. Goldstein, D.K. Owens, and J.P.A. Ioannidis. "Examining parameters that impact incremental cost-effectiveness ratios," Proceedings of the Society for Medical Decision Making Annual Meeting 2012, Phoenix Arizona, October 17-20, 2012.

222. Shaw JG, Goldhaber-Fiebert J, Yore M, Faruque S, Caughey AB, Owens DK. Cost effectiveness of routine use of magnesium sulfate for seizure prophylaxis in mild preeclampsia. Proceedings of the Society for Medical Decision Making Annual Meeting 2012, Phoenix Arizona, October 17-20, 2012.
223. Erickson DF, Japa S, Owens DK, Chertow GM, Garber A, Goldhaber-Fiebert JD. A cost effectiveness analysis of statins for preventing cardiovascular disease in patients with chronic kidney disease. Proceedings of the Society for Medical Decision Making Annual Meeting 2012, Phoenix Arizona, October 17-20, 2012.
224. Kastenberg ZJ, Hurley MP, Luan A, Vasu-Devan V, Owens DK, Goldhaber-Fiebert JD. The cost effectiveness of MRI in the diagnosis of acute appendicitis during pregnancy: a guide for surgical decision making. Proceedings of the Society for Medical Decision Making Annual Meeting 2012, Phoenix Arizona, October 17-20, 2012.
225. Pershing S, Matesic B, Enns E, Owens DK, Goldhaber-Fiebert JD. Cost-effectiveness of treatment options for diabetic macular edema. Proceedings of the Society for Medical Decision Making Annual Meeting 2012, Phoenix Arizona, October 17-20, 2012.
223. Sze-chuan S, Brayton KM, Patel VG, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of same-day discharge after elective percutaneous coronary intervention. Proceedings of the Society for Medical Decision Making Annual Meeting, Baltimore, Maryland, October 20-23, 2013.
224. Leeper A, Goldhaber-Fiebert JD, Owens DK, Goodyear A. Cost effectiveness of multiple sclerosis disease-modifying therapy: accounting for patient risk. Proceedings of the Society for Medical Decision Making Annual Meeting, Miami, Florida, October 18-22, 2014.
225. Pitt A, Woo CY, Strandberg EJ, Schmiegelow MD, Hlatky MA, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of cardiac resynchronization therapy compared with implantable cardioverter-defibrillator alone in mild heart failure. Proceedings of the Society for Medical Decision Making Annual Meeting, Miami, Florida, October 18-22, 2014.
226. Leeper, A, Goodyear, A, Owens, DK, **Goldhaber-Fiebert, JD**. Cost-effectiveness of multiple sclerosis disease-modifying therapy: Accounting for patient risk. Presented to the INFORMS in San Francisco, CA, November 9-12, 2014.
227. Richman I, Asch S, Owens DK. Breast density legislation and breast cancer stage at diagnosis. Proceedings of the Society for Medical Decision Making Annual Meeting, St. Louis, Missouri, October 18-21, 2015.
228. Joyce VR, Sun H, Barnett PG, Bansback N, Griffin S, Bayoumi AM, Anis AH, Owens DK. Predicting the HUI3 and EQ-5d from the MOS-HIV in patients with advanced HIV. Proceedings of the Society for Medical Decision Making Annual Meeting, St. Louis, Missouri, October 18-21, 2015.
229. Bernard C, Brandeau ML, Humphreys K, Bendavid E, Holodniy M, Weyant C, Owens DK, Goldhaber-Fiebert JD. Cost effectiveness of HIV preexposure prophylaxis for injection drug users in the United States. Proceedings of the Society for Medical Decision Making Annual Meeting, St. Louis, Missouri, October 18-21, 2015.
230. Richman I, Fairley M, Joergensen M, Schuler A, Rastatter ES, Owens DK, Goldhaber-Fiebert J. Cost effectiveness of intensive blood pressure control. Society of General Internal Medicine Annual Meeting, Hollywood, FL. May 11-14, 2016.
231. Richman I, Asch S, Bendavid E, Bhattacharya J, Owens DK. Evaluating the effect of breast density notification legislation on breast cancer stage at diagnosis. Society of General Internal Medicine Annual Meeting, Hollywood, FL. May 11-14, 2016.
232. Goldhaber-Fiebert JD, Stauffer D, Prince L, Andrews JR, Basu S, Alsan M, Bendavid E, Brandeau ML, Owens DK. Capturing the health and economic effects of tuberculosis in India via dynamic microsimulation model calibration and validation. Proceedings of the Society for Medical Decision Making Annual Meeting, Vancouver, British Columbia, Canada, October 23-26, 2016.

233. Bernard CL, Owens DK, Goldhaber-Fiebert JD, Brandeau ML. Cost effectiveness of HIV prevention portfolios for people who inject drugs in the United States. Proceedings of the Society for Medical Decision Making Annual Meeting, Vancouver, British Columbia, Canada, October 23-26, 2016.
234. Bendavid E, Prince L, Owens DK, Goldhaber-Fiebert JD, Andrews JR. Tuberculosis in South Africa is more concentrated by race than poverty. Proceedings of the 2017 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, February 13-16, 2017.
235. Yu JX, Russell A, Ching J, Kim N, Bendavid E, Owens DK, Kaltenbach T. Cost effectiveness of endoscopic mucosal resection compared to transanal resection of complex rectal polyps. Digestive Disease Week Annual Meeting, Chicago, Illinois, May 6-9, 2017.
236. Itoga NK, Minami H, Pearson K, Chelvakumar M, Mell MW, Bendavid E, Owens DK. Cost Effectiveness Analysis of Peripheral Arterial Disease Screening with the Ankle- Brachial Index Test. Arteriosclerosis, Thrombosis and Vascular Biology 2017 Scientific Sessions. May 4-7 2017. Minneapolis, MI.
237. Barnes J, Divi V, Coutre S, Owens DK, Goldhaber-Fiebert J. Cost effectiveness of ibrutinib for first-line therapy for chronic lymphocytic leukemia. Proceedings of the Society for Medical Decision Making Annual Meeting, Pittsburgh, Pennsylvania, October 22-25, 2017.
238. Ryckman T, Goetz J, Giron N, Luby S, Owens DK, Bendavid E. Cost effectiveness of cholera vaccination in Bangladesh. Proceedings of the Society for Medical Decision Making Annual Meeting, Pittsburgh, Pennsylvania, October 22-25, 2017.
239. Yu JX, Russell A, Ching J, Kim N, Bendavid E, Owens DK, Kaltenbach T. Modeling the health and economic outcomes of endoscopic resection compared to transanal resection of complex polyps. Proceedings of the Society for Medical Decision Making Annual Meeting, Pittsburgh, Pennsylvania, October 22-25, 2017.
240. Lin JL, Tawfik DS, Gupta R, Owens DK, Bendavid E. Cost effectiveness of posterior spinal fusion for children with neuromuscular scoliosis. Proceedings of the Society for Medical Decision Making Annual Meeting, Pittsburgh, Pennsylvania, October 22-25, 2017.
241. Harris JP, Saraswathula, A, Kaplun B, Qian Y, Chan A, Chan ATC, Le QT, Owens DK, Goldhaber-Fiebert JD, Pollom E. Cost effectiveness of screening for nasopharyngeal carcinoma with plasma Epstein-Barr virus DNA. Proceedings of the 2018 Annual Meeting of the American Society for Radiation Oncology, San Antonio, Texas October 21-24, 2018 (submitted).
242. Sehested T, Bjerre J, Chang A, Ku S, Jahansouz A, Owens DK, Hlatky M, Goldhaber-Fiebert JD. Cost effectiveness of canakinumab to prevent recurrent myocardial infarction. Proceedings of the European Society of Cardiology Congress, Munich, German, August 25-29, 2018. (submitted).
243. Ryckman T, Luby S, Owens DK, Bendavid E, Goldhaber-Fiebert JD. Model-based cost-effectiveness analysis of cholera vaccination in Bangladesh. Proceedings of the Society for Medical Decision Making Annual Meeting, Montreal, Quebec, Canada, October 14-17, 2018.
244. Ryckman T, Luby S, Owens DK, Bendavid E, Goldhaber-Fiebert JD. Model calibration of cholera natural history in Bangladesh. Proceedings of the Society for Medical Decision Making Annual Meeting, Montreal, Quebec, Canada, October 14-17, 2018.
245. Ching JH, Trafton JA, Goldhaber-Fiebert JD, Owens DK. Modeling medication-assisted treatment of opioid use disorder in the Veterans Health Administration: a systems dynamics approach. Proceedings of the Society for Medical Decision Making Annual Meeting, Montreal, Quebec, Canada, October 14-17, 2018.
246. Barnes, James I. Lin, John, Gupta, Divya, Goldhaber-Fiebert, Jeremy D., Owens, Douglas K., Kunz, Pamela L. The Cost-Effectiveness of Initial vs. Delayed Lanreotide for Treatment of Metastatic Enteropancreatic

Neuroendocrine Tumors in the United States - NANETS Annual Multidisciplinary NET Disease Symposium, October 6, 2018, Seattle, WA. Conference Presentation.

247. Sceats LA, Coughran A, Barnes B, Grimm EL, Muffly M, Spain DA, Kin CJ, Owens DK, Goldhaber-Fiebert JD. Operative vs nonoperative management of appendicitis: a long-term cost-effectiveness analysis. *Journal of the American College of Surgeons* 2018 227(4): S157-S158 Supplement: 1, DOI: 10.1016/j.jamcollsurg.2018.07.334. Owen Wangenstein Scientific Forum / Annual Clinical Congress of the American-College-of-Surgeons (ACS), Boston, MA, October 21-25, 2018.

248. Priromprintr B, Owens D, Almond CS, Hong T, Kondragunta R, Mathur S, Shin AY. A cost-effectiveness analysis of interstage home monitoring for infants with hypoplastic left heart syndrome. Annual meeting American Heart Association, Chicago, Illinois, November 10-12, 2018.

249. George EL, Nardacci L, Rao I, Sinawang PD, Owens DK, Garcia-Toca M. Cost-effectiveness analysis of fenestrated endovascular aneurysm repair compared to open surgical repair for patients with juxtarenal abdominal aortic aneurysms. Society for Vascular Surgery 2019 Vascular Annual Meeting 2019.

250. Lin JL, Rigdon J, Saynina O, Bhattacharya J, Owens DK, Sanders LM. Gastrostomy tube placement in children with neurologic impairment: population-wide association with long term morbidity and mortality. Pediatric Academic Societies Meeting. Baltimore, Maryland, April 24-May 1, 2019.

251. Chandler JM, Conway AA, Huckels J, Pooni JK, Zarnett LJ, Lee K, Kin CJ, Salomon JA, Owens DK. Open versus robotic surgery for rectal cancer: a cost effectiveness analysis. American College of Surgeons Clinical Congress 2019, San Francisco, California, October 27-31, 2019.

252. Ching JH, Trafton JA, Goldhaber-Fiebert JD, Owens DK, Salomon JA. Estimated mortality rates among treated and untreated Veterans with opioid use disorder in the Veterans Health Administration. Proceedings of the Society for Medical Decision Making Annual Meeting, Portland, Oregon, October 20-23, 2019.

253. Ching JH, Owens DK, Trafton JA. Co-morbidities and severe adverse events among treated and untreated Veterans with opioid use disorder in the Veterans Health Administration. Proceedings of the Society for Medical Decision Making Annual Meeting, Portland, Oregon, October 20-23, 2019.

254. Ryckman T, Luby S, Owens DK, Bendavid E, Goldhaber-Fiebert JD. Comparing methods for model calibration with high uncertainty: modeling cholera in Bangladesh. Proceedings of the Society for Medical Decision Making Annual Meeting, Portland, Oregon, October 20-23, 2019.

255. Lin JL, Fagerlin A, Owens DK, Bucher B. Quality of life for children undergoing gastrostomy tube placement: parent report before surgery. Pediatric Academic Societies (under review).

256. Ching JH, Trafton JA, Owens DK, Salomon JA, Goldhaber-Fiebert JD. Modeling interventions to expand medication-assisted treatment among veterans with opioid use disorder in the Veterans Health Administration. Proceedings of the Society for Medical Decision Making Annual Meeting, October 6, 2020.

257. Guan G, Joshi NS, Achepohl GD, Dang R, Taylor K, Salomon JA, Owens DK. A cost-effectiveness analysis of approaches to identifying late preterm and term infants at risk for early onset sepsis. Pediatric Hospital Medicine national conference 2021.

258. Tisdale RL, Cusick MM, Aluri KZ, Handley TJ, Joyner AKC, Salomon JA, Chertow GM, Goldhaber-Fiebert JD, Owens DK. Cost effectiveness of dapagliflozin for non-diabetic kidney disease. Proceedings of the Society for Medical Decision Making Annual Meeting 2021.

259. Cusick MM, Tisdale R, Chertow Glenn, Owens D, Goldhaber-Fiebert. Effectiveness of one-time screening for chronic kidney disease among US adults. Society for Medical Decision Making 44th Annual Meeting, Seattle, Washington, October 23-26, 2022.

260. Joyce VR, Oliva EM, Garcia C, Trafton T, Asch SM, Wagner T, Humphreys K, Owens DK, Bounthavong M. Healthcare costs and utilization before and after opioid overdose in patients with opioid use disorder. VA HSR&D 2023 National Meeting Proceedings, 2023.

261. Purdy K, Jeerakathil T, Owens DK, Bendavid E. An effectiveness analysis of walk-in stroke centers in Northern Alberta. American Academy of Neurology Annual Meeting, April 22-27, 2023. (under review).

262. Dossabhoy SS, Mulaney B, George EL, Chang TI, Owens DK, Arya S, Stern JR, Lee JT. Postoperative acute kidney injury predicts long-term renal function decline after fenestrated endovascular aneurysm repair. (under review).

Other Committees and Presentations

1. Abstract Selection Committee, Fifteenth Annual Meeting, Society for Medical Decision Making; Research Triangle, North Carolina; October 24 - 27, 1993.

2. Technology Assessment Steering Committee, Stanford University Hospital 1993 – 1995

2. Session Chair, Sixteenth Annual Meeting, Society for Medical Decision Making; Cleveland, Ohio; October 16 - 19, 1994.

3. Abstract Selection Committee, Sixteenth Annual Meeting, Society for Medical Decision Making; Cleveland, Ohio; October 16 - 19, 1994.

4. Session Chair, Decision Making for HIV/AIDS, Annual Meeting, Institute for Operations Research and the Management Sciences, Los Angeles, California; April 23 - 26, 1995.

5. Session Chair, Medical Decision Making, Eighteenth Annual Meeting, Society of General Internal Medicine, San Diego, California; May 4 - 6, 1995.

6. Abstract Selection Committee, Eighteenth Annual Meeting, Society of General Internal Medicine, San Diego, California; May 4 - 6, 1995.

7. Awards Committee, Eighteenth Annual Meeting, Society of General Internal Medicine, San Diego, California; May 4 - 6, 1995.

8. Awards Committee, National Research Service Award (NRSA) Trainee Research Conference, Chicago, Illinois; June 3, 1995.

9. Session Chair, Health Services Research, National Research Service Award (NRSA) Trainee Research Conference; Chicago, Illinois; June 3, 1995.

10. Chair, Abstract Selection Committee, National Research Service Award (NRSA) Trainee Research Conference; Chicago, Illinois; June 3, 1995.

11. Session Chair, Cardiac Rehabilitation and Health Care Reform, Third Annual Clinical Exercise Physiology and Cardiac Rehabilitation Conference, Palo Alto, California; August 11, 1995.

12. Session Co-chair, Seventeenth Annual Meeting, Society for Medical Decision Making; Tempe, Arizona; October 14 - 17, 1995.

13. Awards Committee, Seventeenth Annual Meeting, Society for Medical Decision Making; Tempe, Arizona; October 14 - 17, 1995.

14. Co-Chair, Abstract Selection Committee for Medical Decision Making and Cost-Effectiveness Analysis, Nineteenth Annual Meeting, Society for General Internal Medicine, Washington, D.C.; May 2-4, 1996.
15. Awards Committee, Nineteenth Annual Meeting, Society for General Internal Medicine, Washington, D.C.; May 2-4, 1996.
16. Planning Committee, Second Annual National Research Service Award (NRSA) Trainee Research Conference, Atlanta, Georgia; June 8, 1996.
17. Awards Committee, Second Annual National Research Service Award (NRSA) Trainee Research Conference, Atlanta, Georgia; June 8, 1996.
18. Awards Committee, Eighteenth Annual Meeting, Society for Medical Decision Making; Toronto, Ontario, Canada; October 13 - 16, 1996.
19. Abstract Selection Committee, Eighteenth Annual Meeting, Society for Medical Decision Making; Toronto, Ontario, Canada; October 13 - 16, 1996.
20. Scientific Program Committee, Eighteenth Annual Meeting, Society for Medical Decision Making, Toronto, Canada; October 13 - 16, 1996.
21. Session Co-chair, Methods in Medical Decision Making, Eighteenth Annual Meeting, Society for Medical Decision Making; Toronto, Ontario, Canada; October 13 - 16, 1996.
22. Planning Committee, VA Health Services Research and Development Service Annual meeting; Washington D.C., February 12 - 14, 1997.
22. Scientific Program Co-chair, Fifth Annual VA HSR&D Career Development and Research Scientist Awardees Conference, Washington DC; February 12, 1997.
23. Abstract Selection Committee, Twentieth Annual Meeting, Society for General Internal Medicine, Washington, D.C.; May 1 - 3, 1997.
24. Sierra Pacific Veterans Integrated Service Network Task Force on Physician Productivity (November 1996 – present).
25. Selection Committee, Research Methods Workshops, Twentieth Annual Meeting, Society for General Internal Medicine, Washington, D.C.; May 1 - 3, 1997.
26. Awards Committee, Twentieth Annual Meeting, Society for General Internal Medicine, Washington, D.C.; May 1 - 3, 1997.
27. Session Co-Chair, Medical Decision Making, Twentieth Annual Meeting, Society for General Internal Medicine, Washington, D.C.; May 1 - 3, 1997.
28. Scientific Program Committee, Nineteenth Annual Meeting, Society for Medical Decision Making; Houston, Texas; October 26 - 29, 1997.
29. Awards Committee, Nineteenth Annual Meeting, Society for Medical Decision Making; Houston, Texas; October 26 - 29, 1997.
30. Publications Committee, Society for Medical Decision Making, Washington, D.C., 1997-1999.
31. Finance Committee, Society for Medical Decision Making, Washington, D.C., 1997-1999.
32. Executive Committee, Society for Medical Decision Making, Washington, D.C., 1997-1999.

33. Membership Committee, Society for Medical Decision Making, Washington, D.C., 1997-1999.
34. Issues Committee, Society for Medical Decision Making, Washington, D.C., 1997-2000.
35. Abstract Selection Committee, Twenty-first Annual Meeting, Society for General Internal Medicine, Chicago, Illinois, April 23-25, 1998.
36. Session Co-Chair, Cost-effectiveness and Decision Analysis, Twenty-first Annual Meeting, Society for General Internal Medicine, Chicago, Illinois, April 23-25, 1998.
37. Search Committee, Editor-in-Chief, Medical Decision Making, Society for Medical Decision Making, Washington, D.C., 1998.
38. Scientific Review Committee, Twentieth Annual Meeting, Society for Medical Decision Making, Cambridge, Massachusetts, October 25-28, 1998.
39. Session Chair, Cost effectiveness and Resource Allocation, Conference on Quantitative Evaluation of HIV Vaccine Programs, Divonne-les-Bains, France, Sponsored by the Societal Institute of the Mathematical Sciences, New Canaan, Connecticut; July 6-8, 1998.
40. Co-chair, Scientific Review Subcommittee (Provider/Organization Abstracts), Twenty-second Annual Meeting, Society for General Internal Medicine, San Francisco, California, April 29 - May 1, 1999.
41. Search Committee, University Tenure Line faculty position, Department of Health Research and Policy, 1998-99.
42. Session Co-Chair, HIV Problems, Twenty-second Annual Meeting, Society for General Internal Medicine, San Francisco, California, April 29 - May 1, 1999.
43. Chair, Scientific Review Subcommittee, Twenty-third Annual Meeting, Society for General Internal Medicine, Boston, Massachusetts, May 4 - 6, 2000.
44. Scientific Review Committee, Twenty-second Annual Meeting, Society for Medical Decision Making, Cincinnati, Ohio, September 24-27, 2000.
45. Search Committee, University Tenure Line faculty position, Center for Primary Care and Outcomes Research, Department of Medicine, 1999 - 2005.
46. Scientific Review Committee, Twenty-third Annual Meeting, Society for Medical Decision Making, San Diego, California, October 20-24, 2001.
47. Nominations Committee, Society for Medical Decision Making, Washington D. C., 2000-2001.
48. Session Co-Chair, Cost-Effectiveness Analysis, Twenty-third Annual Meeting, Society for Medical Decision Making, San Diego, California, October 20-24, 2001.
49. Scientific Review Committee, Twenty-fifth Annual Meeting, Society for General Internal Medicine, Atlanta, Georgia, May 2-4, 2002.
50. Scholarly Tracks Committee, Stanford University School of Medicine, 2002.
51. Co-Chair, Cost Effectiveness and Decision Modeling Scientific Review Subcommittee, Twenty-sixth Annual Meeting, Society for General Internal Medicine, Vancouver, British Columbia, April 20 – May 3, 2003.

52. Session Co-Chair, Clinical Strategies, Twenty-fifth Annual Meeting, Society for Medical Decision Making, Chicago, Illinois, October 19-22, 2003.
53. Theme Plenary Session Co-Chair, 27th Annual Meeting, Society for General Internal Medicine, Chicago, Illinois, May 2004.
54. Scientific Review Committee, 28th Annual Meeting, Society for Medical Decision Making, Boston, Massachusetts, October 14-18, 2006.
55. Session Co-Chair, Simulation and Clinical Strategies, 29th Annual Meeting, Society for Medical Decision Making, Pittsburgh, Pennsylvania, October 20-24, 2007.
56. Search committee, University Tenure Line faculty position, Center for Primary Care and Outcomes Research, Stanford University, Stanford, California, 2007-2008.
57. Co-chair, search committee, University Tenure Line faculty position in biodefense, Stanford University, 2007-2008.
58. Search committee, University Tenure Line faculty position, Chief, Division of Infectious Diseases, Stanford University, Stanford, California, 2009-2010.
59. Search committee, Co-Director of the Center for International Security and Cooperation, Freeman Spogli Institute for International Study, Stanford University, 2011-2012.
60. Search committee, Medical Center Line Hospitalist, Department of General Medical Disciplines, Stanford University, 2011-2012.
61. Search committee, Chief, Immunology and Rheumatology, Stanford University, 2012.
62. Implementation Committee, Population Sciences Initiative, School of Medicine, Stanford University, 2012.
63. Search Committee, Director, Freeman-Spogli Institute for International Studies, 2012.
64. Search Committee, University Tenure Line faculty position, Center for Primary Care and Outcomes Research and Center for Health Policy, Stanford University, Stanford, California, 2012.
65. Search Committee, faculty position, Center for Health Care Evaluation, VA Palo Alto Health Care System, and Division of General Medical Disciplines, Stanford University, 2012.
66. Search Committee, faculty position, Section Chief, Hematology, VA Palo Alto Health Care System, and, Stanford University, 2013.
67. Search Committee, faculty position, Center for Implementation to Innovation, VA Palo Alto Health Care System, and Division of General Medical Disciplines, Stanford University, 2014.
68. Search Committee, Chair of the Department of Ophthalmology, Stanford University 2014.
69. Search Committee, University Tenure Line faculty position in health services research, Division of Immunology, Department of Medicine, Stanford University, 2014-2015.
70. Dean's Task Force on Community Engagement, School of Medicine, Stanford University, 2015.
71. Task Force on the Organization of General Medical Disciplines, Department of Medicine, 2015.
73. Dean's Committee on Precision Health, 2015-2016.

74. Committee on Innovations in Primary Care Training, Department of Medicine, 2015-2016.
75. Search Committee, University Tenure Line faculty position in decision sciences, Center for Primary Care and Outcomes Research/Center for Health Policy, 2015-2016..
76. Search Committee, University Tenure Line faculty position in health services research, Division of General Medical Disciplines, 2015-2016.
77. Search Committee, Division Chief, Division of Hospital Medicine, 2016-2017.
78. Departmental Review Committee, Department of Health Research and Policy, Stanford University, 2018.
79. Search Committee, University Tenure Line faculty position in health services research, Division of Primary Care and Population Health, 2018-2019.
80. Search Committee, Chief of Geriatrics, Primary Care and Population Health, 2019-2020.
81. Recover, Restore, and Re-open [R3] Dean's Task Force, Stanford University School of Medicine, 2020.
82. Search Committee, General Pediatrics faculty position in health services research, 2021.
83. Search Committee, Cardiovascular Medicine faculty position, 2021.
84. COVID Vaccine Principles and Population Prioritization Subcommittee, 2021.
85. Search Committee, Chair of Medicine, Stanford University School of Medicine, 2023-2024.

Paul Shekelle

Discloser Identifier: 00217716

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Agency for Healthcare Research and Quality	Grant / Contract	Self	\$589000.00
<p>Recipient Name: Paul Shekelle Grant / Contract Description: AHRQ Making Health Care Safer IV Contract Start Date: 08/19/2022 Grant / Contract Amount:\$589,000.00 Additional Information: RAND will support John Hopkins University (JHU) in doing a stakeholder engagement which includes creating surveys and doing a Technical Expert Panel stakeholder call with the goal of prioritizing topics for a rapid review or rapid response or full review.</p> <p>Recipient Type: Individual Grant / Contract Purpose: Research Grant / Contract Valuation Date: 03/24/2025 Contract End Date:</p>			
National Institute of Health	Grant / Contract	Self	\$300000.00
<p>Recipient Name: Paul Shekelle Grant / Contract Description: TRUST Gout Trial Contract Start Date: 01/01/2024 Grant / Contract Amount:\$300,000.00 Additional Information: To evaluate where treat to target or treat to symptoms is optimal for patients with gout</p> <p>Recipient Type: Individual Grant / Contract Purpose: Research Grant / Contract Valuation Date: 12/31/2028 Contract End Date:</p>			
U.S. Department of Veterans Affairs	Employment Current Employment	Self	-
<p>Title: Chief, General Internal Medicine Start Date: 01/01/1990 Additional Information:</p> <p>Position Description: End Date: Ongoing / No Known End Date</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Paul G. Shekelle

Name

Paul Shekelle

Signature

04/24/2024

Date

Jeffrey Tice

Discloser Identifier: 03415027

Disclosure Purpose: Annual Governance Disclosure 2024-25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Division of Cancer Epidemiology and Genetics, National Cancer Institute	Grant / Contract	Self	\$4000000.00
<p>Recipient Name: UCSF Grant / Contract Description: P01: The future of breast cancer screening in community practice: Advanced technologies performance, Contract Start Date: 09/27/2011 Grant / Contract Amount:\$4,000,000.00 Additional Information: Co-investigator</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 05/22/2019 Contract End Date: 05/31/2022</p>			
institute for clinical and economic review	Grant / Contract	Self	\$495000.00
<p>Recipient Name: UCSF Grant / Contract Description: Produce comparative effectiveness reviews in support of ICER Contract Start Date: 01/01/2018 Grant / Contract Amount:\$495,000.00 Additional Information:</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 05/22/2019 Contract End Date: Ongoing / No Known End Date</p>			
National MS Society	Other	Self	-
<p>Category: Other End Date: Ongoing / No Known End Date Compensation Type: Unpaid Compensation: Additional Information:</p> <p>Start Date: 01/01/2012</p>			
Patient-Centered Outcomes Research Institute	Grant / Contract	Self	\$10000000.00
<p>Recipient Name: UCSF Grant / Contract Description: Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Contract Start Date: 09/15/2015 Grant / Contract Amount:\$10,000,000.00 Additional Information: Co-investigator</p> <p>Recipient Type: Institution Grant / Contract Purpose: Research Grant / Contract Valuation Date: 05/22/2019 Contract End Date: Ongoing / No Known End Date</p>			
Society of General Internal Medicine	Other	Self	-
<p>Category: Other End Date: Ongoing / No Known End Date Compensation Type: Unpaid Compensation: Additional Information:</p> <p>Start Date: 01/01/2017</p>			
University of California San Francisco	Employment Current Employment	Self	-
<p>Title: Professor of Medicine Start Date: 07/01/1999 Additional Information: Primary job</p> <p>Position Description: Faculty End Date: Ongoing / No Known End Date</p>			
University of California San Francisco	Other	Self	-

Entity	Type	Interest Held By	Value
<p>Category: Other Start Date: 07/01/1999</p> <p>End Date: Ongoing / No Known End Date</p> <p>Compensation Type: Cash</p> <p>Compensation: Yes</p> <p>Additional Information:</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Jeffrey A. Tice, MD

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	CME talks on osteoporosis, no papers or research grants

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Jeffrey A. Tice, MD



Signature

April 9, 2024

Date

William Fox

Disclosure Purpose: Annual Governance Disclosure 2024-25 (Expiration Date: 04/04/2025), Planning and/or Faculty (Expiration Date: 04/04/2025), Faculty/Speakers (Expiration Date: 04/04/2025), Internist Editorial Advisory Board (Expiration Date: 04/04/2025), Internal Medicine Meeting 2024 faculty (Expiration Date: 04/04/2025), AMA Delegation (Expiration Date: 04/04/2025), Faculty Disclosures (Expiration Date: 04/04/2025)

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Fox & Brantley Internal Medicine	Employment Current Employment	Self	-
Title: MD Managing Partner Start Date: 11/01/2003 Additional Information:		Position Description: MD Managing Partner End Date: Ongoing / No Known End Date	
Obagi Cosmeceuticals LLC	Other	Self	-
Category: Other End Date: Compensation Type: Other Compensation: Additional Information:		Start Date: 11/01/2003 Other Compensation: Reseller of Obagi Products	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	NONE
Hypertension	NONE
Menopausal Therapy	NONE
Migraine	NONE
Obesity	NONE
Osteoporosis	NONE
COVID-19	NONE
Cannabis	NONE
Diabetes	NONE
Cardiovascular Disease	NONE

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

WILLIAM FOX

Name



Signature

4/25/24

Date

Laura Baldwin

Discloser Identifier: 01367349

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Director, Public Relations Start Date: 02/06/2006 Additional Information:		Position Description: End Date:	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Laura Baldwin

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Laura Baldwin

Laura Baldwin

Laura Baldwin 4/30/24

Signature

Date

Karen Campos

Discloser Identifier: 04227079

Disclosure Purpose: Annual Staff Disclosure 2023 - 2024

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Associate, Performance Measurement Start Date: 04/04/2022 Additional Information: Full-time exempt		Position Description: - Review measurement science work with the PMC End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	none
Hypertension	none
Menopausal Therapy	none
Migraine	none
Obesity	none
Osteoporosis	none
COVID-19	none
Cannabis	none
Diabetes	none
Cardiovascular Disease	none

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Karen Campos

Name

Karen Campos

4/24/24

Signature

Date

Kate Carroll

Discloser Identifier: 02186486

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Manager, Clinical Policy Start Date: 08/26/2013 Additional Information:			
Position Description: Manage activities related to the Clinical Guidelines Committee and Scientific Medical Policy Committee End Date: Ongoing / No Known End Date			
Council of Medical Specialty Societies	Other	Self	-
Category: Other End Date: 10/31/2022 Compensation Type: Unpaid Compensation: No Additional Information: Co-chair, Clinical Practice Guidelines Developers Professional Peer Group			
Guidelines International Network	Other	Self	-
Category: Other End Date: 09/26/2024 Compensation Type: Unpaid Compensation: No Additional Information: Steering group member, GIN North America Regional Community			
The Beasley Firm, LLC	Employment	Spouse/Partner	-
Title: Technology Specialist Start Date: 09/01/2009 Additional Information:			
Position Description: Provides technical and media support End Date: Ongoing / No Known End Date			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Kate Carroll

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCHID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Kate Carroll

Kate Carroll

Kate Carroll

Signature

4/12/2024

Date

Discloser Identifier: 04490716

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Chief Operating Officer Start Date: 03/04/2024 Additional Information:		Position Description: Executive staff officer responsible for organizational operations, business functions, governance and strategy. End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects
(Bergitta E. Cotroneo)

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCHID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
(Bergitta E. Cotroneo)

(Bergitta E. Cotroneo)

Bergitta E. Cotroneo 04/24/24

Signature

Date

Itziar Etxeandia Ikobaltzeta

Discloser Identifier: 04021574

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Senior Scientist Start Date: 11/07/2022 Additional Information:			
Position Description: Senior Scientist End Date: Ongoing / No Known End Date			
American College of Physicians	Consultant	Self	-
Category: Consultant End Date: 10/31/2022 Compensation Type: Cash Compensation: Additional Information:			
Start Date: 09/01/2018			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Itziar Etxeandia Ikobaltzeta

Name



4/9/2024

Signature

Date

Allison Ewing

Discloser Identifier: 01171611

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-

Title: Senior Vice President, Marketing & PR
Start Date: 06/10/1996
Additional Information:

Position Description: Chief Communications Officer
End Date: Ongoing / No Known End Date

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Allison Ewing

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Allison Ewing

Allison Ewing

4-24-23



Signature

Date

Discloser Identifier: 04354277

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Coordinator, Clinical Policy Start Date: 02/21/2023 Additional Information:		Position Description: Office coordinator for clinical policy division at ACP End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Devon Germanovich
Name

Devon Germanovich 4/12/2024
Signature Date

Andrew Hachadorian

Discloser Identifier: 04028463

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Manager of Media Relations Start Date: 04/27/2020 Additional Information:			
Position Description: I manage media relations for the College. End Date: Ongoing / No Known End Date			
Main Line Health	Employment	Spouse/Partner	-
Title: Medical secretary Start Date: 01/02/1995 Additional Information:			
Position Description: I work at the Perinatal Testing Center at Paoli Hospital. End Date: 12/09/2021			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Andrew Hachadorian

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCHID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Andrew Hachadorian

Andrew Hachadorian

Andrew Hachadorian

Signature

4-11-2024

Date

Discloser Identifier: 04119425

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Senior Scientist Start Date: 05/31/2022 Additional Information:		Position Description: I am a methodologist contributing to or leading work on evidence synthesis to inform clinical guidelines. End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	ACP only
Hypertension	None
Menopausal Therapy	None
Migraine	ACP only
Obesity	None
Osteoporosis	https://www.acpjournals.org/doi/10.7326/M22-0684
COVID-19	ACP only
Cannabis	https://www.cannabisevidence.org/ for related reports https://pubmed.ncbi.nlm.nih.gov/36730710/
Diabetes	ACP only
Cardiovascular Disease	Wow, this is broad. I think none.

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Curtis Harrod

Curtis Harrod

Curtis Harrod

April 9, 2024

Signature

Date

Discloser Identifier: 04360194

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Vice President, Marketing and Public Relations Start Date: 04/10/2023 Additional Information:		Position Description: End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Lisa Johnson

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Lisa Johnson

Lisa Johnson

Lisa Johnson

04/30/2024

Signature

Date

Disclosure Purpose: Annual Governance Disclosure 2024-25, ACP/ Annals Forum, AMA Delegation

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: EVP/CEO Start Date: 01/01/2017 Additional Information: Position Description: EVP/CEO End Date: Ongoing / No Known End Date			
American Medical Association	Other	Self	-
Category: Other End Date: Ongoing / No Known End Date Compensation Type: Unpaid Compensation: Additional Information: Start Date: 01/01/2017			
Brigham and Women's Hospital	Other	Self	-
Category: Other End Date: 07/31/2028 Compensation Type: Unpaid Compensation: No Additional Information: Center for Physician Experience and Practice Excellence Advisory Board Member (not a fiduciary role) Start Date: 07/18/2023			
Council of Medical Subspecialty Societies	Fiduciary Officer	Self	-
Official Title: CMSS Board Member/President Compensation Type: Unpaid Start Date: 10/16/2018 Compensation: Additional Information: Board of Directors 2018-2022, President 1/2020- 12/2021, Immediate Past President 1/2022, Position Description: CMSS Board member/President End Date: 12/31/2022			
Gender Equity in Academic Medicine and Science Alliance	Fiduciary Officer	Self	-
Official Title: Founding Member and Executive Board Member Compensation Type: Unpaid Start Date: 01/01/2022 Compensation: No Additional Information: Position Description: Member, Board of Directors End Date:			
Inspira Health Woodbury	Employment	Spouse/Partner	-
Title: Physician Staff- Inspira Medical Group Start Date: 01/01/2017 Additional Information: Inspira Group Physicians 2950 College Drive Suite 1E Vineland, NJ 08360 Position Description: Salaried Pulmonary Critical Care Sleep Physician End Date: Ongoing / No Known End Date			
PCPCC	Fiduciary Officer	Self	-

Entity	Type	Interest Held By	Value
Official Title: PCPCC Board Member Compensation Type: Unpaid Start Date: 01/01/2017 Compensation: No Additional Information: PCPCC Board Chair, 1/31/2020-12/31/2021, PCPCC Immediate Past Board Chair, 1/1/2022-12/31/2022			
Temple University	Fiduciary Officer	Self	-
Official Title: Lewis Katz School of Medicine at Temple University Medical Alumni Board Compensation Type: Unpaid Start Date: 01/01/2017 Compensation: No Additional Information:			
Temple University Health System / Lewis Katz School of Medicine	Other	Self	-
Category: Other End Date: Compensation Type: Unpaid Compensation: No Additional Information: Appointed to Board of Visitors with a three-year term.			
Temple University Health System / Lewis Katz School of Medicine	Other	Self	-
Category: Other End Date: Ongoing / No Known End Date Compensation Type: Unpaid Compensation: No Additional Information: Nonfiduciary Board (MEd School Alumni Board) member			

Intellectual Property

Type	Is Licensed	Interest Held By	Value
Other Intellectual Property - Multiple presentations and publications	-	Self	-
Description: Multiple presentations and publications Additional Information: Income: Additional Information:			
Other Intellectual Property - Multiple presentations	-	Self	-
Description: Multiple presentations Additional Information: Income: Additional Information:			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)

- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence



Relevant Publications and Other Intellectual Interests for Ongoing Projects

Darilyn V. Moyer

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	Obesity Roundtable Discussion / ACP Strategy & Obesity Initiative
Osteoporosis	None
COVID-19	Multiple Annals pubs after COVID ACP/Annals Forums
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Darilyn V. Moyer

Darilyn V. Moyer

Darilyn Moyer

4/12/24

Signature

Date

Amir Qaseem

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025 (Expiration Date: 04/17/2025), ACP/ Annals Forum (Expiration Date: 04/17/2025), Forums (Expiration Date: 04/17/2025), Population Health Committee (Expiration Date: 04/17/2025), Internal Medicine Meeting 2024 faculty (Expiration Date: 04/17/2025) **Employment Information:** Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Chief Science Officer Start Date: 12/07/2003 Additional Information:			
Position Description: End Date: Ongoing / No Known End Date			
American College of Physicians	Other Current Employment	Self	-
Category: Other End Date: Ongoing / No Known End Date Compensation Type: Compensation: Additional Information: I regularly represent ACP in external initiatives related to clinical and medical policies (such as meetings, workgroups, committees, governance boards).			
Start Date: 12/07/2003			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Amir Qaseem

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Amir Qaseem

Amir Qaseem

4/17/2024

A handwritten signature in black ink that reads "Amir Qaseem". The signature is written in a cursive style with a horizontal line under the name.

Signature

Date

Discloser Identifier: 01975766	Disclosure Purpose: Annual Staff Disclosure 2024 - 2025	Employment Information: Currently Employed
---------------------------------------	--	---

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Senior Research Associate Start Date: 01/13/2021 Additional Information:		Position Description: Center for Evidence Reviews End Date:	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Tatyana A Shamliyan

Name

Tatyana A Shamliyan

Signature

Date April 11, 2024

Discloser Identifier: 03794192

Disclosure Purpose: Annual Staff Disclosure 2023 - 2024

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
American College of Physicians	Employment Current Employment	Self	-
Title: Senior Scientist, Clinical Policy Start Date: 06/15/2020 Additional Information:		Position Description: Leading the performance measurement strategy End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Samantha Tierney

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	I participate in CMS's Expert WG for Suicide Risk Assessment measures in patients w/MDD
Hypertension	
Menopausal Therapy	
Migraine	
Obesity	
Osteoporosis	
COVID-19	
Cannabis	
Diabetes	
Cardiovascular Disease	

Acknowledgements and Attestations


By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects
Samantha Tierney

Samantha Tierney

4/24/2024

A handwritten signature in cursive script, appearing to read "Sam Tierney", enclosed within a rectangular border.

Signature

Date

Discloser Identifier: 04490696

Disclosure Purpose: Annual Staff Disclosure 2024 - 2025

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
ACP	Employment Current Employment	Self	-
Title: Research Associate Start Date: 02/05/2024 Additional Information:		Position Description: Acts as lead staff and project manager for the Population Health and Medical Science Committee. Coordinates timelines, deliverables, logistics, and contracts for manuscripts. Conducts literature searches, creates deliverables as needed. End Date: Ongoing / No Known End Date	
Medidata, A Dassault Systemes Company	Employment	Self	-
Title: Research Analyst Start Date: 01/06/2020 Additional Information:		Position Description: Supported the work in conducting real-world studies by developing code lists, analyzing data, and conducting analyses. Managed client projects. End Date: 04/01/2022	
OM1, Inc.	Employment	Self	-
Title: Epidemiologist Start Date: 04/04/2022 Additional Information:		Position Description: Crafted research plans for real-world studies Wrote real-world study reports Worked cross-collaboratively to ensure accurate implementation of real-world studies in pharmacoepidemiology using open claims and EHR data sources End Date: 11/17/2023	

Intellectual Property

Type	Is Licensed	Interest Held By	Value
Other Intellectual Property - Published Manuscript: Incidental Adrenal Mass Fol	-	Self	-
Description: Published Manuscript: Incidental Adrenal Mass Follow-Up Additional Information: Published on January 31, 2023. Funded by Boston Medical Center. Related to my employment at Boston Medical Center. Involvement ended as of February 11, 2022. https://pubmed.ncbi.nlm.nih.gov/36521629/ Income: No Additional Information: Published on January 31, 2023. Funded by Boston Medical Center. Related to my employment at Boston Medical Center. Involvement ended as of February 11, 2022. https://pubmed.ncbi.nlm.nih.gov/36521629/		Income Source: None	
Other Intellectual Property - Abstract accepted for oral presentation	-	Self	-
Description: Abstract accepted for oral presentation Additional Information: Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of January 10, 2024. Income: No Additional Information: Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of January 10, 2024.		Income Source: None	
Other Intellectual Property - Abstract in development	-	Self	-

Type	Is Licensed	Interest Held By	Value
<p>Description: Abstract in development Income Source: None Additional Information: Included in the acknowledgements only, not as an author. Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of January 23, 2024. Income: No Additional Information: Included in the acknowledgements only, not as an author. Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of January 23, 2024.</p>			
Other Intellectual Property - Abstract in development	-	Self	-
<p>Description: Abstract in development Income Source: None Additional Information: Included in acknowledgements only, not as an author. Funded by a pharmaceutical company. Involvement ended as of January 26, 2024. Income: No Additional Information: Included in acknowledgements only, not as an author. Funded by a pharmaceutical company. Involvement ended as of January 26, 2024.</p>			
Other Intellectual Property - Abstract accepted for presentation	-	Self	-
<p>Description: Abstract accepted for presentation Income Source: None Additional Information: Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of January 5, 2024. Income: No Additional Information: Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of January 5, 2024.</p>			
Other Intellectual Property - Abstract accepted for presentation	-	Self	-
<p>Description: Abstract accepted for presentation Income Source: None Additional Information: Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of December 19, 2023. Income: No Additional Information: Funded by a pharmaceutical company. Related to employment at OM1, Inc. Involvement ended as of December 19, 2023.</p>			
Other Intellectual Property - Published Abstract: Bleeding Rates Associated wit	-	Self	-
<p>Description: Published Abstract: Bleeding Rates Associated with Anticoagulation Treatment for Atrial Fibrillation Income Source: None Additional Information: Published in 2021. Related to my employment at Medidata. Funded by Anthos Therapeutics. Involvement ended as of July 21, 2021. https://abstracts.isth.org/abstract/comparing-the-real-world-and-clinical-trial-bleeding-rates-associated-with-anticoagulation-treatment-for-atrial-fibrillation/ Income: No Additional Information: Published in 2021. Related to my employment at Medidata. Funded by Anthos Therapeutics. Involvement ended as of July 21, 2021. https://abstracts.isth.org/abstract/comparing-the-real-world-and-clinical-trial-bleeding-rates-associated-with-anticoagulation-treatment-for-atrial-fibrillation/</p>			
Other Intellectual Property - Published Abstract: Treatment Patterns of Patient	-	Self	-
<p>Description: Published Abstract: Treatment Patterns of Patients With Soft Tissue Sarcoma Income Source: None Additional Information: Published on 31 March 2022. Funded by Deciphera. Related to my employment at Medidata. Presented at NCCN. Involvement ended on 31 March 2022. https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-179.xml Income: No Additional Information: Published on 31 March 2022. Funded by Deciphera. Related to my employment at Medidata. Presented at NCCN. Involvement ended on 31 March 2022. https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-179.xml</p>			
Other Intellectual Property - Published Manuscript: External Control Arms and I	-	Self	-
<p>Description: Published Manuscript: External Control Arms and Innovative Tools to Enrich Clinical Trial Data Income Source: None Additional Information: Published on March 25, 2024. Funded by Viatrix. Related to my employment at Medidata. Involvement ended as of January 23, 2024. https://link.springer.com/article/10.1007/s43441-024-00627-4 Income: No Additional Information: Published on March 25, 2024. Funded by Viatrix. Related to my employment at Medidata. Involvement ended as of January 23, 2024. https://link.springer.com/article/10.1007/s43441-024-00627-4</p>			
Other Intellectual Property - Published Manuscript: Maternal Prenatal Fish Inta	-	Self	-

Type	Is Licensed	Interest Held By	Value
<p>Description: Published Manuscript: Maternal Prenatal Fish Intake and Child Autism-Related Traits</p> <p>Additional Information: Published on 09 June 2020. Issued in February 2021. Related to my Master's thesis at Drexel University. Involvement ended in 2019. https://link.springer.com/article/10.1007/s10803-020-04546-9</p> <p>Income: No</p> <p>Additional Information: Published on 09 June 2020. Issued in February 2021. Related to my Master's thesis at Drexel University. Involvement ended in 2019. https://link.springer.com/article/10.1007/s10803-020-04546-9</p>	None		

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Chelsea Vigna

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None
Diabetes	None
Cardiovascular Disease	Comparing the Real-world and Clinical Trial Bleeding Rates Associated with Anticoagulation Treatment for Atrial Fibrillation. Funded by Anthos Therapeutics. Related to employment at Medidata. Involvement ended as of July 21, 2021. https://abstracts.isth.org/abstract/comparing-the-real-world-and-clinical-trial-bleeding-rates-associated-with-anticoagulation-treatment-for-atrial-fibrillation/

Acknowledgements and Attestations

By signing this form,

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Chelsea Vigna

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Chelsea Vigna

Chelsea Vigna

Signature

April, 12, 2024

Date

Jennifer Yost

Discloser Identifier: 03994247

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
COVID-END	Other	Self	-
Category: Other End Date: 04/01/2022 Compensation Type: Unpaid Compensation: No Additional Information:			
European Cooperation in Science and Technology	Other	Self	-
Start Date: 05/01/2020 Category: Other End Date: 04/16/2023 Compensation Type: Unpaid Compensation: No Additional Information:			
Evidence Based Research Network	Fiduciary Officer	Self	-
Official Title: Steering Committee Member Compensation Type: Unpaid Start Date: 10/01/2016 Compensation: No Additional Information:			
Evidence Synthesis International	Fiduciary Officer	Self	-
Position Description: Organize and support activities of the organisation End Date: Ongoing / No Known End Date Official Title: Secretariat Compensation Type: Unpaid Start Date: 03/01/2018 Compensation: No Additional Information:			
McMaster University	Employment	Self	-
Title: Assistant Clinical Faculty Start Date: 07/01/2017 Additional Information:			
Position Description: End Date: 06/30/2023			
Sigma Theta Tau International	Fiduciary Officer	Self	-
Official Title: President - Alpha Nu Chapter Compensation Type: Unpaid Start Date: 09/01/2019 Compensation: No Additional Information:			
Position Description: President - Alpha Nu Chapter End Date: 09/30/2021			
Sigma Theta Tau International	Fiduciary Officer	Self	-

Entity	Type	Interest Held By	Value
Official Title: Immediate Past President Compensation Type: Unpaid Start Date: 10/01/2021 Compensation: No Additional Information:			
Villanova University	Employment Current Employment	Self	-
Title: Professor Start Date: 08/22/2017 Additional Information:			
Villanova University	Grant / Contract	Self	\$50000.00
Recipient Name: M. Louise Fitzpatrick College of Nursing Grant / Contract Description: COVID-19 Caring About Health for All Study (CHAMPS) Contract Start Date: 03/31/2020 Grant / Contract Amount: \$50,000.00 Additional Information: Principal Investigators: Kaufman, P., Havens, D., Mensinger, J.; Co-Investigators: Bradley, P., Brom, H., Copel, L., Maldonado, L., Smeltzer, S., Yost, J.			
Villanova University	Other	Self	-
Category: Other End Date: Compensation Type: Unpaid Compensation: No Additional Information: COVID-19 Caring About Health for All Study (CHAMPS) funded with in-kind funding in the amount of \$50,000 USD. A longitudinal study to assess the experience and self-reported health and well-being of essential workers and first responders, service staff, and healthcare professionals who provided support for patients, treatment sites and the community during the COVID-19 pandemic in the short and long-term. CHAMPS will also serve as a registry for future, ancillary- and sub-studies.			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	Relevant publications - https://orcid.org/0000-0002-3170-1956
Hypertension	
Menopausal Therapy	
Migraine	
Obesity	
Osteoporosis	
COVID-19	
Cannabis	
Diabetes	Relevant publications - https://orcid.org/0000-0002-3170-1956
Cardiovascular Disease	

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Jennifer Yost

Name



Signature

April 9, 2024

Date

Lotty Hooft

Discloser Identifier: 04288269

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
<p>Title: Professor Evidence Synthesis & Knowledge Translation in Healthcare Start Date: 01/01/2014</p> <p>Additional Information: No interest to report</p> <p>Position Description: Professor Evidence Synthesis & Knowledge Translation, Head of department Epidemiology & Health Economics at the Julius Center UMC Utrecht, Director Cochrane Netherlands End Date: Ongoing / No Known End Date</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Johanna Damen

Discloser Identifier: 04121105

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Assistant Professor Start Date: 01/01/2014 Additional Information:		Position Description: My tasks include doing research, commissioned projects, teaching, supervising juniors. My research focusses on methodology for systematic reviews and meta-analysis. End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Pauline Heus

Discloser Identifier: 04288282

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Assistant professor Start Date: 01/01/2014 Additional Information:		Position Description: End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04288278

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Junior researcher/teacher Start Date: 05/16/2022 Additional Information: Full time employment		Position Description: Within Cochrane Netherlands, I am helping with the execution and reporting of systematic reviews commissioned by different organisations. End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04288287

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Junior researcher/teacher Start Date: 08/01/2022 Additional Information:		Position Description: Assisting with systematic literature review and evidence synthesis End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04288273

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Clinical epidemiologist (researcher) Start Date: 01/15/2016 Additional Information:		Position Description: Assistant professor in clinical epidemiology, focussing on methodological research regarding prediction models, diagnostic tests, and the impact of these on clinically relevant outcomes. End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Mike Kusters

Discloser Identifier: 04288279

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Junior Researcher & Teacher Start Date: 05/16/2022 Additional Information:		Position Description: End Date:	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Rene Spijker

Discloser Identifier: 04288272

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: Information Specialist/ Senior Scientist Start Date: 07/01/2008 Additional Information: Employment is with Cochrane Netherlands which is hosted at Universitair medisch centrum utrecht. contract is for 2 days a week seconded from AmsterdamUMC Position Description: End Date: Ongoing / No Known End Date			
Universiteit van Amsterdam	Employment Current Employment	Self	-
Title: Information Specialist Start Date: 07/01/2008 Additional Information: host institution is AmsterdamUMC work 3 days a week Position Description: End Date: Ongoing / No Known End Date			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Kim van der Braak

Discloser Identifier: 04288284

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-

Title: Junior researcher and PhD student
Start Date: 09/01/2021
Additional Information:

Position Description: as employee of Cochrane Netherlands
End Date: Ongoing / No Known End Date

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Robin Vernooij

Discloser Identifier: 03392890

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universitair Medisch Centrum Utrecht	Employment Current Employment	Self	-
Title: dr. Start Date: 06/01/2019 Additional Information:		Position Description: Assistant professor End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Gerald Gartlehner

Discloser Identifier: 03994908

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Association of Academic Health Centers	Consultant Current Employment	Self	-
Category: Consultant End Date: Ongoing / No Known End Date Compensation Type: Other Compensation: Additional Information: Start Date: 01/01/2020 Other Compensation: contract			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Andrea Chapman

Discloser Identifier: 03994905

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
University of Krems	Employment Current Employment	Self	-
Title: Research Associate Start Date: 06/01/2019 Additional Information:		Position Description: End Date: 03/31/2026	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Andreea-Iulia Dobrescu

Discloser Identifier: 04095851

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
University for Continuing Education Krems	Employment Current Employment	Self	-
Title: Researcher Start Date: 09/01/2019 Additional Information:			
Position Description: End Date: Ongoing / No Known End Date			
University for Continuing Education Krems	Employment Current Employment	Self	-
Title: MD, PhD Start Date: 09/01/2019 Additional Information:			
Position Description: Researcher End Date: Ongoing / No Known End Date			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Johanna Feyertag

Discloser Identifier: 04351085

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Bildungscampus Mostviertel	Employment Current Employment	Self	-
Title: Teacher Start Date: 10/01/2023 Additional Information: Position Description: Teacher End Date:			
Dr. Feyertag-Leidl	Employment Current Employment	Self	-
Title: Assistance Start Date: 05/08/2015 Additional Information: Position Description: doctors receptionist End Date: Ongoing / No Known End Date			
Dr. Kaiser	Employment Current Employment	Self	-
Title: Staff Start Date: 03/26/2021 Additional Information: Position Description: Dentist End Date: Ongoing / No Known End Date			
Karl Landsteiner University of Health Sciences	Employment Current Employment	Self	-
Title: Tutor Start Date: 10/01/2022 Additional Information: Position Description: tutor in the dissection course End Date: 06/30/2024			
NZD Linz	Employment Current Employment	Self	-
Title: Staff Start Date: 01/22/2023 Additional Information: Position Description: Dentist End Date: Ongoing / No Known End Date			
University for Continuing Education Krems	Employment Current Employment	Self	-
Title: Student Assistance Start Date: 08/15/2022 Additional Information: 5h/week Position Description: Assistance in writing scientific papers End Date: 12/31/2023			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence



Arianna Gadinger

Discloser Identifier: 04351087

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Austria	Employment Current Employment	Self	-
Title: University for Continuing Education Krems Start Date: 09/01/2021 Additional Information:			
Position Description: Research assistant End Date: Ongoing / No Known End Date			
Karl Landsteiner University	Other Current Employment	Self	-
Category: Other End Date: 09/30/2024 Compensation Type: Unpaid Compensation: No Additional Information: Student			
Start Date: 10/01/2018			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04378264

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Danube University Krems	Employment Current Employment	Self	-
Title: Information specialist Start Date: 04/01/2014 Additional Information:		Position Description: Conducting systematic searches for evidence syntheses, supporting evidence synthesis methods research, teaching literature search methods End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04387934	Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25	Employment Information: Currently Employed
---------------------------------------	---	---

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
University for Continuing Education Krems	Employment Current Employment	Self	-
<p>Title: Department for Evidence-Based Medicine and Evaluation Start Date: 09/01/2022 Additional Information: Projects: Evidence-based Nursing Centre (Cochrane Austria), ACP, projects of the department for Evidence-based Medicine and Evaluation: 26h/week; conducting evidence synthesis; MA BSc</p> <p>Position Description: Research Associate End Date: 12/31/2026</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Claus Nowak

Discloser Identifier: 04486525

Disclosure Purpose: TEP drug review

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Novartis Pharma AG	Employment	Self	-
Title: Principal Biostatistician Start Date: 11/01/2021 Additional Information:			
Position Description: Trial statistician End Date: 10/31/2023			
Universität für Weiterbildung Krams	Employment Current Employment	Self	-
Title: Senior Scientist Start Date: 11/01/2023 Additional Information:			
Position Description: Statistician End Date: Ongoing / No Known End Date			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04243065

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Cochrane	Other	Self	-
Category: Other Start Date: 11/21/2021 End Date: Ongoing / No Known End Date Compensation Type: Unpaid Compensation: No Additional Information: Governing Board Trustee			
Danube University Krems	Employment Current Employment	Self	-
Title: Researcher Position Description: Researcher Start Date: 03/10/2017 End Date: Ongoing / No Known End Date Additional Information:			
Karolinska Institutet	Employment Current Employment	Self	-
Title: Study coordinator, PhD student Position Description: Study coordinator, PhD student Start Date: 02/01/2023 End Date: Ongoing / No Known End Date Additional Information:			

Additional Questions

1. Please specify any additional information which you consider relevant to this disclosure.

Cochrane Governing Board November 2021-present

2. ACP requires your annual affirmation to abide by its Disclosure of Interests and Management of Conflicts Policy, Non-Disclosure Agreement, Intellectual Property Policy, and Anti-Harassment Policy if you're submitting your disclosures to ACP as a member of an ACP governance group or as College staff, as part of ACP's annual disclosure process.

a. Are you submitting your disclosures to ACP as a member of one of the following groups:

- ACP board, committee, council, task force, and/or other governance group?
- Chapter Council or other Chapter leadership role?
- National or chapter staff?
- Annals of Internal Medicine editorial staff?
- Other (meeting guests, contractors, authors, etc.)

Yes.

i. I, the undersigned, acknowledge I have read and agree to abide by the American College of Physician's **Disclosure of Interests and Management of Conflicts Policy**.

Yes

- ii. **I, the undersigned, enter into the [Non-Disclosure Agreement](#) between myself and the American College of Physicians, which governs the disclosure and furnishing of ACP's members of the Board of Regents, Board of Governors, Committees, Councils, Governors-elect and Chapter Personnel in any such Work Group of ACP, with information developed for ACP, deemed "Proprietary Information."**

Yes

- iii. **I, the undersigned, intending to be legally bound, hereby declare and agree to terms of participation in the ACP Group activities of ACP as specified in the [ACP Intellectual Property Policy](#).**

Yes

- iv. **I, the undersigned, acknowledge I have read and agree to abide by the American College of Physician's [Anti-Harassment Policy](#).**

Yes

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Kylie Thaler

Discloser Identifier: 04243064

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Austrian Social Insurance	Employment Current Employment	Self	-
<p>Title: Medical Doctor Start Date: 07/03/2017 Additional Information:</p> <p>Position Description: Physician working in a diabetes outpatient clinic. End Date: Ongoing / No Known End Date</p>			
Edwards Lifesciences	Travel	Spouse/Partner	\$1500.00
<p>Location(s): Vienna, Cologne Travel End Date: 01/15/2024 Valuation Date: 01/22/2024 Additional Information:</p> <p>Travel Start Date: 06/14/2023 Estimated Value: \$1,500.00 Purpose: Speaker at an education event</p>			
Eli Lilly	Travel	Self	\$545.00
<p>Location(s): Salzburg, Austria (my country of residence) Travel End Date: 11/19/2022 Valuation Date: 04/04/2023 Additional Information: 3 nights in a 4-star hotel and conference attendance fee for the annual conference of the Austrian Diabetes Society.</p> <p>Travel Start Date: 11/17/2022 Estimated Value: \$545.00 Purpose: Hotel and conference fee</p>			
Eli Lilly	Travel	Self	\$600.00
<p>Location(s): Salzburg, Austria (my country of residence) Travel End Date: 11/18/2023 Valuation Date: 01/22/2024 Additional Information:</p> <p>Travel Start Date: 11/15/2023 Estimated Value: \$600.00 Purpose: Attendance at the Austrian Society of Diabetes annual conference and hotel accommodation</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Discloser Identifier: 03994921	Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25	Employment Information: Currently Employed
---------------------------------------	---	---

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Department for Evidence-based Medicine and Evaluation, Danube University Krems	Employment Current Employment	Self	-
Title: Research associate Start Date: 01/18/2016 Additional Information:		Position Description: Research associate End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 03889409	Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25	Employment Information: Currently Employed
---------------------------------------	---	---

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Universität für Weiterbildung Krems	Employment Current Employment	Self	-
<p>Title: none Start Date: 04/19/2019 Additional Information:</p> <p>Position Description: Research Assistant End Date: Ongoing / No Known End Date</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Discloser Identifier: 04536061

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Retired/Unemployed

Summary of Interests

I do not have any interests to disclose at this time.

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years If none, write "None"
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Connor Burns

Name

Connor Burns

Signature

04-30-24

Date

Discloser Identifier: 04536062

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
Tredyffrin/Easttown School District	Employment Current Employment	Self	-
<p>Title: Principal Valley Forge Middle School Start Date: 07/01/2004 Additional Information: I work about 50 hours a week and am a salaried employee</p> <p>Position Description: I am responsible for the educational program of the school. End Date: Ongoing / No Known End Date</p>			

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for Ongoing Projects

Print Name

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCHID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write "None"</i>
Depression	NONE
Hypertension	NONE
Menopausal Therapy	NONE
Migraine	NONE
Obesity	NONE
Osteoporosis	NONE

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Print Name

Matthew Gibson

Signature

Matthew Gibson

Date

5/2/24

Disclosure Purpose: Annual Governance Disclosure 2024-25, Population Health Committee

Employment Information: Currently Retired/Unemployed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
NAPCRG	Other	Self	-
<p>Category: Other Start Date: 11/03/2023 End Date: Compensation Type: Unpaid Compensation: No Additional Information: Member, Board of Directors</p>			

Additional Questions

1. Please specify any additional information which you consider relevant to this disclosure.

I serve as the US Co-chair of the Patient and Clinician Engagement Committee of the North American Primary Care Research Group (NAPCRG)

2. ACP requires your annual affirmation to abide by its Disclosure of Interests and Management of Conflicts Policy, Non-Disclosure Agreement, Intellectual Property Policy, and Anti-Harassment Policy if you're submitting your disclosures to ACP as a member of an ACP governance group or as College staff, as part of ACP's annual disclosure process.

a. Are you submitting your disclosures to ACP as a member of one of the following groups:

- ACP board, committee, council, task force, and/or other governance group?
- Chapter Council or other Chapter leadership role?
- National or chapter staff?
- Annals of Internal Medicine editorial staff?
- Other (meeting guests, contractors, authors, etc.)

Yes.

i. I, the undersigned, acknowledge I have read and agree to abide by the American College of Physician's [Disclosure of Interests and Management of Conflicts Policy](#).

Yes

ii. I, the undersigned, enter into the [Non-Disclosure Agreement](#) between myself and the American College of Physicians, which governs the disclosure and furnishing of ACP's members of the Board of Regents, Board of Governors, Committees, Councils, Governors-elect and Chapter Personnel in any such Work Group of ACP, with information developed for ACP, deemed "Proprietary Information."

Yes

iii. I, the undersigned, intending to be legally bound, hereby declare and agree to terms of participation in the ACP Group activities of ACP as specified in the [ACP Intellectual Property Policy](#).

Yes

iv. **I, the undersigned, acknowledge I have read and agree to abide by the American College of Physician's Anti-Harassment Policy.**

Yes

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence



Relevant Publications and Other Intellectual Interests for Ongoing Projects

Raymond A. Haeme

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee and Population Health and Medical Sciences Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP.

You may also share a list of publications via a link to list of your published works (such as ORCID or PubMed) or as an attachment (write “see attachment” in table).


Clinical Topic Area	Relevant Interests from Last 3 Years <i>If none, write “None”</i>
Depression	None
Hypertension	None
Menopausal Therapy	None
Migraine	None
Obesity	None
Osteoporosis	None
COVID-19	None
Cannabis	None

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants’ disclosure of interests will be publicly available on ACP’s website and a link to the disclosures will be included in each published work.
- I attest that I have reviewed the above topic areas and that my disclosures are up to date.

Raymond A. Haeme



Signature

April 10, 2024

Date

Discloser Identifier: 04536063

Disclosure Purpose: Contractor/Guest Annual Disclosure 2024 - 25

Employment Information: Currently Employed

Summary of Interests

Company or Organization

Entity	Type	Interest Held By	Value
20th Century Fox	Employment Current Employment	Self	-
Title: VP Financial System Support Start Date: 08/15/1994 Additional Information: Full-time		Position Description: Financial System Deployment and maintenance End Date: Ongoing / No Known End Date	

Certification

By submitting this form, I attest that I have disclosed all interests related to healthcare from the last 3 years on behalf of myself and any household members, including consideration of interests in the following areas:

- Research and consulting support (e.g., grants, contracts, sponsorships, honoraria, or any other fees related to role as consultant, speaker's bureau participation, or expert as part of regulatory, legislative, or judicial process)
- Investments and proprietary interests excluding broadly diversified investments such as mutual or pension funds (e.g., stocks, bonds, stock options, commercial business interests, patents, trademarks, copyrights)
- Membership on boards, workgroups, panels, or committees through other medical societies or healthcare organizations
- Participation in advocacy or lobbying activities, including any roles or relationships with disease advocacy organizations

Other aspects of my background or present interests not addressed above that might be perceived as affecting my objectivity or independence

Relevant Publications and Other Intellectual Interests for
Ongoing Projects

Print Name *Connie Robinson*

Disclosures of Interests: Supplemental Questions

Please review the following topic areas and report any intellectual or other relevant interests held by you or any household members from the last 3 years that may be relevant to the below topic areas.

- *Intellectual interests* are defined as academic ideas or activities or specific viewpoints and relate to such issues as academic advancement, clinical revenue streams, or community standing.
- Examples of types of intellectual interests include publications, unpaid participation on workgroups, panels, or committees, or membership in special interest groups.

Clinical Guidelines Committee: Topics Currently Under Development

In the table below, please list any relevant intellectual interests (including relevant publications from peer- and non-peer-reviewed sources or other relevant interests not captured in your Convey.

You only need to report interests from the last 3 years and you do not need to report publications developed on behalf of ACP. You may also share a list of publications via a link to list of your published works (such as ORCHID or PubMed) or as an attachment (write "see attachment" in table).

Clinical Topic Area Relevant Interests from Last 3 Years

If none, write "None"

Depression	<i>None</i>
Hypertension	<i>None</i>
Menopausal Therapy	<i>None</i>
Migraine	<i>None</i>
Obesity	<i>None</i>
Osteoporosis	<i>None</i>

Acknowledgements and Attestations

By signing this form,

- I acknowledge that in order to maintain transparency, all participants' disclosure of interests will be publicly available on ACP's website and a link to the disclosures will be included in each published work.
 - I attest that I have reviewed the above topic areas and that my disclosures are up to date.
-

Print Name *Connie Robinson*

Signature *Connie Robinson*

Date *4/30/2024*
